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1 Introduction 
One of mankind’s greatest achievements has been the development of vaccines to prevent 
infectious diseases. The introduction of vaccination by Jenner more than two hundred 
years ago and the discovery of chemotherapeutics by Ehrlich and antibiotics by Fleming a 
century later contributed to the decline of diseases that had been responsible for most of 
human mortality and morbidity during history. Now, vaccination is considered the most 
cost-effective and efficacious medical intervention against pathogens (Rappuoli et al. 
2002). 
1.1 Vaccination and immunotherapy 
The term “vaccine” was first coined by Edward Jenner in 1796 after his discovery that 
prior exposure to cowpox virus prevents infection by the smallpox virus. Louis Pasteur 
later extended the concept of inducing a protective immune response to other pathogens 
(Silverstein 1999). Today, many bacterial and viral diseases like diphtheria, tetanus, 
measles and yellow fever can be prevented by vaccination. As proposed by Jenner, his new 
vaccination procedure could be used to eliminate smallpox. Indeed, the global eradication 
of smallpox was declared in 1980 (Fenner et al. 1988). Due to the immunization programs 
of the World Health Organization, poliomyelitis is expected to be eradicated in the near 
future.  
Despite this success, a number of pathogens can not be controlled by current vaccination 
approaches. These pathogens include the three major killers HIV, Mycobacterium 
tuberculosis and the malaria parasite Plasmodium falciparum (Fig. 1.1). Consequently, 
about 11 million of 57 million annual deaths worldwide are estimated to be related directly 
to infectious diseases. The re-emergence of old diseases, as well as newly emerging 
diseases like SARS greatly magnify the global burden of infections (Morens et al. 2004). 
Microbial adaptation and evolution, e.g. the occurrence of drug-resistant microbes due to 
the vast use of antibiotics in veterinary and human medicine, in addition to international 
travel and inconsiderate human behavior are factors that contribute to the challenges of 
infectious diseases to public health. To meet these challenges, there is a need to 
continuously develop novel vaccines, as well as to improve existing vaccines in terms of 
safety and efficacy. There is also increasing interest in designing vaccines for so called 
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immunotherapeutic approaches that may be effective as therapeutic measure for chronic 
established infections but also for cancer and other diseases.  
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Fig. 1.1: Leading causes of death worldwide, estimates for 2002 (WHO 2004). 
1.1.1 Requirements of an effective vaccine 
The requirements of an effective vaccine depend on the nature of the infectious agent and 
the person to be immunized. Protective immunity against most viruses as well as against 
bacteria and parasites replicating extracellularly is mediated by humoral immune responses. 
In contrast, some bacteria such as Mycobacterium tuberculosis are obligate intracellular 
organisms, as they only replicate inside a susceptible cell. To control such infections, the 
induction of an effective cell mediated immune response, particularly of cytotoxic T cells 
and T-helper-1 (Th1) CD4+ cells, is essential (Ada 2005). For some viral infections like 
human immunodeficiency virus (HIV) both humoral and cellular response are likely to be 
required (Lima et al. 2004). Thus, a successful vaccine should elicit a suitable type of 
immunity. Furthermore, an effective vaccine has to induce protective immunity preferably 
in a high proportion of the population. In addition, it is desirable to induce lifelong 
immunological memory via a single administration of the vaccine, as it is impractical to 
administer booster immunizations to large populations especially in developing countries. 
Moreover, practical and safety issues have to be considered in designing vaccines. This 
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includes low costs, biological stability (e.g. no need for a cold chain), ease of 
administration and not least few side effects (Babiuk 1999).  
1.1.2 Types of vaccines 
The principle of vaccination is to mimic a natural infection in order to induce a long lasting 
immune response such that subsequent exposures to the infectious agent do not cause 
disease. One conventional way is to administer whole-cell vaccines that consist either of 
killed or live, attenuated microorganisms. Attenuated strains can be made by repeated 
passage of the infectious agent in tissue culture or animal host until loss of virulence and 
retention of immunogenicity are properly balanced (Ada 2001). Today, attenuation can be 
achieved more reliable by employing recombinant DNA techniques. Examples for live, 
attenuated viruses include the measles, mumps and rubella vaccines. Although live 
vaccines are often effective in stimulating strong immune responses, their application is 
limited due to safety concerns regarding the risk of virulence reversion. In contrast, 
inactivated whole microorganisms are non-infectious but also less immunogenic especially 
in terms of cell-mediated immunity and therefore often require booster injections and 
adjuvants (Ulmer et al. 2006). However, killed vaccines are useful for antibody-mediated 
prevention of viral diseases such as influenza.  
Knowledge of microbial pathogenesis, identification of major virulence factors and 
characterization of the immune response after infection have led to the development of 
subunit vaccines based on purified antigenic components such as toxoids, bacterial 
polysaccharides and viral surface proteins (Scarselli et al. 2005). Effective vaccines against 
Clostridium tetani and Corynebacterium diphteriae are based on the generation of 
neutralizing antibodies against detoxified versions of their secreted toxins. Similarly, 
antibodies, which protect via opsonization, can be induced against polysaccharides 
extracted from cultures of capsular bacteria.  
Application of modern molecular biology techniques has resulted in the ability to clone, 
purify and engineer subunit antigens to remove toxic effects while retaining 
immunogenicity. These techniques gave rise to the first recombinant subunit vaccine 
against the hepatitis B virus (HBV), whose surface antigen is produced in recombinant 
yeast (McAleer et al. 1992).  
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Purified antigens are often administered with adjuvants to enhance their immunogenicity 
(Marciani 2003). Adjuvants represent products that increase or modulate the humoral or 
cellular immune response against an antigen. They can act via immunomodulation, 
induction of cytotoxic T lymphocytes (CTL), targeting of specific cells and depot 
generation (Cox and Coulter 1997). Adjuvants may for example provide “danger signals” 
which are recognized by pattern recognition receptors present on cells of the innate 
immune system thereby activating them (Medzhitov and Janeway, Jr. 2002). Alum 
(aluminum potassium phosphate), the adjuvant most often used, delays the release of an 
antigen such as the Hepatitis B vaccine at the injection site and therefore creates a depot 
(Lima et al. 2004).  
1.1.3 Novel vaccination approaches 
To date, most licensed vaccines generate protective antibodies that directly attack 
microorganisms and subsequently prevent infection. The many remaining challenges, such 
as vaccines against HIV, malaria, chronic infections and cancer, may require the induction 
of cellular immune responses. To achieve these types of responses, new approaches in 
vaccine development have to be made concerning the way vaccine antigens are presented, 
delivered and administered (Ulmer et al. 2006). 
1.1.3.1 Genetic immunization 
Genetic immunization is the use of DNA encoded antigens for vaccination. First 
experiments have shown that the direct injection of eukaryotic expression plasmids into 
mouse muscle lead to gene expression in vivo (Wolff et al. 1990) and to immune responses 
against the expressed protein (Tang et al. 1992). Since then, the induction of cell-mediated 
immune responses and protective antibodies was described in a number of animal models 
against viral, bacterial and parasitic diseases (Donnelly et al. 1997). The DNA can be 
injected either directly into muscles or as DNA-coated gold beads using a gene gun. After 
injection, antigen-encoding plasmids are taken up either by muscle or skin cells, or directly 
by antigen-presenting cells (APC) and remain episomally in these cells (Fig. 1.2) (Ertl and 
Xiang 1996). Subsequently, the gene is expressed. The resulting protein is processed 
similarly to a viral antigen and presented bound to MHC class I molecules. This leads to 
activation of CTL (Ulmer et al. 1993). Transfer of the antigen to APC can also occur via 
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cross-presentation (Stevenson 2004). Thus, T helper cells and B cells can be stimulated 
(Davis et al. 1993).  
Advantages of genetic immunization include low costs of the plasmid DNA, its stability 
and the absence of infectious properties (Leitner et al. 1999). The plasmid DNA can be 
produced in E. coli using standard fermentation and downstream processing techniques 
that yield a highly stable and pure vaccine (Schleef and Schmidt 2004). Moreover, 
bacterial plasmids possess unmethylated CpG motifs that can function as adjuvant (Krieg 
2000). These CpG motifs are recognized by Toll-like receptor (TLR) 9 and support a 
strong Th1-like inflammatory response (Hemmi et al. 2000).  
CpG
antigen
DNA vaccine
Antigen-presenting cell
Muscle cell
Skin cell
Indirect route Direct route
Adjuvant activity
Cross-presentation
Antibody response Cellular response
CD4+ Th1 > Th2
CD8+
 
Fig. 1.2: Principle of genetic immunization. Administration of an antigen-encoding plasmid leads 
to transfection of muscle or skin cells or directly of APC. Transfer of the antigen to APC can also occur via 
cross-presentation, so that all arms of the immune response are induced. CpG sequences act as adjuvant 
supporting a Th1-like inflammatory response.  
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The flexibility of the vaccine is another advantage since elements of the plasmids can be 
altered easily using recombinant DNA technologies. Coexpression of cytokines or 
costimulatory molecules for example can enhance and modulate the immune response 
elicited (Iwasaki et al. 1997). Although the DNA acts as antigen depot, the immune 
response provoked by genetic immunization is usually weak compared to that induced by 
traditional vaccines (Donnelly et al. 1997). The effective transfer of the genetic material 
into immune cells represents the limiting factor of this method, indicating the need for new 
delivery systems. 
1.1.3.2 Live viral and bacterial carriers 
As alternative to plasmid DNA, attenuated or nonpathogenic bacteria (see section 1.2.1) 
and viruses can be engineered to carry foreign antigens. Gene-based vaccines consisting of 
recombinant viral vectors derived mainly from adenoviruses, poxviruses (e.g. vaccinia and 
the highly attenuated strain Ankara - MVA) and fowlpox are being investigated as vectors 
for DNA coding for heterologous antigens (Ada 2005). Techniques to incorporate foreign 
DNA into vaccinia virus were first described in 1982 (Mackett et al. 1982). Vaccinia 
viruses have a wide host range and can accommodate large amounts of DNA rendering 
them attractive for the development as multivalent vaccines. Viral vectors deliver DNA 
with more efficiency. Thereby they induce stronger immune responses than DNA vaccines 
alone (McConkey et al. 2003). However, drawbacks concerning preexisting and vector-
induced immunity that limit the effectiveness of the viral vaccine must be overcome for a 
broad application of this type of vaccine. In addition, viral vector vaccines are demanding 
in terms of manufacturing (Ulmer et al. 2006).  
1.1.3.3 Routes of immunization 
Needles and syringes are the most commonly used means for administration of vaccines 
and therapeutics (Mitragotri 2005). Despite their common use, needle-based 
immunizations have several limitations. They are stressful, laborious, dangerous when 
used improperly and above all cost-intensive. Moreover, most infections, including 
gastrointestinal, respiratory and sexually transmitted infections enter via mucosal surfaces. 
To prevent these infections, the induction of a mucosal immune response is required 
(Holmgren and Czerkinsky 2005). Parenterally administered vaccines are inefficient to 
induce a protective immune response against mucosal pathogens due to the 
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compartmentalization of the systemic and mucosal immune system (McGhee et al. 1992). 
Therefore it is important to develop vaccines that induce both systemic and mucosal 
immune responses and can be applied mucosally by the oral, nasal, rectal or vaginal route. 
The oral immunization route is particularly appealing, as it offers ease of administration, 
high patient compliance and a long history of use for live attenuated pathogens (Mitragotri 
2005). Oral delivery of vaccines was started almost 50 years ago with the oral polio 
vaccination. Several other needle-free vaccines (e.g. against Salmonella typhi, Vibrio 
cholerae and rotavirus) are now available (Neutra and Kozlowski 2006). However, the oral 
administration of most vaccines has proved to be challenging, especially for non-living 
vaccines (that is killed pathogens, subunit, protein and DNA vaccines). Problems like the 
inactivation of vaccines in the gastrointestinal tract and the requirement of high doses have 
to be faced. A multitude of vehicles are therefore explored for oral delivery of vaccine 
antigens, including transgenic plants (Kong et al. 2001), viral vectors (Sullivan et al. 2000) 
commensal or attenuated pathogenic bacterial strains (Green and Baker 2002) as well as 
various inert systems. Best known among the inert systems are lipid-based structures with 
entrapped antigens, such as liposomes and immunostimulating complexes (ISCOMS), and 
mucosa-binding proteins (e.g. the binding subunits of cholera toxin or E. coli enterotoxin) 
to which antigens have been linked either chemically or as gene fusion proteins (reviewed 
by Holmgren and Czerkinsky 2005).  
Another effort to replace administration by needles is direct application of the antigen with 
a strong adjuvant like cholera toxin to skin using a patch. This so-called transcutaneous 
immunization technique elicits rapid up-take of antigen by dendritic cells (Langerhans 
cells) in the epidermis and later presentation in the draining lymph nodes (Glenn et al. 
2000). 
1.1.3.4 Sequential immunization 
The idea of “boosting” immune response is as old as the use of vaccines. Repeated 
administrations with the same vaccine (homologous boosting) have been shown to be 
effective for humoral responses. This method is sometimes inefficient in case of cellular 
immunity since prior immunity to the vector impairs the generation of an immune response 
(Woodland 2004). In contrast to the approach of giving several doses of the same 
preparation of an antigen to enhance immune responses, the concept arose of priming with 
one formulation of an antigen and boosting with a different formulation (Ada 2005). It was 
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shown that mice immunized with a DNA preparation and later boosted with fowlpox virus 
both expressing the same antigen (influenza hemagglutinin) exhibited 50-fold higher anti-
hemagglutinin titers than those immunized with two injections of the same preparation 
(Ada 2001). The validity of this heterologous “prime-boost” approach has been confirmed 
and extended. Many strategies use DNA vaccines to prime and recombinant viral vectors 
as a booster. For example, priming with DNA and boosting with MVA induces cellular 
immunity against the malaria parasite Plasmodium falciparum (Schneider et al. 1998) and 
HIV (Amara et al. 2001). Heterologous prime-boost vaccination schemes starting with a 
bacille Calmette-Guerin (BCG) prime followed by a subunit boost consisting of protein, 
DNA or recombinant virus are also promising in tuberculosis vaccination schemes 
(Kaufmann and McMichael 2005).  
1.1.4 Immunotherapy 
Vaccines are, by definition, prophylactic. Besides preventing infectious diseases, the 
development of therapeutic treatments against cancer, chronic infections and autoimmune 
diseases is of utmost importance. Immunotherapy aims at mobilizing or manipulating a 
patient’s immune system to treat or cure disease (Steinman and Mellman 2004). Strategies 
range from mobilizing vaccines (so-called “active” immunotherapy) to administration of 
biological reagents such as monoclonal antibodies, cytokines or previously activated 
immune cells (“passive” immunotherapy). 
1.1.4.1 Therapeutic vaccines for chronic infections 
Some infectious microorganisms cause persistent infections due to evasion or subversion 
of immune control (Ada 2005).The treatment of such chronic infections including HIV, 
human papillomavirus (HPV) and hepatitis B and C virus (HBV/HCV) often fails due to 
ineffective antibiotic or antiviral therapy (Autran et al. 2004). Consequently, severe 
complications can occur – including immune deficiency caused by HIV, liver cirrhosis and 
hepatocarcinoma induced by HBV/HCV and cancer induced by HPV. Therapeutic 
vaccination is an alternative medical intervention that aims to prevent such severe 
complications by reinforcing host defenses. Vaccination is proposed to be most suitable 
after decreasing the pathogenic burden with antimicrobials (Zajac et al. 1998). Several 
different strategies are explored for the treatment of chronic infections including 
recombinant viral vectors, antigen-loaded dendritic cells (DC) (Wack and Rappuoli 2005) 
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as well as chemokines and cytokines used as adjuvants to enhance T cell function and 
maintenance (Autran et al. 2004). 
1.1.4.2 Therapeutic vaccines for cancer therapy 
There are two types of cancer from the vaccine standpoint. One type is associated with 
viral infections, such as genital carcinomas that are associated with HPV infections. 
Consequently, it was demonstrated that vaccination against the virus prevents 
tumorigenesis. The development of the recently licensed prophylactic HPV vaccine is the 
outstanding success story (Schiller and Lowy 2006). Other types of cancers amenable to 
vaccines include spontaneous tumors such as melanoma that express endogenous tumor 
antigens. Immune cells play an important role in the control of such malignancy 
(Shankaran et al. 2001). Innate immune cells respond to “danger” signals, which can be 
provided by growing tumors due to cell transformation and disruption of the surrounding 
microenvironment. Ideally, these signals induce inflammation, activation of innate effector 
cells with antitumor activity and stimulation of DC to present tumor-derived antigens and 
to trigger an adaptive immune response (reviewed by Blattman and Greenberg 2004). 
Tumors often exhibit strategies to escape this immunosurveillance, such as exclusion of 
immune cells from tumor sites, impairing antigen presentation by DC and poor 
immunogenicity due to reduced expression of MHC molecules and costimulatory proteins 
(Marincola et al. 2000). Even if a response is induced, tumor cells may escape elimination 
due to immunoediting, e.g. by losing targeted antigens or rendering reactive T cells anergic. 
In addition, breaking self-tolerance is an important challenge in developing cancer 
vaccines because the targets may be self-molecules as opposed to foreign antigens 
(Henderson et al. 2005).  
Therapeutic vaccines against cancer that manipulate T cell immunity can consist of tumor 
cells, lysates thereof or defined antigens. Antigens can be delivered as proteins, liposomes, 
by viral and bacterial vectors or ex vivo treated DCs (Yannelli and Wroblewski 2004). 
Since the preparation of antigen-loaded DCs from individuals with cancer is a laborious 
and costly procedure, it is desirable to develop vaccines, which deliver antigens and 
activation signals directly to DCs (Collins and Cerundolo 2004). An alternative to these 
immunogenic vaccines has been the isolation of autologous tumor-reactive T cells, 
expansion of cells in vitro and return into the patient. It is also possible to genetically 
modify T cells before infusion to increase tumor-specificity, tumor-homing and effector 
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functions (Kershaw et al. 2005). Moreover, strategies to manipulate the innate immune 
response by administration of adjuvants, cytokines or ligands for costimulatory proteins 
directly triggering innate immune cells have been developed (Blattman and Greenberg 
2004). As the global activation of the innate immune system often leads to toxicity, it is 
desirable to combine this approach with specific targeting of the tumor, e.g. provide 
effector molecules like TNFα specifically at the tumor site. Passive immunotherapeutic 
approaches have been explored in terms of humoral immunity, for instance the 
administration of monoclonal antibodies directed against cell-surface proteins on tumor 
cells (von Mehren et al. 2003). These antibodies can bind to tumors and activate effector 
cells, e.g. by mediating antibody-dependent cell-mediated cytotoxicity (ADCC), or 
interfere with tumor growth by blocking survival or inducing apoptotic signals. For 
example, a monoclonal antibody approved for clinical use reacts with the Her-2/Neu 
receptor on breast cancer cells thereby blocking growth signals (Rueckert et al. 2005).  
Despite these promising results in developing immunotherapeutic treatments for cancer a 
strong need for practical immunization strategies remains. In this respect, the use of 
bacteria as vaccine vectors and delivery systems for therapeutic molecules represents a 
very promising alternative.  
1.2 Bacteria as delivery systems for prophylactic and 
therapeutic molecules 
1.2.1 Bacteria as antigen delivery systems 
Antigen delivery systems often suffer from low efficiencies, safety concerns and/or 
demanding manufacturing processes. Moreover, it is desirable to develop carriers for 
mucosal application of vaccines to trigger appropriate immune responses against the vast 
amount of pathogens that enter the host via mucosal surfaces. In this respect, live bacterial 
vectors represent an alternative to the commonly used systems due to several advantages. 
First of all, they offer simple and inexpensive handling and production as well as the 
possibility to administer them as lyophilized organisms abrogating the need for a cold 
chain. Bacteria are easy to manipulate so that improved strains with desired properties can 
be generated in a short time. In addition, bacterial components, e.g. lipopolysaccharides, 
lipoproteins, flagella and bacterial DNA possess strong adjuvant properties as they are 
recognized via TLRs (Aderem and Ulevitch 2000). Another advantage is the ability to 
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control bacterial live vaccines with antibiotics in case of undesired side effects after 
administration.  
Enteropathogenic bacteria are the main group to be explored for the mucosal delivery of 
protein and DNA vaccines. They are able to enter the gut mucosa after oral application and 
target immune inductive sites of the lymphoid tissues of the gut and the periphery (Shata et 
al. 2000). Therefore, resembling a natural infection, oral immunization with such bacterial 
strains should stimulate the mucosal and systemic, humoral and cellular compartments of 
the immune system. Attenuation of these pathogenic strains can be accomplished through 
the deletion of different genes, including virulence, regulatory and metabolic genes. 
Thereby an appropriate balance between minimal toxicity and maximal immunogenicity 
has to be found in order to develop effective and safe carriers for delivering antigens to the 
immune system. The antigen can be encoded by a prokaryotic expression plasmid or 
chromosomally integrated and by this means expressed by the bacteria themselves. 
Alternatively, bacteria harboring eukaryotic expression plasmids can be used as carrier for 
genetic immunization.  
1.2.1.1 Bacteria-mediated delivery of heterologous antigens 
There are currently three live bacterial vaccines commercially available: Salmonella 
enterica serovar Typhi Ty21a, Vibrio cholerae CVD 103-HgR and Mycobacterium bovis 
BCG. These strains and many other commensal and attenuated strains have been used as 
vectors for the expression of foreign (heterologous) antigens derived from bacterial, fungal, 
viral or parasitic organisms (reviewed by Kotton and Hohmann 2004). The use of 
attenuated pathogens seems to be especially attractive, since the limited infection 
established by the attenuated strain leads to the induction of natural immune responses in 
the host specific for the carrier itself as well as the heterologous antigen (Medina and 
Guzman 2001). Live recombinant bacteria such as Salmonella spp. (see section 1.3.3.1), 
Vibrio cholerae (Butterton et al. 1995), Yersinia entercolitica (Gundel et al. 2003), 
Shigella flexneri (Koprowski et al. 2000), Escherichia coli (Critchley et al. 2004) and 
Listeria monocytogenes (Gentschev et al. 2000) have been explored as potential vaccine 
delivery systems for foreign antigens. Although such live bacterial vectors have been 
shown to induce humoral and cell-mediated immune responses against passenger antigens 
in animal and human studies, there are at this stage no licensed vaccines in clinical use.  
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In particular, the bacteria that are able to replicate and release antigen within the cytosol of 
host cells are attractive candidates for the elicitation of cell-mediated immunity against 
passenger antigens. Shigella flexneri is a gram-negative bacterium that targets the 
lymphoid tissues in the colonic mucosa and infects phagocytic and epithelial cells of the 
gut. Within host cells, it efficiently escapes the endosomes and directly accesses the 
cytoplasm (Cossart and Sansonetti 2004). The gram-positive bacterium Listeria 
monocytogenes exhibits similar properties as it expresses the pore-forming toxin 
listeriolysin O (LLO), which is activated at low pH and reducing environment in the 
phagosome (Gentschev et al. 2001). The bacteria are thus able to enter the cytosol, move 
around due to recruitment of host cell actin and spread from cell to cell (Tilney and 
Portnoy 1989). Shigella and Listeria are therefore able to replicate and grow within the 
cytosol of the eukaryotic host cell, where they are protected from extracellular and 
phagosomal immune responses (Mollenkopf et al. 2001). Consequently, secreted proteins 
can directly enter the endogenous MHC class I antigen processing pathway leading to the 
stimulation of CTL.  
1.2.1.2 Bacteria-mediated delivery of DNA  
Recently, intracellular bacteria have also been recognized as carriers for the delivery of 
eukaryotic expression plasmids to mammalian cells in vitro and in vivo. The first direct 
transfer of plasmid DNA from bacteria to mammalian cells was described in 1980 
(Schaffner 1980) when tandem copies of the SV40 virus genome carried by non-invasive 
E. coli were transferred into cocultured mammalian cells. Since then, several other, mostly 
invasive bacteria have been studied for gene transfer, most extensively recombinant 
Salmonella enterica spp. (see section 1.3.3.2), Shigella flexneri and Listeria 
monocytogenes (reviewed by Loessner and Weiss 2004). Using live bacterial carriers for 
genetic immunization combines the advantages and versatilities of both vaccination 
approaches. In addition, the amount of plasmid required for bacteria-mediated DNA 
transfer is small compared to injection of naked DNA, since bacteria directly target 
immune inductive sites of the host. Moreover, bacteria can be used to deliver therapeutic 
molecules (e.g. cytokines) or genes to complement genetic defects (Loessner and Weiss 
2004). In contrast to delivery of foreign proteins, delivery of DNA allows also the 
expression of post-translationally modified antigens (Devico et al. 2002). In comparison to 
most viral DNA carriers, bacteria are easy to manufacture and safe in use. The existence of 
established attenuated bacterial strains and effective antibiotics in case of complications 
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represent an important advantage over viral delivery systems (Schoen et al. 2004). In 
addition, the tissue tropism of certain bacteria can be employed for specific targeting. 
Cellular spreading occurs for instance in the case of Listeria and Shigella thereby reaching 
tissue layers in vivo that are potentially inaccessible to viral vectors.  
Salmonella spp.,
invasive E.coli
Listeria monocytogenes,
Shigella flexneri a
b
c
 
Fig. 1.3:  The intracellular tropism of bacterial DNA vectors. (a) Shigella and Listeria are 
cytosolic replicating bacteria that are able to escape the vacuolar compartment, replicate inside the host cell 
cytosol and spread to neighboring cells via protrusions and invaginations. DNA transfer occurs following 
lysis of the bacteria in the cytosol. (b) Intracellular bacteria like Salmonella and invasive E. coli remain in the 
phagosome where bacterial replication ensues, DNA transfer into the cytosol occurs by an unknown 
mechanism. (c) In both cases, the plasmid reaches the nucleus, where the antigen is transcribed and later, in 
the cytosol, translated into protein.  
The transfer of DNA from different bacteria to the nucleus of mammalian cells is 
hampered by several barriers (Fig. 1.3). After invasion of the host cell, Listeria and 
Shigella escape from the phagocytic vacuole to the cytoplasm, whereas invasive E. coli 
and Salmonella are localized in phagosomes (Schoen et al. 2004). In both cases, the release 
of the eukaryotic expression plasmid into the cytosol or the phagosome is a prerequisite for 
gene transfer. In order to achieve this, bacterial cell death and lysis has to occur. This can 
be induced due to the attenuation of the carrier, bacteriophage lysis components or 
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antibiotics (Loessner and Weiss 2004). Upon translocation into the nucleus of the host cell, 
the plasmid-encoded antigen is expressed and can induce humoral and cellular immune 
responses against bacterial, viral and tumor antigens (reviewed by Vassaux et al. 2006). 
The first functional gene transfer regarding subsequent production of a functional foreign 
protein was observed using an attenuated Shigella flexneri strain (Sizemore et al. 1995). To 
attenuate the bacterial vector, a deletion mutation in the asd gene encoding aspartate 
ß-semialdehyde dehydrogenase was introduced (Noriega et al. 1994). This essential 
enzyme is required to synthesize the bacterial cell wall constituent diaminopimelic acid 
(DAP). A lack of DAP leads to lysis of growing bacteria and release of macromolecules 
(Loessner et al. 2006). Using this modified strain, liberation of a ß-galactosidase reporter 
plasmid in human cells as well as subsequent expression of the plasmid encoded lacZ gene 
could be demonstrated in vitro (Sizemore et al. 1995). Various other metabolically 
attenuated strains of S. flexneri have been demonstrated to successfully deliver plasmid 
DNA in vitro in the meantime (Sizemore et al. 1997, Loessner and Weiss 2004). Since 
these bacteria are not invasive in the mouse intestine, intranasal application was used to 
investigate its potential as carrier for DNA vaccines in vivo. By this route, Shigella 
mediated delivery of DNA vaccines has been shown to induce cellular and humoral 
immune responses against a range of antigens (Sizemore et al. 1997, Fennelly et al. 1999, 
Vecino et al. 2004). 
Similarly, an attenuated L. monocytogenes strain has been engineered to undergo self-
destruction by production of a phage lysine under the control of the listerial promoter PactA, 
which is preferentially activated in the cytosol (Dietrich et al. 1998). This bacterial vector 
could deliver functional plasmids in mouse macrophage cell lines. In addition to these first 
experiments, in vitro gene transfer into a broad range of cells has been described for 
L. monocytogenes, including cell lines of epithelial origin, murine primary macrophages as 
well as human DCs (Hense et al. 2001, Krusch et al. 2002, Pilgrim et al. 2003). However, 
high bacterial doses were required to achieve DNA transfer. A recent study showed that 
such low rates of Listeria-mediated transfection are not due to poor invasion frequency, 
bacterial lysis or DNA degradation but to association of the plasmid DNA with 
macromolecules or organelles, which limits gene transfer to the nucleus and consequently 
its expression (Zelmer et al. 2005).  
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Alternatively, E. coli that are usually not invasive were manipulated to effectively deliver 
DNA to mammalian cells. Transformation of DAP-auxotroph E. coli with the virulence 
plasmid of S. flexneri rendered the bacteria able to enter epithelial cells and deliver plasmid 
DNA to their host cells (Courvalin et al. 1995). Grillot-Courvalin et al. further 
demonstrated that invasive E. coli carrying the invasion gene inv from Yersinia 
pseudotuberculosis were able to transfer DNA more efficiently than non-invasive bacteria 
(Grillot-Courvalin et al. 1998). Co-production of LLO together with the invasion gene by 
recombinant E. coli further increased the DNA transfer in vitro in several epithelial cell 
lines, indicating that bacterial escape from the phagosome might improve gene transfer 
efficiency. More recently, transfer of DNA using recombinant E. coli was also 
demonstrated in vivo (Castagliuolo et al. 2005).  
1.2.2 Bacteria in cancer treatment 
New effective and better tolerated cancer treatments are urgently needed. They should 
replace current relatively toxic regimes of chemo- and radiotherapy (Theys et al. 2003). In 
this respect, bacteria that are genetically engineered to express a specific therapeutic gene 
specifically in the tumor microenvironment represent a powerful treatment modality. The 
preferential accumulation of bacteria in certain experimental tumors was initially reported 
in the 1950s when spores of Clostridium tetani were shown to germinate exclusively in the 
tumor after intravenous administration into tumor-bearing mice (Malmgren and Flanigan 
1955). It was assumed that the obligate anaerobic bacteria were replicating in the 
necrotic/hypoxic centers of these tumors, leaving the well-oxygenated normal tissues 
unaffected. Thereafter, studies involving different strains of Clostridia led to the 
conclusion that bacterial growth was associated with “oncolysis” of large tumors with a 
necrotic/hypoxic centre but had little effect on metastatic lesions. Moreover, some animals 
became ill and died during the peak of oncolysis probably due to bacterial inflammation 
and the release of necrotic tumor debris (reviewed by Theys et al. 2003). In an initial 
clinical trial in humans using spores of Clostridia incapable of producing toxins, most 
patients showed no objective regression (Carey R.W. et al. 1967). Thus, further studies 
were abandoned due to the lack of clinical efficiency. Nevertheless, these initial studies 
have supported the idea to use bacteria for the selective delivery of anticancer agents to 
tumors.  
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More recently, investigators have attempted to use the tumor-targeting properties of 
Clostridia for the selective delivery of pro-drug converting enzymes (Minton 2003). For 
instance, the E. coli enzyme cytosine desaminase was expressed and shown to convert the 
non-toxic pro-drug 5-fluorocytosine (5-FC) into the toxic chemotherapeutic compound 
5-fluorouracil (5-FU). This product diffuses in the tumors and kills cancer cells through a 
bystander effect. Using a similar principle, a Clostridium strain was engineered in which a 
radio-responsive promoter drove the expression of TNF-α (Nuyts et al. 2001a).  
An optimized strain devoid of its lethal toxin (C. novyi-NT) could eradicate large 
established tumors in mice in the absence of additional chemotherapy and radiation due to 
the induction of a potent immune response (Agrawal et al. 2004). Once germinated within 
the tumor, these Clostridia destroy adjacent tumor cells through the secretion of 
degradative enzymes, at the same time the host reacts to the bacterial infection by 
producing cytokines that lead to the influx of inflammatory cells. The inflammatory 
reaction restricts on the one hand bacterial growth; on the other hand it may also contribute 
to the destruction of tumor cells. Moreover, it might stimulate a cellular immune response, 
which could destroy tumor cells not lysed by the bacteria. Whether a tumor is cured 
depends on the balance between bacteriolysis, angiogenesis, regrowth of residual tumor 
cells and the rate of development of the immune response (Agrawal et al. 2004). The same 
attenuated Clostridia strain and its membrane-disrupting properties was recently used to 
enhance the release of the liposome-encapsulated toxic drug doxorubicin within a tumor 
thereby mediating complete eradication of the established tumor (Cheong et al. 2006).  
Anaerobic Bifidobacteria have also been investigated and shown to colonize tumors. In 
contrast to Clostridia, Bifidobacteria are non-pathogenic bacteria found naturally in the 
digestive tract of humans and other mammals and therefore may represent a safer 
alternative compared to Clostridia (reviewed by Vassaux et al. 2006). First studies with 
Bifidobacteria described colonization of several types of mouse tumors after systemic 
administration. However, no antitumor effects could be observed (Kimura et al. 1980). 
More recently, strains of these bacteria were modified to produce cytosine desaminase and 
the antiangiogenic protein endostatin (Michl and Gress 2004). The latter approach resulted 
in inhibition of angiogenesis and retardation of growth of the tumor after systemic 
administration. In addition, oral administration of B. longum carrying the endostatin gene 
was efficient in a liver tumor model (Fu et al. 2005). 
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In contrast to anaerobic Clostridia and Bifidobacteria, facultative anaerobic bacteria have 
also been tested in tumors. They have the potential to colonize not only the anaerobic 
necrotic parts of the tumor but also oxygenated proliferative and quiescent tumor regions 
as well as metastatic lesions (Forbes et al. 2003, Saltzman 2005). Selective accumulation in 
tumors of immunocompromised and immunocompetent rodents has been observed after 
intravenous administration of Salmonella enterica serovar Typhimurium (S. typhimurium), 
the laboratory strain E. coli DH5α and attenuated Vibrio cholerae (Yu et al. 2004). Such 
bacteria were engineered to encode light-emitting proteins, which might be applied as 
diagnostic tool for the detection of tumors and metastases in the future. Invasive E. coli 
were used to deliver functional, natural E. coli proteins to mouse tumors (Critchley et al. 
2004). Thereby, a therapeutic effect of the product of the E. coli gene deoD was observed 
in association with the prodrug 6-MPDR (6-methylpurine-2’deoyriboside). However, the 
bacteria were injected directly into the tumor in this study. Thus, E. coli awaits to be 
explored in detail as vector for targeted delivery of therapeutic molecules to tumors. In 
contrast, extensive research is carried out using attenuated strains of S. typhimurium for 
tumor therapy, as discussed below. 
1.3 Salmonella as vectors for vaccination and tumor therapy 
Salmonella are gram-negative, facultative anaerobic, rod-shaped bacteria, which belong to 
the group Enterobactericeae and are established as one of the most important causes of 
food borne illness worldwide (Adams and Moss 2000). They are transmitted via the fecal-
oral route and depending on the species variant cause disease in animals or man. In humans, 
gastroenteritis, correlated with serovar Typhimurium and Enteritidis, and a systemic 
infection, provoked by serovar Typhi and Paratyphi, can be distinguished. Whereas 
gastroenteritis proceeds mostly harmless, serovar Typhi and Paratyphi belong to life-
threatening infectious agents (Ohl and Miller 2001). S. typhimurium is the causative agent 
of murine typhoid fever and serves as experimental model for human typhoid fever 
(Hapfelmeier and Hardt 2005). This mouse model has been of great importance for the 
investigation of virulence mechanisms and of immune responses against S. typhimurium.  
1.3.1 The course of a Salmonella infection 
After oral uptake, Salmonella pass the acidic environment of the stomach and reach the gut 
(Rychlik and Barrow 2005). Invasion of the gut mucosa occurs mainly via M cells of the 
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follicle-associated epithelium (FAE) in the Peyer’s Patches (PP) of the ileal portion of the 
small intestine as ports of entry (Jones et al. 1994). M cells are specialized for the 
transepithelial up-take of macromolecules, particles and microorganisms, such that 
antigens can cross the epithelial barrier of the gut and induce mucosal immune responses 
(Neutra et al. 1996). Salmonella selectively adhere to M cells and initiate signal 
transduction pathways that induce their uptake and subsequent translocation to the 
basolateral side of the epithelial cell (Fig. 1.4).  
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Fig. 1.4: Course of a Salmonella infection. (a) Salmonella are taken up by M cells (M) of the PP 
and (b) invade DC and macrophages (Mp) in the subepithelial dome (SED). (c) Dead macrophages are 
phagocytosed by DC. (d) Infected DC stimulate T cells (CTL, Th). (e) Direct uptake of Salmonella by 
intraepithelial DC. (f) Secretion of Salmonella-specific antibodies by B cells (B). (g) Migration of infected 
phagocytes to other organs. 
This event is triggered by genes located on Salmonella pathogenicity island 1(SPI-1), a 
distinct region of the Salmonella chromosome (Cossart and Sansonetti 2004). SPI-1 
encodes a type III secretion system (TTSS) that is expressed due to high osmolarity and 
low oxygen tension when the bacteria are moving extracellularly in the gut lumen before 
the first encounter with host cells. Therefore, the bacteria target the M cells as “loaded 
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weapons” equipped with the syringe-like TTSS apparatuses as well as a pre-formed pool of 
effectors (Schlumberger and Hardt 2006). Upon encounter of M cells, the effector proteins 
are delivered into the host cell cytoplasm by the translocon complex consisting of proteins 
SipB and SipC. The injected effectors reorganize the cytoskeleton of the cell to cause 
localized membrane ruffling, bacterial engulfment into membrane-bound vesicles and 
transcytosis (Ohl and Miller 2001). After transcytosis, the bacteria reach the dome area of 
the organized mucosa associated lymphoid tissue (MALT), which is the inductive site of 
the mucosal immune system (Brandtzaeg and Pabst 2004). Here, bacteria are taken up by 
phagocytic cells, mainly resident and recruited macrophages and DC (Richter-Dahlfors et 
al. 1997). Alternatively to this process, Salmonella can also directly enter intestinal cells by 
the apical pole of the cell (reviewed by Abrahams and Hensel 2006) or be captured by DC 
that emit pseudopods between epithelial cells (Rescigno et al. 2001).  
During evolution, Salmonella have developed several strategies to resist innate immune 
defenses to survive phagocytosis and establish infection. Initially, Salmonella can cause 
macrophage apoptosis through activation of caspase-1, thereby also triggering the 
production of pro-inflammatory cytokines like IL-1ß and IL-18 (Hueffer and Galan 2004). 
The elicited inflammatory reaction leads to the recruitment of polymorphonuclear cells 
(PMN) and simultaneously disintegrates the epithelial lining to allow their transmigration 
to the gut lumen. At the same time inflammation helps bacteria to cross the epithelial 
barrier (Sansonetti 2004). Additionally, Salmonella express a second TTSS encoded in 
SPI-2, which is of key importance for their ability to replicate and survive inside host cells 
(Schlumberger and Hardt 2006). Different regulatory systems are responsible for the 
activation of the second TTSS within the vacuolar environment were Salmonella resides 
(Bijlsma and Groisman 2005). First, the SPI-2 encoded local regulatory system SsrA/B, 
which is activated by low Ca2+ levels, acidic pH and low osmolarity, induces genes 
encoding the components of the SPI-2 TTSS and SPI-2 effectors (Garmendia et al. 2003). 
Furthermore, the global regulatory system PhoP/Q has been identified to modulate the 
expression of SPI-2 genes by regulating expression of the regulator SsrB (Bijlsma and 
Groisman 2005). The transcriptional regulator PhoP itself is activated by PhoQ mediated 
phosphorylation that occurs when the sensor protein PhoQ encounters low Mg2+ levels in 
the vacuolar environment (Lejona et al. 2003).  
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The second TTSS allows injection of effector proteins from the phagosome into the host 
cell cytoplasm, thereby enabling bacteria to modify the vacuole into a Salmonella-
containing vacuole (SCV). A key role plays the SPI-2 effector SifA, which is required for 
the recruitment of vesicles to increase the amount of SCV membrane in order to avoid 
rupture of the vacuole and transition into a lysosome (Cossart and Sansonetti 2004). This 
strategy allows further dissemination via infected phagocytes to deep organs, such as 
lymph nodes, liver and spleen. 
The cells of the innate immune system play an essential role in the early responses to 
Salmonella, especially macrophages and polymorphonuclear neutrophils 
(Vassiloyanakopoulos et al. 1998). Stimulation of these cells by ligands of TLR (e.g. LPS, 
lipoprotein, flagellin) and Salmonella effectors gives rise to pro-inflammatory cytokines 
including IFN-γ and TNF-α (Galan 2001). IFN-γ and TNF-α lead to activation of anti-
microbial effector mechanisms and impair bacterial replication within macrophages (Gulig 
et al. 1997). Although the innate immune system can initially control Salmonella infection, 
the acquired immune response is required for clearance of the infection as well as for 
protection against reinfection (Mittrucker and Kaufmann 2000). T cells are of special 
importance, particularly Th1 CD4+ cells, whose induction is stimulated by the pro-
inflammatory cytokine environment (Pie et al. 1997). In addition to T cell-mediated 
immunity, the production of antibodies has been proposed to be important in mediating 
immunity to Salmonella (Mittrucker et al. 2000). The induction of Salmonella-specific 
CD4+ T cells and CD8+ T cells is dependent on the capacity of DC to process Salmonella 
antigens for presentation on MHC class I and MHC class II (Svensson et al. 1997, 
Svensson et al. 2000, Yrlid and Wick 2002). Thus, Salmonella-infected DC in the 
subepithelial dome (SED) of the PP migrate to the interfollicular region to present the 
antigen to T cells (Ravindran and McSorley 2005). Moreover, Salmonella-induced 
apoptosis of macrophages provides a reservoir of antigens that can be presented by 
bystander DC on MHC-I and MHC-II (Yrlid and Wick 2000), a process called cross-
presentation. In addition, Salmonella entry into the PP may lead to the release of soluble 
bacterial antigens into the SED, which can be acquired by DC and presented or 
alternatively result in activation of Salmonella-specific IgA secreting B cells (Ravindran 
and McSorley 2005). Migrating DC may also lead to the generation of systemic responses. 
Thus, during infection, a bacteria specific effector population expands rapidly in lymphoid 
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tissues and redistributes effectively to the major sites of bacterial infection mediating 
bacterial clearance (Mittrucker and Kaufmann 2000). 
1.3.2 Attenuation of Salmonella for the use as live vector 
Previously, inactivated whole-cell vaccines have been used to provide protection against 
typhoid fever in man. Due to the high incidence of adverse reactions, these vaccines are 
considered to be unsuitable for use as public health vaccines. The licensed live attenuated 
oral vaccine strain S. enterica serovar Typhi strain Ty21a has provided an alternative 
(Germanier and Fuer 1975). This strain was generated by chemical mutagenesis and has 
been evaluated in several efficacy trials and shown to be safe and effective, though it 
requires several doses to elicit protection (Levine et al. 1987, Ferreccio et al. 1989, Black 
et al. 1990).  
The mouse typhoid model was extensively used in the search for attenuated strains with 
defined mutations (Pasetti et al. 2003). Recent progress in the understanding of the 
genetics of Salmonella virulence as well as recombinant DNA technology helped 
identifying target genes involved in house-keeping, biosynthesis of structural components 
and metabolites, pathogenesis, and bacterial resistance to host-defense mechanisms 
(Garmory et al. 2002). Target genes for the development of S. typhimurium vaccine strains 
include heat-shock protein htrA (Chatfield et al. 1992b), global regulatory components 
cya/crp and phoP/phoQ (Curtiss, III and Kelly 1987, Galan and Curtiss, III 1989, 
Mastroeni et al. 2001), amino acid biosynthesis pathway aro (O'Callaghan et al. 1988) and 
the transcriptional regulator rfaH (Nagy et al. 2006). Such attenuated strains invade the gut 
mucosa and reach the MALT as well as lymph nodes and spleen thereby inducing a 
protective immune response protecting against a challenge infection. But they do not cause 
adverse clinical responses or bacteremia. 
Mutations in the bacterial prechorismate pathway belong to the best characterized 
attenuations for Salmonella vaccine strains. Prechorismate or aro mutants do not produce 
chorismate, an essential intermediate in the de novo synthesis of aromatic compounds 
including aromatic amino acids (Dunstan et al. 1998). Salmonella typhimurium strain 
SL7207 ∆aroA carries a non-reverting mutation in the gene aroA encoding for the enzyme 
5-enolpyruvylshikimate-3-phosphate synthase, which results in a block of the aromatic 
biosynthesis pathway (Hoiseth and Stocker 1981). This mutation renders the bacteria 
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auxotrophic for the metabolites para-aminobenzoic acid and 2, 3-dihydroxybenzoate that 
are synthesized from chorismate. Since these compounds are not available in vertebrate 
tissues, such auxotrophic mutants cause only a mild infection, after which the bacteria are 
cleared by the immune system (Hormaeche 1991). Nevertheless, these derivatives confer 
protection against challenge with a virulent strain (Hoiseth and Stocker 1981) showing 
their suitability as live vaccine. In addition, the safety of such live vaccines can be 
increased by introducing a mutation in a second locus thereby reducing the odds of 
reversion (Karem et al. 1995). As established live vaccines, Salmonella are promising 
candidates for the delivery of foreign proteins and DNA for vaccination and therapeutic 
applications. 
1.3.3 Salmonella as antigen delivery system 
Orally administered live attenuated Salmonella ssp. are promising delivery systems since 
they are safe and highly immunogenic and can elicit long-lasting protective systemic and 
mucosal immune responses against heterologous antigens (Bumann et al. 2000). Moreover, 
they have been extensively studied regarding the delivery of DNA (reviewed by Loessner 
and Weiss 2004). For both applications it is advantageous that Salmonella can be 
genetically manipulated by simple means. When applied orally, such recombinant 
attenuated vaccine strains harboring either eukaryotic or prokaryotic expression plasmids 
invade the gut mucosa and eventually reach the MALT. Here, they target professional APC, 
therefore delivering the cargo directly to immune inductive sites (Fig. 1.5).  
Bacterial components lead to activation of the phagocytic cells, which involves production 
of cytokines, expression of co-stimulatory molecules and surface expression of MHC 
molecules (Blander and Medzhitov 2006). At the same time, the bacteria reside in the 
phagosomal compartment until they die due to their metabolic attenuation or host cell 
defense mechanisms (Darji et al. 2000). In case of protein delivery, the passenger antigens 
are processed for presentation on MHC class I and MHC class II by activated DC. In case 
of DNA delivery, the expression plasmid is liberated after bacterial lysis and transferred to 
the nucleus (Loessner and Weiss 2004). Expression of the antigen leads to presentation on 
MHC class I and the stimulation of CTL by activated DC. In addition, DC can present 
antigen via cross-presentation after phagocytosis of apoptotic infected macrophages, thus 
efficiently inducing also helper T cells (Darji et al. 1997). Free antigen from dying 
macrophages might also be responsible for the induction of humoral responses. Infected or 
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antigen-carrying DC, migrating from PP to lymph nodes and spleen via the bloodstream 
and lymphatics, most likely cause systemic immune responses. 
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Fig. 1.5:  Principles of Salmonella-mediated delivery of DNA or proteins. Attenuated Salmonella 
are transformed with a eukaryotic (a) or prokaryotic (b) expression plasmid for the delivery of DNA or 
protein, respectively. After infection of the APC, Salmonella die within the phagosome due to the attenuation 
leading to liberation and transfer of the DNA vaccine to the nucleus (c) and subsequent expression and 
presentation of the antigen (d, f). In case of protein delivery, the passenger antigen is expressed by the 
bacteria (e) and after bacterial lysis presented (f). 
1.3.3.1 Salmonella-mediated delivery of heterologous antigens 
Salmonella were among the first bacteria used as recombinant vectors for antigen delivery 
(Curtiss, III 2002) and up to now numerous studies have been performed in mice and man. 
In mice, there is an increasing body of evidence suggesting that live attenuated 
S. typhimurium constitute an effective delivery system for recombinant antigens from a 
wide variety of pathogens (Garmory et al. 2003) including parasitic, bacterial and viral 
antigens (Ben Yedidia et al. 1999, Igwe et al. 2002, Baud et al. 2004). The recombinant 
Salmonella have been shown to elicit humoral, secretory and cell-mediated immunity, 
thereby conceivably providing the capability to elicit the immune responses necessary for 
the protection against the heterologous antigen (Mollenkopf et al. 2001). Most of these 
studies used oral, intraperitoneal or intravenous immunizations, but alternative mucosal 
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routes such as intranasal, vaginal and rectal have also been employed successfully (Pasetti 
et al. 2003). However, human clinical trials using S. typhi showed mixed results so far 
(reviewed by Garmory et al. 2002). Some vaccines were able to induce detectable immune 
responses against heterologous antigens while others have not. In a human study with 
phoP/phoQ-deleted S. typhimurium expressing H. pylori urease, oral immunization 
induced urease-specific immune responses in 50% of the volunteers (Angelakopoulos and 
Hohmann 2000) in contrast to a previous trial with phoP/phoQ-deleted S. typhi expressing 
the same antigen (DiPetrillo et al. 1999). This could probably be attributed to a greater 
stability of the antigen-expressing plasmid in the S. typhimurium carrier and/or prolonged 
intestinal colonization.  
Stability of the recombinant phenotype is one of the major limitations that have been 
encountered during the development of Salmonella for the delivery of foreign antigens. An 
efficient vaccination depends on the ability of the vector to present the foreign antigen to 
the immune system in a stable manner and sufficient amount, since immune responses are 
generally dose-dependent (Zinkernagel et al. 1997). On the other hand, vigorous antigen 
expression represents an additional metabolic burden for the bacteria, especially when 
plasmid-based systems are used, resulting in plasmid loss, reduced viability, invasiveness 
and immunogenicity (Medina and Guzman 2001). Other problems besides plasmid 
stability include low immunogenicity of the antigen due to its location and vector 
immunity against Salmonella, whereby the latter is controversial. Reports suggested that 
prior experience with the vaccine strain might be able to potentiate subsequent immune 
responses (Bao and Clements 1991, Whittle and Verma 1997), whereas other studies 
showed impaired immune responses in situations of pre-existing immunity (Attridge et al. 
1997, Attridge and Vindurampulle 2005). Thus, this issue requires further studies in order 
to understand the impact of vector immunity for the further use of Salmonella as carrier for 
heterologous antigens but also plasmid DNA. 
1.3.3.2 Salmonella-mediated delivery of plasmid DNA 
Salmonella remains in the endosomal compartment of infected cells. Therefore it is 
puzzling how these bacteria transfer eukaryotic expression plasmids to host cells and 
consequently mediate a high level of reporter gene activity (Darji et al. 1997, Paglia et al. 
1998). Oral administration of a single dose of the auxotrophic mutant strain SL7207 
bearing the plasmid-encoded lacZ gene under control of the cytomegalovirus (CMV) 
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immediate-early promoter elicited high levels of ß-galactosidase specific antibodies, T cell 
proliferation and CTL response in BALB/c mice (Darji et al. 1997). In comparison, the 
Salmonella DNA vaccine induced superior immune responses than recombinant bacteria 
expressing the same antigen constitutively at high levels. In the same study, protection of 
mice against a lethal challenge with L. monocytogenes was observed using the virulence 
factor LLO as antigen. These findings could be confirmed in outbred strains and mouse 
strains more resistant to Salmonella than BALB/c mice, although several administrations 
of the bacteria were needed to induce CTL, T-helper cell and antibody responses (Darji et 
al. 2000). In this study, Salmonella-mediated genetic immunization induced strong 
systemic humoral and cell-mediated immune responses after oral application, but hardly 
any antigen specific secretory IgA antibodies could be detected. Thus, the cells that are 
transfected by Salmonella in the PP  might not initiate antibody production and/or the 
switch of B cells to IgA (Urashima et al. 2000). Viral infections have also been targeted 
through DNA vaccination by S. typhimurium. Oral immunization with a strain encoding 
hepatitis B virus surface antigen has been shown to elicit CTL in BALB/c mice (Woo et al. 
2001). Moreover, vaccination against HIV was attempted using Salmonella carrying a 
eukaryotic expression plasmid encoding HIV env (Shata et al. 2001). Again, oral 
administration of the recombinant bacteria led to the activation of antigen-specific CTL 
responses both in systemic and mucosal lymphoid tissue. Furthermore, Salmonella-
mediated oral DNA delivery was applied for the vaccination against fungi and parasites as 
well as for the treatment of monogenic defects (reviewed by Loessner and Weiss 2004). 
Salmonella strains have also been used for the delivery of plasmid DNA encoding tumor 
antigens. In the first instance, “model” tumor antigens such as ß-galactosidase were 
encoded in eukaryotic expression plasmids such that the oral application of bacteria 
carrying these plasmids conferred protection against challenges with tumor cells 
expressing the relevant model antigen. For example, strain SL7207 transformed with 
plasmid pCMVß was shown to induce protection against a fibrosarcoma cell line that 
stably expressed lacZ (Paglia et al. 1998). The next studies assessed the efficacy of 
Salmonella to transfer autologous tumor antigens, which were expressed by the tumor 
itself but also by normal tissues. In this case, successful protection was observed with 
transgenes such as melanoma-associated antigen gp100 fused to the invariant chain and 
epitopes of gp100 and melanoma-associated antigen TRP2 fused to ubiquitin (Xiang et al. 
2000, Weth et al. 2001). This suggested that Salmonella-mediated DNA vaccination can 
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overcome immunological tolerance against self antigens, maybe due to bacterial danger 
signals resulting in enhanced stimulation of the immune system. Moreover, tumor-targeted 
coadministration of IL-2 further enhanced the protective effect of the immunization (Xiang 
et al. 2000). Alternatively, cotransformation of a second plasmid encoding secretory IL-18, 
a cytokine known to suppress angiogenesis and to stimulate INF-γ production, resulted in a 
stronger antitumor effect in a murine breast cancer model than vaccination with Salmonella 
carrying only the tumor antigen plasmid (Luo et al. 2003).  
To circumvent the problem of targeting genetically unstable tumor cells, an interesting 
novel approach has been used to target stable, proliferating endothelial cells in the tumor 
vasculature in order to inhibit angiogenesis. Strong cellular immune responses were 
elicited against these cells by vaccinating with Salmonella carrying a plasmid containing 
the vascular-endothelial growth factor receptor 2 (Niethammer et al. 2002). The study 
showed that protection against tumor challenge and reduced growth of metastases in a 
therapeutic setting could be achieved. Furthermore, this effect was enhanced, when the 
plasmid additionally encoded the IL-12 gene (Feng et al. 2005). 
Several prerequisites have to be fulfilled in order to efficiently transfer DNA to host cells. 
The Salmonella carrier has to stably maintain the expression plasmid preferably in a high 
amount until invasion of the host cell takes place. Thereafter, the plasmids have to be 
released from the phagocytic compartment into the cytosol after lysis of the carrier strain, 
probably via leakage from host cell phagosomes (Schoen et al. 2004). The transfer of 
plasmid DNA from the bacteria into the cytosol and nucleus is still puzzling. Notably, cell 
specificity has been observed in Salmonella’s ability to mediate DNA transfer in vitro. 
Salmonella was found to transfect primary macrophages and DC (Darji et al. 1997, 
Dietrich et al. 2001b), whereas transfer into established cell lines was rather inefficient 
(Darji et al. 1997, Grillot-Courvalin et al. 2002). Thus, maybe host cell-specific pathways 
are exploited by the bacteria for the transfer of plasmid DNA into the cytosol (Weiss 2003). 
Finally, once released from the carrier, the plasmid has to enter the nuclear compartment 
for transcription. Therefore, beside inefficient release from the phagosome and detrimental 
effects of cytosolic as well as bacterial nucleases, this import constitutes an important 
obstacle in the transfection process. In summary, these different parts of the DNA transfer 
constitute starting points for the improvement of Salmonella as delivery system of DNA 
(see section 1.4).  
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1.3.4 Salmonella in cancer treatment 
Besides using oral Salmonella-mediated DNA vaccination in tumor models, their capacity 
to preferentially target and replicate in tumor tissue has also been used in tumor therapy. 
This capacity was first demonstrated in 1997, when injected auxotrophic Salmonella were 
shown to specifically accumulate in the malignant tissue of tumor-bearing mice (Pawelek 
et al. 1997). The ratio of bacteria in the tumor to bacteria in normal tissues ranged between 
250:1 and 9000:1 and this accumulation was accompanied by retarded tumor growth. 
Other studies have confirmed these findings and shown that attenuated Salmonella have 
bacteriolytic activity (Saltzman 2005). The precise molecular mechanisms for this anti-
tumor effect are not known, but since SPI-1 mutant bacteria retain antitumor activity, it 
was suggested that invasion of the cancer cells seems not to be involved (Pawelek et al. 
2002). In contrast, another group reported that infected tumor cells present antigens of 
bacterial origin and become targets for Salmonella-specific T cells (Avogadri et al. 2005). 
Additionally, massive recruitment of innate and adaptive effector cells at the site of 
infection and Salmonella-induced cross-presentation of tumor antigens were proposed to 
contribute to the antitumor activity. However, to amplify this effect, strains capable of 
delivering therapeutic molecules such as the herpes simplex thymidine kinase protein 
(Pawelek et al. 1997), endostatin (Lee et al. 2004) and thrombospondin-1 (Lee et al. 2005) 
have been produced.  
A safety barrier for the utilization bacteria as systemically administered anticancer agents 
in humans is that they often massively stimulate TNF-α induction, which could lead to a 
cytokine cascade responsible for septic shock (Clairmont et al. 2000). In gram-negative 
bacteria this effect is mediated by lipid A, a component of the bacterial cell wall. By 
disrupting the msbB gene encoding myristil transferase, which is involved in the synthesis 
of this lipid, TNF-α induction could be reduced without losing the tumor-targeting and 
tumor-inhibiting properties (Low et al. 1999). VNP20009, a safe attenuated strain of 
S. typhimurium was generated that harbors deletions in the purI gene and msbB gene and 
remains susceptible to antibiotics (Clairmont et al. 2000). In initial clinical trials, this strain 
showed tumor colonization but no tumor regression was observed (Toso et al. 2002), even 
when a pro-drug converting enzyme was expressed (Nemunaitis et al. 2003).  
Both bacterial and tumor-related factors have been implicated for the preferential 
accumulation of Salmonella in tumors. Within the tumor, areas of necrosis and apoptosis 
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may provide additional nutrients such as purines that are required by the auxotrophic strain 
(Mengesha et al. 2006). Likewise, Salmonella may exploit the hypoxic microenvironment 
(Anderson et al. 2006). Chemoattractive compounds produced by quiescent tumor cells 
have also been shown to contribute to the preferential accumulation (Kasinskas and Forbes 
2006). Moreover, the tumor may provide an immunosuppressive environment, which 
protects bacteria from effectors of the immune system (Low et al. 1999). However, 
following the administration of Salmonella to tumor-bearing animals, also normal tissues 
are colonized, albeit transiently and to a lesser extent. In case of constitutive expression of 
therapeutic genes this might cause adverse side effects. Thus, it would be desirable to use 
regulated promoters that can be turned on either specifically in tumors or at certain time 
points when the bacteria have been cleared from normal tissues.  
1.4 Improvement of Salmonella as delivery system in 
vaccination and tumor therapy 
The development of Salmonella as delivery vector for therapeutic and prophylactic 
molecules has faced several problems, which resulted in vaccine failure or inefficient 
tumor therapy. However, progress in recombinant DNA technology and in the 
understanding of Salmonella pathogenicity as well as the generation of immune responses 
have provided solutions at least to some of these problems. Thus, a number of strategies 
hold promise for the improvement of the bacterial carrier and/or the properties of the cargo. 
1.4.1 Attenuation of the bacterial carrier 
Besides intrinsic properties of the antigen, the background of the carrier strain and the type 
of mutation selected to achieve attenuation critically affect the extent and quality of 
elicited immune responses (Dunstan et al. 1998, Valentine et al. 1998). Depending on the 
attenuating mutation specific types of immune responses can be stimulated (Medina et al. 
1999). For example, a Salmonella PhoP mutant promotes potent innate immune responses 
of macrophages that are sufficient for host defense (VanCott et al. 1998). This mutant is 
more efficiently processed by macrophages in vitro than wild-type bacteria (Wick et al. 
1995). In contrast, administration of an aroA attenuated strain elicits stronger antibody and 
T-helper cell responses, wherein Th1 T cells are required for clearance of the bacteria 
(VanCott et al. 1998). Thus, the type of immune response induced against the antigen can 
be already influenced by selecting an appropriate attenuation of the strain. Alternatively, 
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the type of mutation can also affect the ability of Salmonella to transfer the cargo. 
Salmonella with a sifA deletion can not preserve the SCV and have been shown to be more 
efficient in delivering eukaryotic expression plasmids in vitro than the wild-type 
counterpart (Michael et al. 2004, Petrovska et al. 2004). Moreover, increased specificity of 
the growth in tumor tissue could be recently achieved by creating Leu/Arg-dependent 
auxotrophic Salmonella mutants (Zhao et al. 2005, Zhao et al. 2006). These mutants were 
cleared from normal tissue even in immunodeficient mice, whereas the tumors were still 
colonized. Moreover, Salmonella were found to be dispersed throughout the malignant 
tissue and not only confined to necrotic tumor areas.  
1.4.2 Stability of the recombinant phenotype 
The instability of recombinant plasmids within the bacterial carrier is a serious problem in 
Salmonella-mediated delivery of heterologous proteins and DNA. Plasmid replication and 
retention represent a high metabolic burden for the bacteria (Galen and Levine 2001), 
potentially compromising the growth rate, fitness, persistence and immunogenicity. Studies 
with E. coli have established that plasmid-bearing bacteria grow more slowly than 
plasmid-less bacteria (McDermott et al. 1993). During biotechnological production steps, 
antibiotic selection keeps the pressure in favor of plasmid retention, but high-copy 
plasmids are often unstable in vivo leading to segregational loss of the foreign antigenic 
determinant and consequently to suboptimal vaccination or therapy (Spreng and Viret 
2005). One possible solution of this problem is to integrate heterologous antigen-encoding 
genes into the chromosome of the Salmonella carrier. This approach increases the stability 
of the expression cassette but the amount of antigen may be insufficient to generate an 
efficient immune response (Hone et al. 1988, Strugnell et al. 1990, Cardenas and Clements 
1993). Therefore, for ease of manipulation and copy number effects, plasmids are 
preferable which are stable in vivo and possess a copy number sufficient for the induction 
of an immune response without compromising fitness of the vector.  
Plasmid-intrinsic properties, such as origin of replication, copy number, size and 
complexity can affect the plasmid retention by the bacterial carrier. For example, with 
increasing size of the plasmid, its stability decreases (Galen and Levine 2001). In addition, 
a relationship between plasmid stability and the copy number has been observed in vitro 
and in vivo (Dunstan et al. 2003). In this study, high-copy number prokaryotic expression 
plasmids were rapidly lost from the bacteria, whereas a reduction in copy number reduces 
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metabolic burden and consequently enhances plasmid retention. Moreover, the level of 
antigen-specific antibody induced by Salmonella directly correlated with the stability of 
the expression plasmid. Similarly, the effect of copy number was addressed in Salmonella-
mediated delivery of DNA vaccines (Bauer et al. 2005). By exchanging the high-copy 
number pUC origin of replication of plasmid pCMVß with different low-copy number 
replicons (pMB1, p15A and pSC101) the plasmid stability could be increased both in vitro 
and in vivo. This increased stability of the eukaryotic expression plasmids resulted in an 
enhancement of antigen-specific CD4+ and CD8+ T cell and antibody responses even after 
a single oral immunization. On the other hand, the copy number should be as high as 
possible, since a very low-copy number plasmid induced weaker immune responses, 
despite being stably retained in Salmonella. Therefore, strategies that enhance antigen 
expression in vivo, e.g. a system for inducible amplification of copy numbers, have to be 
considered (Fig. 1.6). Such an approach allows maintenance of the plasmid copy number at 
low levels during culture of the vaccine strain. At a certain time point, e.g. upon entry of 
target cells, the plasmid copy number is increased. This strategy minimizes the metabolic 
burden of the bacteria during the invasion phase and is therefore suited for the 
improvement of Salmonella as carrier for therapeutic and prophylactic molecules. 
inoculum in vivo
Ag
 
Fig. 1.6: Strategy for inducible plasmid amplification in a Salmonella vaccine strain. The 
plasmid is amplified starting from a minimal number in the inoculum to a high-copy number in vivo. Thus, 
sufficient plasmid DNA and antigen is provided. 
As alternative to antibiotic resistance markers whose selective pressure is absent in vivo, 
balanced lethal stabilization systems have been developed (Spreng and Viret 2005). These 
systems are based on expression plasmids, which encode a gene that complements a defect 
of the carrier strain in trans. The asd system is a classic example for that approach 
(Nakayama 1988, Galan et al. 1990, Tacket et al. 1997, Nayak et al. 1998). The deletion of 
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the chromosomal asd gene that is required for cell wall synthesis results in absolute 
requirement for DAP. Since DAP is not found in mammalian tissue, only Salmonella 
carrying a plasmid that complements this defect are able to survive in the host. This does 
not solve the problem of general instable plasmids per se, but overgrowth of plasmid-less 
bacteria is prevented. Moreover, it abrogates the need for antibiotic resistance genes as 
selective markers. The criteria for live vaccines by the Food and Drug Administration 
(FDA) prohibit the use of resistance genes, since they may spread to pathogenic organisms 
in the environment (Garmory et al. 2002). Besides the asd system, balanced lethal systems 
based on the thyA gene have been explored (Morona et al. 1991, Yoshikawa et al. 1995). 
The thyA gene encodes the enzyme thymidilate synthase, which plays a key role in the de 
novo DNA synthesis. Mutants that lack the enzymatic activity are dependent on exogenous 
thymidine or thymine (Ross et al. 1990), thus undergoing “thymidineless death” without 
such nutrients (Ahmad et al. 1998).  
1.4.3 Targeting of antigen delivery 
Heterologous antigens that are expressed in the cytoplasm of the bacterial carrier are only 
accessible to the immune system after disintegration of the bacteria. In addition, 
conventional antigen expression might lower the genetic stability of the vaccine strain due 
to intrinsic toxicity of the antigen or reduce the immunogenicity due to rapid degradation 
of the candidate antigen. To circumvent this problem, several systems for the secretion of 
antigens into the extracellular milieu or the expression of foreign proteins on the surface of 
the vector have been developed. The latter include insertion of the antigen into cell surface 
proteins of Salmonella, such as flagellar components (Newton et al. 1989) and outer 
membrane proteins (Isoda et al. 2007). Furthermore, autotransporter secretion pathways of 
gram-negative bacteria have been employed for surface display of antigenic determinants 
in Salmonella vaccine strains (Kramer et al. 2003). Autotransporters are expressed as a 
single polypeptide chain that provides all functions necessary to translocate a passenger 
antigen and to display it on the bacterial cell surface. Consequently, antigen expression via 
the MHC class II pathway occurs when the antigen is displayed by Salmonella residing in 
the phagosome. Fusion of the antigen to the autotransporter domain of the E. coli adhesion 
involved in diffuse adherence AIDA-I resulted in high genetic stability of the vaccine 
strain and in a pronounced Th1-biased MHC class II restricted cellular immune responses 
(Kramer et al. 2003). Foreign antigens may also be secreted by the use of signal sequences. 
A popular system is the hemolysin A (HlyA) export-expression system of uropathogenic 
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E. coli (Gentschev et al. 2002). Heterologous antigens are linked at their carboxyl terminus 
to the secretion signal of HlyA and secreted by the hemolysin type I secretion apparatus. A 
variety of antigens of bacterial, viral and parasitic origin have been expressed and secreted 
in attenuated Salmonella spp., thereby triggering humoral and/or cell-mediated immune 
responses. In the murine listeriosis model a superior protective efficacy of secreted versus 
somatic LLO expression was observed (Hess et al. 1996).  
Antigen secretion by a phagosomal vaccine carrier like Salmonella preferentially induces 
CD4+ T cell responses. In contrast, direction of antigens to the cytosol will consequently 
enhance the capacity of the vector to induce CTL responses. For example, Salmonella were 
modified to secrete active LLO fused to the HlyA secretion signal, which resulted in lysis 
of the phagosomal membrane and access to the host cell cytosol (Dietrich et al. 2001a). 
Access to the cytosol was found to enhance presentation of passenger proteins in vitro 
(Catic et al. 1999). In the same study, such modified Salmonella were also used to deliver a 
eukaryotic expression plasmid into macrophages. This phagosomal escape strategy was 
found to enhance DNA delivery. Recently, the Salmonella type III secretion system has 
been used as delivery means for heterologous proteins. It offers the advantage to directly 
inject the proteins from the bacteria into the host cell cytosol (Russmann et al. 1998). This 
can be achieved by fusing antigens to effector proteins translocated by TTSS (Husseiny et 
al. 2007). Alternatively, it was shown that effector protein YopE of the TTSS of Yersinia 
spp. can also mediate the translocation of fusion proteins by the SPI-1 TTSS (Russmann et 
al. 2001).  
1.4.4 Lysis of the bacterial carrier 
The delivery of antigens or DNA vaccines requires liberation of the molecules after 
invasion of the host. Besides the use of secretion systems that encounter limitations 
regarding size, structure and amount of the cargo, an alternative for that purpose would be 
release upon rupture of the cell wall. The introduction of an appropriate attenuation into 
the carrier strain is a simple method to achieve the lysis of the carrier. For example, 
Salmonella ∆asd quickly undergo lysis in environments lacking DAP, which leads to the 
release of protein, such as active LLO, and DNA (Loessner et al. 2006). Since Salmonella 
∆asd might be overattenuated in vivo regarding host colonization, conditional mutant 
strains might have to be constructed for therapeutic or prophylactic purposes. In an 
alternative effort to produce Salmonella strains for improved DNA vaccine delivery, a 
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system for the programmed lysis of the bacteria has been described (Jain and Mekalanos 
2000). The S and R gene products of phage lambda were used to lyse S. typhimurium under 
control of the L-arabinose inducible promoter PBAD in vitro. Additionally, it was shown that 
the release of plasmid DNA from bacteria could be augmented by the use of mutants 
lacking nuclease activity. 
1.4.5 Multivalent Salmonella vaccines 
The ability of attenuated Salmonella to elicit a broad spectrum of immune responses 
against a wide range of pathogens is well established (Detmer and Glenting 2006). Using 
the variety of expression systems developed so far, it should be possible to engineer 
multivalent Salmonella vaccines that express antigens derived from several pathogens 
(Atkins et al. 2006). For example, the use of compatible eukaryotic expression plasmids in 
the same carrier conferred immunity to the different plasmid derived antigens (Bauer et al. 
2005). This strategy is also applicable for the coadministration of plasmids encoding 
cytokines or costimulatory molecules. In addition it might be possible to simultaneously 
express chromosomally integrated heterologous antigens and plasmid-encoded antigens or 
to transfer a DNA plasmid at the same time (Garmory et al. 2002). In order to develop such 
bivalent strains the use of appropriate regulatory elements might be of great importance. 
1.4.6 Regulatory elements 
1.4.6.1 Choice of promoter 
The promoter controling expression of the antigen determines the amount of antigen 
produced. In the case of DNA vaccines, virally derived promoters, especially the CMV 
immediate early promoter, have been extensively used to drive antigen expression in the 
eukaryotic host cell. They ensure strong expression in vivo compared to other eukaryotic 
promoters (Norman et al. 1997). On the other hand, it was demonstrated that virally 
derived promoters are downregulated by cytokines such as IFN-γ or TNF-α (Qin et al. 
1997), which are induced during Salmonella-mediated DNA vaccination. Alternatively, 
strong promoters of housekeeping genes or promoters that are active in APC, e.g. the DC-
specific CD11c promoter, can be applied for genetic immunization.  
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In case of protein delivery, a strong promoter increases the bacterial metabolic burden, 
which often results in the instability of expression plasmids. Recently, Salmonella vectors 
with regulated instead of constitutive antigen expression have been employed in order to 
decrease the toxicity to the carrier and the metabolic burden during early phases of host 
colonization (Chatfield et al. 1992a, Bullifent et al. 2000, Huang et al. 2000, McKelvie et 
al. 2004, Stratford et al. 2005, Husseiny and Hensel 2005). In these studies the antigen is 
expressed using in vivo inducible (IVI) promoters that are upregulated when the vector 
enters the APC of the host thereby receiving certain environmental stimuli. One example is 
the nirB promoter, which is induced in anaerobic environments and by entry of Salmonella 
into cells. (Chatfield et al. 1992a). Using this promoter to express an immunogenic 
fragment of tetanus toxin, superior immune responses have been observed in comparison 
to the strong constitutive tac promoter, which could be attributed to higher plasmid 
stability. The macrophage-inducible pagC promoter, controlled by the two-component 
regulatory system PhoP/PhoQ, has also been shown to provide stable, high-level 
expression of passenger antigens in Salmonella (Dunstan et al. 1999, Bullifent et al. 2000, 
Arnold et al. 2004). A comparison of seven different promoters in Salmonella used flow 
cytometry to quantify in vivo antigen levels and to simultaneously monitor the early steps 
of antigen-specific T cell responses in mice (Bumann 2001b). The study demonstrated that 
in vivo expression levels for an antigen can be rationally selected by choosing from a set of 
promoters with defined properties, perhaps enabling the fine-tuning and timing of 
expression to direct specific immune responses. Additionally, it pointed out that the very 
high in vitro activity of the strong constitutive tac promoter led to impaired early 
colonization of the recombinant S. typhimurium strain, which consequently reduced the 
efficacy in generating an immune response. Most of the IVI promoters, which have been 
tested for antigen expression, are part of operons encoding for Salmonella virulence genes, 
thereby taking advantage of the spatiotemporal expression patterns of these genes (Brown 
et al. 2005). In this context, a possible limitation for promoters of genes located on SPI-1 
might be their downregulation after uptake by host cells. In contrast, effector proteins of 
SPI-2 are specifically induced by intracellular Salmonella after entering lymphatic tissues 
(Bumann 2002), highlighting their suitability for in vivo inducible antigen expression for 
vaccination.  
Following the administration of attenuated Salmonella to tumor-bearing animals, the 
bacteria colonize also normal tissues to a certain extent. Therefore, the use of a constitutive 
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promoter to drive therapeutic genes of interest might cause undesired side-effects. One 
way to address this problem is to exploit promoters, which are specifically activated in the 
tumor microenvironment. The lower oxygen levels compared to normal tissue are a 
characteristic feature found in solid tumors. Recently, a prokaryotic Salmonella gene 
delivery vector was genetically engineered to spatially control gene expression using the 
hypoxia-inducible promoter HIP-1 (Mengesha et al. 2006). Using this promoter, reporter 
gene expression was confined to tumors made hypoxic. In another study, bacteria were 
engineered to invade cancer cells in vitro under control of certain environmental stimuli, 
that is hypoxia, cell density and L-arabinose (Anderson et al. 2006). This strategy could be 
applied to processes other than invasion, such as the release of a therapeutic protein. 
Moreover, stimuli that are not intrinsic to the host but can be administered at will provide a 
possibility to temporally and/or spatially control gene expression in order to increase 
specificity of tumor therapy.  
1.4.6.2 Remote control of bacterial carriers 
A range of bacterial promoters have been identified, which respond to various stimuli, such 
as particular substrates, temperature, hypoxia, ionic strength, radiation, pH, cation levels 
and other environmental conditions (Cases and de Lorenzo 1998, Lucas and Lee 2000). To 
deliberately modify gene expression of bacterial carriers in vivo at a defined time, e.g. for 
tumor therapy and vaccination, a combination of a suitable promoter and extrinsic inducer 
is needed. Thus far, only one bacterial system has been described to spatially and 
temporally control expression within the host. Nuyts et al. recently identified two 
clostridial promoters, recA and recN, which could be induced by ionizing radiation (Nuyts 
et al. 2001b). Using this approach, the expression of therapeutic genes by Clostridia could 
be further enhanced by simultaneous application of radiotherapy (Nuyts et al. 2001a). 
However, the application of irradiation as inducer is hampered since it also results in 
damage of normal tissue.  
An ideal inducer to control bacterial carriers for therapeutic and prophylactic purposes 
should fulfill several prerequisites, some of which are: it should be i) nontoxic and non-
immunogenic to the host, ii) able to be administered repeatedly by established routes (e.g. 
orally and intravenously) in a wide range of doses, iii) able to reach the bacterial niches in 
vivo iv) readily available at low cost. Additionally, it is desirable that the activity of the 
responding promoter is very tightly controlled. In this context, one promising expression 
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system is based on the L-arabinose-inducible promoter PBAD (Guzman et al. 1995). The 
PBAD promoter from the arabinose operon of E. coli offers high-level expression and very 
inexpensive induction with the sugar L-arabinose. In E. coli, PBAD controls the transcription 
of the genes araB (ribulokinase), araA (isomerase) and araD (epimerase), whose products 
mediate the metabolic conversion of the sugar L-arabinose (reviewed by Schleif 2003). 
This promoter is regulated by the protein AraC, which negatively controls its own 
transcription. In the absence of L-arabinose, the dimeric AraC protein binds to the initiator 
region I1 and the operator region O2, thus leading to the formation of a DNA loop 
upstream of PBAD that represses the promoter. In the presence of L-arabinose, AraC binds 
the sugar, changes its conformation and releases the DNA loop. In this state, it binds to the 
initiator regions I1 and I2 upstream of PBAD and stimulates binding of the activating 
complex formed by cyclic AMP (cAMP) and cAMP receptor protein as well as binding of 
the RNA polymerase, thus efficiently starting transcription. In summary, PBAD is very 
tightly regulated, since the uninduced levels can be reduced even further by growth in the 
presence of glucose. Glucose reduces levels of cAMP, consequently lowering expression 
of the catabolite-repressed PBAD promoter (Miyada et al. 1984). Therefore, this system is 
widely used to control expression in bacterial cultures. As the inducer L-arabinose is also 
in wide use for dietary purposes as well as a formulation agent for pharmaceutical 
preparations, this system is an attractive candidate for in vivo remote control of Salmonella. 
1.5 Aims of this work 
Live attenuated Salmonella are explored as vectors for the delivery of heterologous 
antigens and DNA vaccines as well as for tumor therapy. Efficacy of vaccination often 
corresponds to the amount of antigen presented or the DNA dose delivered. However, 
antigen expression at high levels and maintenance of the plasmid DNA at high-copy 
numbers seriously weakens the bacteria resulting in a decreased potential of the bacteria in 
terms of invasiveness, fitness and immunogenicity. The aim of this work was the 
development of novel Salmonella strains with amplifiable expression plasmids.  
In the first part of the thesis, a strategy should be established to amplify expression 
plasmids under control of Salmonella-specific in vivo inducible promoters. The vaccine 
strain should maintain the expression plasmid in a single copy state in the inoculum and 
initiate amplification to a high-copy number upon induction of the in vivo inducible 
promoters after bacterial administration. Novel strains developed with these promoters 
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should be evaluated by using reporter plasmids whose amplification could be followed in 
vitro and in vivo. As a second step, the inducible system for plasmid amplification should 
be further improved by enhancing expression due to simultaneous control of plasmid copy 
number and protein transcription for the delivery of passenger antigens. Finally, the novel 
vaccine strains should be tested in the mouse model regarding colonization capabilities and 
stability of the vector system. Additionally, their immunogenicity should be tested using 
the model antigens ovalbumin and listeriolysin.  
Complementary, plasmid amplification should be developed to be inducible at any time in 
vivo. To remotely control the bacterial carrier in this aspect, the amplifiable system had to 
be linked with the L-arabinose inducible PBAD promoter. The ability of the sugar 
L-arabinose to induce plasmid amplification in medium, in cell culture and in vivo had to 
be evaluated. Subsequently, L-arabinose-mediated plasmid amplification and simultaneous 
protein expression should be characterized in tumor-bearing mice. 
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2 Material and methods 
2.1 Bacterial strains and growth conditions 
The Escherichia coli (E. coli) strains DH5α and Top10 (Invitrogen, Groningen, The 
Netherlands) were used for general cloning. The auxotrophic Salmonella enterica Servorar 
Typhimurium strain SL7207 (hisG46, ∆407[aroA544::Tn10], kindly provided by Dr. B. A. 
D. Stocker, (Stanford, CA, USA) was used as plasmid carrier for the in vitro and in vivo 
studies. E. coli strain DH5αλpir was used for cloning of plasmids with the λpir-dependent 
R6K origin of replication and E. coli strain SM10λpir was used for Tn7-mediated 
transposition in SL7207. E. coli and SL7207 were routinely grown in Luria Bertani (LB) 
broth or on LB-agar plates (Sambrook et al. 1989) at 37°C or 30°C (DH5αλpir and 
SM10λpir). SL7207 was grown in induction medium (IM) when indicated. IM is M9 
(Sambrook et al. 1989) without CaCl2 supplemented with 100 µM MgSO4, 40 µg ml-1 
histidine, 40 µg ml-1 phenylalanine, 40 µg ml-1 tryptophane, 40 µg ml-1 tyrosine, 10 µg ml-1 
para-aminobenzoic acid, 10 µg ml-1 2,3-dihydroxybenzoate; the pH was adjusted to 5,5 
with concentrated HCl. Antibiotics were added at the following concentrations where 
required: 30 µg ml-1 streptomycin; 12,5 µg ml-1 chloramphenicol; 30 µg ml-1; kanamycin; 
100 µg ml-1 ampicillin. Listeria monocytogenes EGDe for in vivo cytotoxicity assays was 
grown in Brain Heart Infusion (BHI) broth or on BHI-agar plates (Difco, Detroit, MI) at 
37°C (Leimeister-Wachter and Chakraborty 1989). 
2.2 Cell lines 
TS/A (Nanni et al. 1983), CT26 (ATCC CRL-2638) and J774-A.1 (ATCC TIB67) were 
cultured in IMDM (Gibco BRL, Eggenstein, Germany) supplemented with 10% heat-
inactivated FCS (Integro, Zaandam, The Netherlands), 250 mM ß-mercaptoethanol (Serva, 
Heidelberg, Germany) and 100 µg ml-1 penicillin/streptomycin (Biochrom, Berlin, 
Germany). Cells were cultured at 37°C and 5% CO2 in a humidified atmosphere. 
2.3 Mouse strains 
Female or male BALB/c (H-2d) mice were purchased from Harlan Winkelmann (Borchen, 
Germany) and used at age 8-12 weeks for all experiments. Transgenic DO11.10 mice were 
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bred and maintained in a specific pathogen-free animal facility at the HZI or obtained from 
the Bundesinstitut für Risikobewertung (BfR), Berlin.  
2.4 Oligonucleotides 
Primer Nucleotide sequence (5’-3’-direction) 
AEN22 GGATATCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATAT
ACCATGAACGGACGTTTGA 
AEN23 GGATATCAAGCTTCTGCAGGTCGACCTAGC GTTTGCAATGC 
AEN32 AAGGCACCGACGTTGACCA 
AEN43 ATGTTGGACGAGTCGGAATC 
AEN61 GATATCCATATGGAACAAAAACTTATTTCTGAAGAAGATCTGAT
GCCTAAGACGCCAATCGAAAAG 
AEN63 GATATCCTGCAGGGATCCTTAGTCGATGATTTGAACTTCAT 
Primers were ordered from Operon (Köln, Germany). 
2.5 Plasmids 
2.5.1 Outgoing plasmids for cloning 
Plasmid Source/reference 
pETcoco-1 Expression plasmid, which is amplifiable from 1-2 to 20-50 copies/cell 
under control of PBAD (Novagen, Merck KgaA, Darmstadt, Germany) 
p3.6B Expression plasmid derived from pGFP_ova (Bumann 2002), contains 
PsifA (kindly provided by Dr. Dirk Bumann) 
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Plasmid Source/reference 
p2.2A Expression plasmid derived from pGFP_ova (Bumann 2002), contains 
PphoN (kindly provided by Dr. Dirk Bumann) 
pCLII.3A Expression plasmid derived from pGFP_ova (Bumann 2002), contains 
Pstm1630 (kindly provided by Dr. Dirk Bumann) 
pHL49 GFP-expression plasmid (Cormack et al. 1996) with the ß-lactamase 
promoter Pbla (H. Lößner, unpublished) 
pHL230 Plasmid derived from pET-11 (Novagen), contains a T7 terminator 
sequence (H. Lößner, unpublished) 
pHL222 Expression plasmid for firefly luciferase derived from pGL3-basic 
(Promega, Mannheim, Germany) with the ß-lactamase promoter Pbla 
(H. Lößner, unpublished) 
pCMVßm4A Eukaryotic expression plasmid with pSC101 origin of replication (Bauer 
et al. 2005) 
pHL259 L-arabinose inducible luciferase expression plasmid (Loessner et al. 
2007) 
pCMVßm2A Eukaryotic expression plasmid with pMB1 origin of replication (Bauer et 
al. 2005) 
pCMVßm3A Eukaryotic expression plasmid with p15A origin of replication (Bauer et 
al. 2005) 
pUX-BF13 Tn7-helper plasmid (Bao et al. 1991) 
pCMVhly Eukaryotic expression plasmid for LLO (Darji et al. 1997) 
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Plasmid Source/reference 
pSLE1f Carrier plasmid for Tn7-mediated transposition (S. Leschner, 
unpublished), derivative of pUX-BF5 (Bao et al. 1991) 
pHL260a Carrier plasmid for Tn7-mediated transposition, contains gene E under 
control of PBAD (Loessner et al. 2007) 
pHL238 L-arabinose inducible GFP expression plasmid (Loessner et al. 2007) 
pSL1 Expression plasmid with luxCDABE operon (Winson et al. 1998), 
derivative of pSMART-LCKan (Lucigen, Middleton, USA)  
2.5.2 Reporter plasmids for L-arabinose inducible amplification 
A Pbla-gfp_ova reporter construct was made by cloning a SalI/XbaI fragment of pHL49 
containing the promoter of the ampicillin resistance gene (bla) into the SalI/XbaI fragment 
of the vector p3.6B. The resulting plasmid was digested with NaeI and HindIII to introduce 
the Pbla-gfp_ova reporter construct into the HpaI/HindIII fragment of the expression vector 
pETcoco-1, yielding plasmid pAEN7. A T7 terminator sequence was introduced into 
pAEN7 by ligating a blunt-ended EcoRV fragment of plasmid pHL230 with the HindIII-
digested, blunt-ended vector, yielding plasmid pAEN9 (Fig. 2.1).  
To create plasmid pAEN17 with gfp instead of gfp_ova, the Pbla-gfp fragment was removed 
from pHL49 by digestion with NotI/HindIII, followed by Klenow treatment to generate 
blunt-ends and inserted into the NotI digested blunt-ended vector pAEN9. Similarly, 
plasmid pAEN38 contains luc instead of gfp_ova as reporter gene. A Pbla-luc fragment was 
isolated from plasmid pHL222 by digestion with EcoRI/NaeI, blunt-ended and inserted 
into the NotI digested and blunt-ended vector pAEN9. The pSC101 origin of replication 
containing fragment from plasmid pCMVm4A was isolated by BglII/XbaI digestion and 
subsequent Klenow treatment to generate blunt-ends. The vector pAEN38 was digested 
with BglII and NotI, blunt-ended and the two fragments were ligated, resulting in plasmid 
pAEN59 (Fig. 2.2).  
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pAEN9
11382 bp
Not I
Avr II
EcoRV
Sal I
Bgl II
IIBgl
HIBam
INot
IXba
araC
PC
PBAD
trfA
CmR
oriV
oriS
repE
parA
parB
parC
Pbla
gfp_ova
ova319-343
tT7
 
Fig. 2.1:  Plasmid map of pAEN9. The lacI containing fragment of pETcoco-1 was replaced by 
Pbla-gfp_ova and a T7 terminator, see text for construction details. 
pAEN59
9212 bp
Blp I
EcoRV
IXba
araC
PC
PBAD
trfA
CmR
oriV
pSC101 ori
Pbla
luc
 
Fig. 2.2:  Plasmid map of pAEN59. In contrast to plasmid pAEN38, this plasmid carries the pSC101 
origin of replication to maintain the minimal-copy state. 
The Pbla-gfp_ova fragment of pAEN9 was excised with XbaI/EcoRV and inserted into the 
XbaI/EcoRV sites of pAEN59. The resulting plasmid pAEN60 was then digested with 
XbaI and BlpI to exchange the reporter gene with the PBAD-luc containing XbaI/BlpI 
fragment of pHL259, yielding pAEN64 (Fig. 2.3).The PBAD-trfA cassette was isolated by 
digesting pAEN64 with EspI/NdeI, blunt-ending and subsequent ligation, yielding plasmid 
pAEN110. 
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pAEN64
10205 bp Nde I
IXba
IBlp
araC
PC
PBAD
trfA
CmR
oriV
pSC101 ori
araC
Pc
PBAD
luc
 
Fig. 2.3:  Plasmid map of pAEN64. Plasmid pAEN110 is similar but not amplifiable via 
L-arabinose due to excision of PBAD-trfA. 
2.5.3 Reporter plasmids for in vivo inducible plasmid amplification 
pAEN35
8419 bp
Xho I
HIBam
oriV
oriS
repE
parA
parB
parC
gfp_ova
tT7
CmR
Pbla
ova319-343
 
Fig. 2.4:  Plasmid map of pAEN35. This plasmid is a derivative of pAEN9, which was digested 
with AvrII and SalI to remove the PBAD-trfA cassette, treated with Klenow fragment and ligated.  
Plasmid pAEN9 was digested with SalI and BamHI, blunt-ended and the fragment 
containing the F plasmid replicon, oriV and CmR was ligated with a blunt-ended 
PsifA-gfp_ova fragment derived from p3.6B that was digested with SalI/HindIII. The 
resulting plasmid pAEN51 (Fig. 2.5) was used to introduce the pSC101 replicon by 
digesting the plasmid with BglII and BspLU11I, blunt-ending and ligation with the blunt-
ended BglII/XbaI fragment of pCMVßm4A, yielding pAEN61 (Fig. 2.6).  
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pAEN51
8814 bp
Bgl II
LU11Bsp
CmR
oriV
oriS
repE
parA
parB
parC
ova319-343
gfp_ova
PsifA
 
Fig. 2.5:  Plasmid map of pAEN51. This plasmid is similar to pAEN35, but the Pbla-gfp_ova 
reporter was replaced with PsifA-gfp_ova. 
pAEN61
6043 bp
Sal I
IBgl
IPst
INde
oriV
pSC101 ori
gfp_ova
CmR
ova319-343
PsifA
 
Fig. 2.6:  Plasmid map of pAEN61. In contrast to plasmid pAEN51, this plasmid carries the pSC101 
origin of replication to maintain the minimal-copy state. 
Plasmid pAEN61 was used to introduce the pMB1 and p15A replicon by digesting the 
plasmid with BglI and SalI, blunt-ending and ligation with the blunt-ended BglII/XbaI 
fragment of pCMVßm2A and pCMVßm3A, yielding pAEN108 and pAEN109, 
respectively. 
To create a reporter plasmid for in vivo imaging, the coding sequence for the luxCDABE 
operon originating from Photorhabdus luminescens was obtained by restriction digestion 
of pSL1 with SnaBI and NcoI followed by blunt-ending. Then the coding sequence for 
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gfp_ova was removed from pAEN61 by digestion with NdeI/BglI, the vector was treated 
with T4 DNA polymerase and ligated with the luxCDABE operon. 
2.5.4 Plasmids for Tn7-mediated transposition 
Plasmid pSL1f was used to construct carrier plasmids for Tn7-mediated transposition in 
SL7207. pSLE1f carries a kanamycin resistance gene between the transposon ends Tn7L 
and Tn7R as well as a single SalI restriction site for the insertion of DNA fragments. To 
construct derivatives of this plasmid, the vector was opened with SalI and treated with 
Klenow to generate blunt-ends.  
The PBAD-gfp containing fragment of plasmid pHL238 was isolated by digestion with 
PvuII/HindIII, subsequently treated with Klenow and ligated with the vector pSLE1f. The 
resulting plasmid pAEN44 was used to generate a SL7207 strain that contained the 
reporter gfp under control of the L-arabinose inducible promoter PBAD. Plasmid pAEN46 
served as carrier plasmid for the insertion of a PBAD-trfA cassette into the chromosome of 
SL7207. This cassette was derived from plasmid pAEN9 after digestion with AvrII/SalI 
and Klenow treatment and inserted into pSLE1f.  
PIVI-gfp reporter constructs were made using plasmid pHL49 by inserting the SalI/NdeI 
promoter fragments of p2.2A, pCLII.3A and p3.6b into the SalI/NdeI digested vector. The 
resulting plasmids were digested with SalI and HindIII, blunt-ended and ligated with SalI 
opened, blunt-ended pSLE1f yielding pAEN45.1 (PphoN-gfp), pAEN45.2 (Pstm1630-gfp) and 
pAEN45.3 (PsifA-gfp). To construct transcriptional fusions of in vivo inducible promoters 
with trfA, the gene was amplified from pETcoco-1 by PCR using primers AEN22 and 
AEN23. The PCR product was digested with XbaI and HindIII and exchanged for gfp_ova 
in p2.2A, pCLII.3A and p3.6b to yield pAEN8.1-3. The plasmids were digested with SalI 
and the PIVI-trfA fusions inserted into the unique SalI restriction site of pSLE1f yielding 
pAEN47.1(PphoN-trfA), pAEN47.2 (Pstm1630-trfA) and pAEN47.3 (PsifA-trfA).  
Carrier plasmid pAEN106 was made by inserting the PsifA-trfA containing SalI fragment of 
pAEN47.3 into the unique SalI restriction site of pHL260a. Plasmid pAEN106 was used to 
generate a chromosomal integration derivative of SL7207, which contains PsifA-trfA as well 
as gene E of bacteriophage ΦX174 under control of the PBAD promoter. 
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2.5.5 Expression plasmids with listeriolysin O as antigen 
To introduce another antigen instead of ova, a part of the hly gene (amino acids 49-361) 
was amplified by PCR using primers AEN61 and AEN63 and pCMVhly as template. 
Primer AEN61 contains a recognition sequence for NdeI and a myc-tag, primer AEN63 
introduces the recognition sequence for PstI and BamHI as well as a stop codon. The PCR 
product was cloned into pCR2.1-TOPO (Invitrogen, Groningen, The Netherlands) and the 
insert was verified by sequencing. The insert was retrieved with NdeI and PstI and cloned 
into NdeI/PstI sites of pAEN61, yielding plasmid pAEN95 (Fig. 2.7). To replace the 
pSC101 replicon with the F plasmid replicon, plasmid pAEN95 was digested with 
XhoI/BamHI and the fragment containing the antigen and the resistance cassette was 
cloned into the XhoI/BamHI sites of pAEN35.  
pAEN95
6232 bp
Xho I
HIBam oriV
pSC101 ori
LLO49-361
CmR
PsifA
 
Fig. 2.7:  Plasmid map of pAEN95. Plasmid pAEN95 is similar to pAEN61 but it contains LLO49-361 
as antigen instead of gfp_ova. Likewise, pAEN98 carries LLO49-361 as antigen in contrast to pAEN51. 
2.6 Chromosomal integration derivatives of SL7207 
In this work, transcriptional fusions of inducible promoters with the reporter gene gfp and 
the replication protein TrfA were integrated into the chromosome of strain SL7207 by 
Tn7-mediated transposition (Fig. 2.8). The specific insertion occurs at the transcriptional 
inactive site attTn7, which is flanked by the bacterial genes phoS and glmS. 
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SL7207::AEN45.2
Pstm1630
PsifA
SL7207::AEN45.3
SL7207::AEN47.3
PsifA
Pstm1630
SL7207::AEN47.2
SL7207::AEN45.1
phoS Tn7L gfp KnR Tn7R glmSPphoN
A
B
AEN43 AEN32
phoS Tn7L gfp PBAD Pc
araC KnR
Tn7R
glmS
SL7207::AEN44
SL7207::AEN47.1
Tn7L Tn7RphoS PphoNtrfA glmSKnR
AEN43 AEN32
SL7207::AEN46
glmSTn7RKnRPBAD Pc
araCtrfATn7LphoS
C
E T7
Terminator
Tn7R glmSKnRPBADPc
araC
T7
Terminator
Tn7LphoS PsifAtrfA
SL7207::AEN106
AEN43 AEN32
 
Fig. 2.8:  Schematic display of the chromosomal integration derivatives of SL7207. 
Transcriptional fusions of gfp (A) and trfA (B) with different inducible promoters. (C) SL7207::AEN106 
contains a fusion of PsifA with trfA as well as gene E of bacteriophage ΦX174 under control of the PBAD 
promoter. To check the correct chromosomal integration, a PCR with the primers AEN32/43 amplifying a 
708 bp fragment between KnR and glmS was performed. 
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2.7 Molecular biological methods 
2.7.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate linearized, double-stranded DNA 
fragments for analytical and preparative purposes. This method is based on the size-
dependent migration of DNA fragments in an electric field. The size of the fragments was 
estimated by comparison with marker DNA of known size, a mix of HindIII-digested λ-
DNA and HaeIII-digested pφX174-DNA (MBI Fermentas, St. Leon-Rot, Germany). In this 
study, 0,8% agarose (Appligene, Heidelberg, Germany) was used in TAE buffer 
(Sambrook et al. 1989) and gels were run at 80-150 V. Gels were stained with ethidium 
bromide, visualized with UV light and documented. 
2.7.2 Preparation of DNA 
2.7.2.1 Isolation of DNA from agarose gels 
DNA was extracted from agarose gels using the “QIAquick Gel Extraction Kit” (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions and subsequently eluted in 
35 µl H2O. 
2.7.2.2 Isolation of plasmid DNA 
The isolation of plasmid DNA from bacteria was carried out in mini or midi plasmid 
preparation depending on the required amount. The “GFX Micro Plasmid Prep Kit” 
(Amersham Biosciences, Freiburg, Germany) and the “Qiagen Plasmid Midi Kit” (Qiagen, 
Hilden, Germany) were used to purify plasmids from E. coli strains. To isolate plasmids 
from Salmonella strains, the “Qiagen Plasmid Mini Kit” was employed. 
2.7.2.3 Determination of DNA concentration 
The DNA concentration was determined optically by measuring the extinction of a sample 
at 260 nm in a BioPhotometer (Eppendorf, Hamburg, Germany). Using a 1 cm cuvette, an 
OD260 of 1 corresponds to a concentration of 50 µg ml-1. Alternatively, the concentration of 
linearized DNA was estimated by visual comparison of the band intensity with that of 
marker DNA containing defined quantities of DNA. 
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2.7.3 Molecular cloning 
For analytical or preparative purposes, DNA was digested with appropriate restriction 
endonucleases of different manufacturers (MBI Fermentas, St. Leon-Roth, Germany; New 
England Biolabs, Frankfurt am Main, Germany; Roche Diagnostics, Mannheim, Germany). 
The digestion was carried out using optimal buffer and temperature conditions according to 
the manufacturer’s instructions. 
To ligate two DNA strands without compatible restriction sites, overhanging DNA ends 
were modified to generate blunt-ends. In case of 3’ overhangs, 1 unit of T4 DNA 
polymerase (MBI Fermentas, St. Leon-Roth, Germany) and 2,5 µl 2 mM dNTP were 
added to a restriction digestion of 20 µl and incubated at room temperature for 10 min. To 
fill-in 5’ overhangs, the same reaction was performed using 2 U Klenow fragment of 
E. coli DNA-polymerase I (MBI Fermentas, St. Leon-Roth, Germany) and incubating at 
30°C for 15 min. Prior to ligation with blunt-ended DNA fragments, the vector DNA was 
dephosphorylated in order to increase the insertion frequency by avoiding self-ligation of 
the plasmid vector. The reaction was carried out by adding 2 µl Calf Intestinal Phosphatase 
(CIP) (Roche Diagnostics, Mannheim, Germany) , 4 µl CIP buffer and 20 µl H2O to a 
restriction digestion of 20 µl and incubating at 37°C for 1 h. 
To construct new plasmids, linearized plasmid vectors and inserts with compatible 
overhanging ends or blunt-ends were ligated to form phosphodiester bonds. The reaction 
was carried out in 20 µl containing vector and insert in a molar ratio of 1:5, 2 µl T4 DNA 
ligase (MBI Fermentas, St. Leon-Roth, Germany), 2 µl 10×ligation buffer and 2 µl PEG 
2000 (50% w/v in H2O) and incubated at room temperature for 1-2 h. 
2.7.4 Polymerase chain reaction 
AmpliTaq Gold (Roche Diagnostics, Mannheim, Germany) was used to amplify and detect 
small amounts of specific DNA via PCR. This enzyme is a thermostable DNA polymerase, 
which was activated by incubation at 95°C for 10 min at the beginning of the PCR 
program. The reaction was run on thermocycler PCRSprint (Hybaid, MWG, Ebersberg, 
Germany). The reaction was carried out in a volume of 50 µl as follows: 5 µl 10×PCR 
buffer, 5 µl 2 mM dNTP, 5 µl primer 1 (10 µM), 5 µl primer 2 (10 µM), 5 µl plasmid DNA, 
2 Material and methods 
 
50 
0,5 µl AmpliTaq Gold, H2O ad 50 µl. To detect genomic DNA sequences, a bacterial 
colony was added via a pipette tip to the reaction mix instead of plasmid DNA. 
PCR program (plasmid DNA):  1×10 min 95°C 
 40× 20 s 94°C, 20 s 50°C, 30 s 72 °C 
 1×10 min 72°C 
PCR program (colony PCR) 1×10 min 95°C 
 6× 20 s 94°C, 20 s 50°C, 30 s 72 °C 
 35× 20 s 94°C, 20 s 56°C, 30 s 72 °C 
 1×10 min 72°C 
Subsequently, 5 µl of the PCR reaction were analyzed by gel electrophoresis. PCR 
products were purified using the “QIAquick PCR-Purification Kit” (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions 
The “TOPO TA Cloning Kit“ (Invitrogen, Groningen, The Netherlands) was used to clone 
PCR products into the pCR2.1-TOPO plasmid vector. The reaction was carried out 
according to the manufacturer’s instructions and the inserts were verified by sequencing 
(performed by GATC Biotech, Konstanz, Germany) using M13 Reverse and M13 Forward 
primer. 
2.8 Microbiological methods 
2.8.1 Long-term storage of bacteria 
To store bacteria for a long-term period, 700 µl of a logarithmic growing culture were 
mixed with 300 µl glycerin (50% v/v in H2O) and frozen at –70°C. 
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2.8.2 Transformation of chemically competent bacteria 
For cloning procedures, aliquots of competent E. coli strains DH5α and Top10 (Invitrogen, 
Groningen, The Netherlands) were thawed on ice, mixed with 10 µl of a ligation reaction 
and incubated on ice for 10 min. Subsequently, the bacteria were transformed via the heat-
shock method at 42°C for 45 s. 250 µl SOC medium (provided by the manufacturer) were 
added immediately and the suspension was incubated at 37°C for 1-2 h. Finally, the 
bacterial suspension was plated on LB-agar plates containing selective antibiotics and 
incubated overnight at 37°C. 
2.8.3 Transformation of electrocompetent bacteria 
To prepare electrocompetent E. coli DH5α and SM10λpir and Salmonella for the 
transformation with plasmid DNA, the strains were grown in LB medium at 37°C or 30°C 
(SM10λpir) and 180 rpm until an optical density (OD600) of approximately 0,8 was reached. 
The bacteria were harvested by centrifugation at 4°C and 3000 × g for 5 min and washed 
twice with ice-cold H2O. Finally, the pellet was resuspended in 50 µl ice-cold H2O, mixed 
with 2 µl plasmid DNA and transferred into a cuvette for electroporation. The 
electroporation was carried out using ice-cold 0,2 cm cuvettes (Biorad, Munich, Germany) 
and a “Gene Pulser II” (Biorad). Electroporation parameters were 2,5 kV, 25 µF and 200 Ω 
(DH5α) and 400 Ω (Salmonella) respectively. Subsequently, the bacteria were resuspended 
in 1 ml LB medium, shaken at 37°C or 30°C (SM10λpir) for 1 h before plating on 
selective LB-agar plates and incubation overnight at 37°C or 30°C (SM10λpir). 
2.8.4 Preparation and transformation of chemically competent 
DH5αλpir 
Chemically competent DH5αλpir were prepared according to the protocol of  Inoue H. et 
al. (Inoue et al. 1990). Bacteria were incubated overnight on LB-agar plates at 28°C and 
10-12 colonies were used to inoculate 400 ml SOB medium (Sambrook et al. 1989). The 
suspension was shaken in a 2 l Erlenmeyer flask at 18°C and 200 rpm until it reached an 
OD600 of 0,6. After cooling on ice for 10 min, the bacteria were harvested by centrifugation 
at 4°C and 3000 × g for 10 min. The pellet was resuspended in 80 ml ice-cold TB buffer 
(0,604 g Pipes; 0,442 g CaCl2; 3,72 g KCl;189 ml H2O; pH adjusted to 6,7 with KOH; 
11 ml 1 M MnCl2) and 1 ml DMSO was added drop-wise before incubating again on ice 
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for 10 min. Aliquots (1 ml per sample) were stored at –70°C. For transformation, the 
aliquots were thawed on ice and 100 µl of the competent cells were mixed with 10 µl of a 
ligation reaction and incubated on ice for 30 min. Subsequently, the bacteria were 
incubated at 42°C for 45 s and afterwards on ice for 2-3 min. 1 ml LB medium were added 
and the suspension was incubated at 30°C for 1-2 h. Finally, the bacteria were plated on 
LB agar plates containing selective antibiotics and incubated overnight at 30°C. 
2.8.5 Determination of reporter gene expression and plasmid 
amplification in vitro 
The recombinant Salmonella strains were cultured in LB medium overnight, washed twice 
in M9, resuspended in IM and used to inoculate LB medium and IM at 1:100 dilution. The 
cultures were grown at 200 rpm for 6 h before being submitted to plasmid preparation, 
flow cytometry, luciferase assay or SDS-PAGE/Western Blot. Furthermore, the colony 
forming units (cfu) per ml of the culture were determined by plating serial dilutions. 
Plasmid DNA was extracted from 3 ml culture by mini plasmid preparation. The amount of 
DNA per ml culture was determined by comparison with marker DNA after digestion with 
appropriate restriction enzymes. The number of plasmid molecules per ml culture was 
calculated using the formula: 1 µg of 1000 bp DNA = 9,1 × 1011 molecules. To determine 
the plasmid copy number per cfu, the number of plasmid molecules per ml was divided by 
the cfu per ml. To prepare samples for the luciferase assay, 500 µl of the cultures were 
washed once with PBS (Sambrook et al. 1989), resuspended in lysis buffer (25 mM Tris-
HCl, 2 mM DTT, 10% glycerin, 1% Triton-X, 1 mg ml-1 lysozyme in H2O) and incubated 
at room temperature with shaking for 10 min. Luciferase assays of the lysates were 
performed by using the Promega Luciferase Assay System (Promega, Mannheim, 
Germany) according to the manufacturer’s specifications. In brief, 10 µl of sample were 
mixed with 100 µl of the Luciferase Assay Reagent (LAR) and the emission of light was 
subsequently measured during a 10 s time interval in a Lumat LB9507 luminometer 
(Berthold Technologies, Australia) as relative light units (RLU). To prepare samples for 
SDS-PAGE/Western Blot, bacterial pellets were lysed by sonification after adding 
2×loading buffer (1,5 g Tris pH 6,8, 20 ml glycerine, 46 ml 10% w/v SDS, 10 ml 
ß-mercaptoethanol, 4 ml 0,05% w/v bromphenolblue in 100 ml H2O). 
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2.8.6 Tn7-mediated transposition in Salmonella 
The chromosome of E. coli strain SM10λpir carries the transfer elements of the mobile 
plasmid RP4 (Simon et al. 1983) as well as the prophage λpir (Miller and Mekalanos 1988). 
The carrier plasmids are derivatives of pSLE1f that are suitable for the site-specific 
insertion of foreign DNA into the genome of gram-negative bacteria. These plasmids 
contain the mobilizing region of plasmid RP4 and the foreign DNA between the 
transposon ends Tn7L and Tn7R. The helper plasmid pUX-BF13 provides the Tn7 
transposition functions in trans as well as the mobilizing region of plasmid RP4 (Bao et al. 
1991). Importantly, due to the λpir-dependent R6K origin of replication, both plasmids can 
only be propagated in strains, which express pir, e.g. DH5αλpir and SM10λpir, not in the 
target strain SL7207. Tn7-mediated transposition in SL7207 was carried out according to 
the filter conjugation method (de Lorenzo et al. 1990). Briefly, the helper plasmid as well 
as the carrier plasmid was used for transformation of SM10λpir. Both strains and SL7207 
were then grown at 28°C in LB medium until they reached OD600 0,8. Then 200 µl of each 
culture were mixed, washed in LB medium, resuspended in 20µl LB medium and 
incubated on a 0,45 µm cellulose filter (ME25, Schleicher&Schüll, Dassel, Germany) on a 
LB-agar plate at 28°C overnight. Streptomycin- and kanamycin-resistant clones that were 
sensitive to ampicillin, indicating loss of helper and carrier plasmid, were selected and 
tested by colony PCR for chromosomal integration using primer AEN32 and AEN43. 
2.8.7 Determination of plasmid stability in vitro 
Transformed Salmonella strains were cultured in LB medium at 37°C and 180 rpm 
overnight and passaged for 5 days every 12 h at 1:100 dilution in fresh medium with and 
without antibiotic selection. The cfu of the respective cultures were determined by plating 
serial dilutions. The stability was calculated by dividing cfu on antibiotic agar plates by 
total cfu on LB-agar without selecting antibiotics. 
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2.8.8 Flow cytometry of bacteria 
2.8.8.1 Flow cytometry of bacterial cultures 
To measure the in vitro expression of Gfp or Gfp_ova, 5 µl of bacterial cultures were 
analyzed in 1 ml buffer (2 mM EDTA in PBS) for scattering properties and green 
fluorescence without compensation using a FACSCalibur and WinMDI software. 
2.8.8.2 Flow cytometry of bacteria from infected cells and mice 
Bacteria from infected cells and mice were analyzed by two color flow cytometry 
(Bumann 2002). This method allows distinguishing GFP expressing bacteria from 
autofluorescent cellular debris since GFP expressing Salmonella have a substantially lower 
orange/green emission ratio (Fig. 2.9). Additionally, forward and sideward scatter were 
used to distinguish Salmonella from larger particles by setting an appropriate scatter gate. 
 
Fig. 2.9:  Two color flow cytometry of S. typhimurium expressing GFP. A threshold value (grey 
shaded area) and a gate were set in the orange/green acquisition plot for detection of GFP expressing bacteria 
in the lysates of cells and organs. 
2.8.8.3 Live/dead staining of bacterial cultures for flow cytometry 
Bacterial live/dead staining was carried out using the BD Cell Viability Kit (BD 
Bioscience, Erembodegem, Belgium,) according to the manufacturer’s instruction. This 
assay is based on staining the bacteria with two reagents: the membrane permeable dye 
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thiazole orange (TO) and the membrane impermeable dye propidium iodide (PI). Both 
dyes intercalate into the DNA thereby increasing fluorescence intensity. 
2.9 Tissue culture 
2.9.1 Determination of viable cells 
An aliquot of a cell suspension was diluted 1:10 or 1:2 with 0,5% w/v trypanblue in PBS 
and 10 µl of this mixture were analyzed in a Neubauer chamber. Trypanblue stains only 
dead cells with a leaky membrane; viable cells remain unstained and were counted. The 
number of cells ml-1 equals the number of viable cells within a big square multiplied with 
the dilution factor and 104. 
2.9.2 Detachment of adherent cells 
Adherent cells were detached from culture dishes for counting and transfer. Cells were 
washed once with PBS and incubated at 37°C after adding trypsin-EDTA (TE) solution 
(0,5 g ml-1 trypsin; 0,2 g ml-1 EDTA in PBS) until the cells were detached. Subsequently, 
TE was inactivated by addition of IMDM containing FCS and the cells were separated by 
careful repeated pipetting. 
2.9.3 Cryoconservation and thawing of cells 
Cells from a dense growing 12- or 6-well plate were suspended in 0,5 ml ice-cold freezing 
medium (10% v/v DMSO in FCS), frozen at –70°C and stored in liquid nitrogen. Frozen 
cells were thawed at 37°C in a water bath, resuspended in prewarmed medium and washed 
twice before culturing. 
2.9.4 CFSE labeling 
To monitor in vivo cell proliferation or in vivo killing, cells were labeled with CFSE. After 
determining the cell number, cells were stained with the Vybrant CFDA SE (CFSE) cell 
tracer kit (Molecular Probes/Invitrogen, Karlsruhe, Germany) at 5 × 107 cells per ml CFSE 
in PBS for adoptive transfer experiments and in vivo cytotoxicity assays. The suspension 
was incubated at 37°C for 10 min, 25 ml complete IMDM were added and an incubation 
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step on ice for 5 min was performed. Subsequently, cells were centrifuged at 1000 rpm for 
10 min and washed twice with PBS. 
2.10 Biochemical methods 
2.10.1 SDS-PAGE 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins 
under denaturing conditions by molecular weight. In this study, 12% polyacrylamid gels 
were used. To prepare the resolving gel, 3,3 ml H2O, 4 ml 30% acrylamide (Rotiphorese 
Gel 30, Roth, Karlsruhe, Germany), 2,5 ml 1,5 M Tris pH 8,8, 0,1 ml 10% w/v SDS, 
0,1 ml 10% w/v APS and 0,004 ml TEMED were mixed. The stacking gel consisted of 
2,7 ml H2O, 0,67 ml 30% acrylamide, 0,5 ml 1 M Tris pH 6,8, 0,04 ml 10% v/v SDS, 
0,04 ml 10% w/v APS and 0,004 ml TEMED. Before loading, the samples were 
denaturized at 95°C for 5 min. Rainbow-Marker RPN 756 (Amersham Biosciences, 
Freiburg, Germany) was used as protein marker for Western Blots. The gels were run at 
150 V. 
2.10.2 Western Blot 
Western Blot is a method to specifically detect separated proteins on gels. After gel 
electrophoresis, the proteins were transferred on a 0,45 µm polyvinylidene fluoride transfer 
membrane (Immobilon-P, Millipore, Schwalbach, Germany) using the semi-dry method. 
The transfer membrane and Whatman 3 MM paper was soaked in blotting buffer (5,8 g 
Tris base, 28,5 g glycine, 1,0 g SDS, 200 ml methanol in 1 l H2O) and the blot was 
assembled in the following order, starting from the bottom electrode plate (the cathode): 3 
layers of wet Whatman paper, polyacrylamide gel, wet transfer membrane, 3 layers of wet 
Whatman paper. After removing air bubbles, the upper electrode was placed on top of the 
stack and the blot was run with 1 mA/(cm² of gel) for 1 h. Then the membrane was 
incubated in blocking buffer (5% w/v skim milk powder in 0,1% v/v Tween 20/PBS) at 
room temperature for 1-2 h before the first antibody (polyclonal rabbit-anti-LLO) was 
added in 1:3000 dilution in staining buffer (3% w/v skim milk powder in 0,1% v/v 
Tween 20/PBS) for 1 h at room temperature. After 3 washing steps with 0,1% v/v Tween 
20/PBS, the proteins were stained with the secondary antibody (goat-anti-rabbit-
horseradish peroxidase, 1:6000 dilution) at room temperature for 1 h. Subsequently, the 
2 Material and methods 
 
57 
membrane was washed and specific bands were detected using the ECL-
chemiluminescence kit (Amersham Biosciences, Freiburg, Germany) according to the 
manufacturer’s instructions. 
2.10.3 Determination of L-arabinose concentration in blood plasma 
The concentration of L-arabinose in blood plasma of mice was enzymatically determined 
by the method of Melrose and Sturgeon (Melrose and Sturgeon 1983). In brief, 200 µl 
blood were obtained by retro orbital bleeding and 25 units heparin sodium were added 
immediately. Samples were centrifuged at 10000 x g for 5 min and 50 µl of the supernatant 
were mixed with 830 µl of 0,1 mM Tris-HCl (pH 8,6) and 100 µl of 5 mM nicotinamide-
adenine dinucleotide (ß-NAD, Sigma-Aldrich). Absorbance at 339 nm (A1) was measured 
using the Spectronic 401 photometer (Milton Roy) and subsequently 20 µl 5 U ml-1 
galactose dehydrogenase (Roche Diagnostics, Mannheim, Germany) were added. After 
incubating the reaction mixture at room temperature for 40 min, measurement (A2) was 
repeated. The concentration of L-arabinose was calculated from the change of absorbance 
(A2-A1) multiplied with factor 475,9. 
2.11 Immunological methods 
2.11.1 Flow cytometry 
Flow cytometry measures the properties of individual particles, e.g. the size and 
granularity of cells and bacteria. Moreover, by staining cells with appropriate 
fluorochrome-conjugated antibodies, this method allows sensitive detection of cell surface 
molecules. Cells for flow cytometric analysis were obtained from cell cultures or from 
homogenized organs. In general, single cell suspensions were prepared in FACS buffer 
(2% FCS, 2 mM EDTA in PBS) at a density of 106–107 cells ml-1 in 96-well plates or 
FACS tubes. To block Fc-receptors, cells were then treated with rat-anti-mouse 
CD16/CD32 (FcγIII/II-receptor) (BD Pharmingen, San Diego, USA) on ice for 15 min. 
After washing, cells were stained with antibodies on ice for 15 min and washed once. 
Biotinylated antibodies were then counterstained with conjugated Streptavidin-APC-Cy7 
(BD Pharmingen) on ice for 15 min. Cells were again washed once and resuspended in 
FACS buffer. Before analysis, 1 µg ml-1 propidium iodide (Sigma-Aldrich, Taufkirchen, 
Germany) was added to discriminate live and dead cells. For analysis a FACSCalibur or a 
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FACSCanto Flow Cytometer (Becton Dickinson, Heidelberg, Germany) were used and 
data were analysed using BD CellQuest Pro, BD FACSDiva or WinMDI software. 
2.11.2 Antibodies for flow cytometry 
rat-anti-mouse CD4 APC (RM4-5, BD Pharmingen) 
anti-mouse DO11.10 TCR biotin (KJ1-26, Caltag Lab., Burlingame, CA, USA) 
2.11.3 Magnetic cells sorting 
Magnetic cell sorting (MACS) was developed to separate magnetically labeled cells from 
unlabeled cells by retaining them on a column in a magnetic field. In this study a CD4+ T 
Cell Isolation Kit together with LS Columns and a MidiMACS Separator (Miltenyi Biotec, 
Bergisch Gladbach, Germany) was used according to the manufacturer’s instructions. 
Briefly, non-CD4+ T cells are labeled with a mix of biotin-conjugated antibodies and anti-
biotin antibodies conjugated to magnetic beads. By applying the cell suspension onto the 
columns within a magnetic field, unlabeled CD4+ T cells pass through and can be isolated 
via negative selection. This method was used in the present work to obtain highly pure 
CD4+ T cells from DO11.10 mice for adoptive transfer experiments. 
2.12 Determination of reporter gene expression in mouse 
macrophages 
2.12.1 Infection of macrophages with recombinant Salmonella 
Cells of the macrophage line J774-A.1 were seeded in 6-well plates at a density of 2 × 105 
cells/well in IMDM medium without antibiotics one day before infection with recombinant 
Salmonella, Bacteria were grown overnight in LB medium at 37°C without shaking to an 
OD600 of 0,8. After washing once with PBS, the bacteria were resuspended in antibiotic-
free IMDM and the cells were infected with a multiplicity of infection (MOI) of 10. Cells 
were incubated at 37°C for 1 h, washed twice with PBS and extracellular bacteria were 
killed by incubation with medium containing 50 µg ml-1 gentamycin (Biochrom, Berlin, 
Germany). The medium was replaced after 1 h with medium containing 10 µg ml-1 
gentamycin and incubation continued for 22 h to measure plasmid amplification by in vivo 
inducible promoters. To test L-arabinose inducible plasmid amplification, the sugar was 
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dissolved in medium and added at different concentrations into wells 3 h p.i. The cells 
were incubated for another 4 h before reporter gene expression was analyzed. 
2.12.2 Preparation of infected mouse macrophages for flow 
cytometry 
After washing twice with PBS, infected J774-A.1 cells were lysed in PBS containing 
0,1% v/v Triton-X and incubated at 37°C for 10 min. Then, an equal volume of buffer 
(2mM EDTA in PBS) was added and the cell extract was filtered using 30 µm CellTrics 
(Partec GmbH, Münster, Germany) before samples were analyzed via two color flow 
cytometry. 
2.12.3 Preparation of infected mouse macrophages for luciferase 
assay 
After washing twice with PBS, infected J774-A.1 cells were detached in 1 ml PBS using a 
cell scraper. 500 µl of the sample were mixed with an equal volume of lysis buffer (50 mM 
Tris-HCl pH 8,3, 4 mM DTT, 20% v/v glycerol, 2% v/v Triton-X, 2 mg ml-1 lysozyme) 
and the mixture was incubated at room temperature with shaking for 10 min. Luciferase 
activity of the supernatants was determined using the Luciferase Assay System according 
to the manufacturer’s instructions. To determine intracellular bacterial numbers, 500 µl of 
detached cells were lysed by adding PBS containing 0,5% v/v Triton-X and cfu were 
enumerated by plating serial dilutions. 
2.13 Immunization with recombinant Salmonella 
2.13.1 Infection of mice 
Recombinant Salmonella strains for i.v. infection were cultured in LB medium until they 
reached OD600 0,8 – 1,0. The bacteria were harvested by centrifugation at 6000 rpm for 
5 min, washed twice in PBS and resuspended in PBS to 5 × 105-7 cfu ml-1. A sample of 
100 µl of this suspension was administered i.v. to mice. The bacteria for oral infection 
were grown in LB medium containing 1,5% NaCl until they reached OD600 0,8. After 
centrifugation, the bacterial suspension was adjusted to a concentration of 
5-10 × 109 cfu ml-1 in PBS and mice were inoculated with 100 µl intragastrically using a 
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gavage needle. Prior to immunization, 100 µl of 6,6% sodium bicarbonate in PBS was 
administered intragastrically immediately before. 
2.13.2 Colonization and plasmid stability in vivo 
At different time points after oral application of the different recombinant Salmonella 
strains, Peyer’s Patches (PP), mesenteric lymph nodes (MLN) and spleen were removed 
and homogenized in PBS containing 0,1% Triton-X to lyse the cells and release 
intracellular bacteria using a Polytron PT3000 homogenizer (Kinematica AG, Littau-
Lucerne, Switzerland). Serial dilutions were plated on LB-agar plates with or without 
antibiotics to determine the organ colonization and to calculate the percent of plasmid 
stability. 
2.13.3 Preparation of infected mouse organs for flow cytometry 
To determine reporter gene expression of bacteria in vivo, mice were sacrificed two days 
after i.v. infection. The spleen was removed and flushed with 2 ml PBS. Then, the 
suspensions were diluted 1:10 in 0,1% Triton-X/PBS containing 2 mM EDTA, filtered 
using 30 µm CellTrics and 300 µl of the samples were analyzed via two color flow 
cytometry. 
2.13.4 Adoptive transfer of DO11.10 T cells and immunization with 
Ova323-339 expressing Salmonella 
DO11.10 mice were used as cell donors for adoptive transfer into sex-matched BALB/c 
mice. Lymphocytes were isolated from MLN and spleen, the CD4+ T cell population was 
isolated by MACS and labeled with 5 µM CFSE before transferring 5 × 106 transgenic 
CD4+ T cells per recipient mouse by tail vain injection. One day later, the mice were 
immunized orally or i.v. with 1 × 109 cfu or 0,5-1 × 106 cfu, respectively. As positive 
control, mice were fed 15 mg ovalbumin (Grade III, Sigma-Aldrich, Taufkirchen, 
Germany) in 200 µl PBS by gavage needle. Mice were sacrificed 7 d after immunization 
and single-cell suspensions of spleens and MLN were prepared by mincing through a 70 
µm nylon mesh (BD Biosciences, Erembodegem, Belgium). Spleens were treated with 
erythrocyte lysis buffer (17 mM Tris, 140 mM NH4Cl in H2O, pH 7,2) for 5 min and taken 
up in complete IMDM containing DNase I (20 U ml-1, Sigma-Aldrich, Taufkirchen, 
2 Material and methods 
 
61 
Germany) whereas MLN were treated immediately with IMDM containing DNase I at 
37°C for 15 min. After washing with FACS buffer and blocking, the cells were stained 
with biotinylated anti-tgTCR clonotype-antibody KJ1-26 and CD4-APC, followed by 
Streptavidin-APC-Cy7 and FACS analysis was performed on a FACSCanto Flow 
Cytometer. 
2.13.5 In vivo cytotoxicity assay for LLO91-99 specific immune 
responses 
2.13.5.1 Immunization of mice 
For in vivo cytotoxicity assays, mice were immunized with LLO49-361 expressing 
Salmonella. Mice received three doses of recombinant Salmonella in 14 day intervals 
orally or i.v. with 1 × 109 cfu or 0,5-1 × 105 cfu, respectively. The assay was performed 
9-11 days after the last immunization. Control mice were uninfected or infected with 
1 × 103 L. monocytogenes i.v. 10 days before the assay. Practically, Listeria were incubated 
overnight at 180 rpm and 37°C in BHI broth. Next morning the culture was diluted 1:10 in 
fresh BHI broth and grown for approximately 2 h. Concentration of bacteria was 
determined by measuring the OD600. Then the bacteria were washed in PBS and 
resuspended in PBS obtaining 1 × 103 ml-1. Bacterial numbers were confirmed by plating 
serial dilutions of the suspension.
 
2.13.5.2 In vivo cytotoxicity assay 
The in vivo cytotoxicity assay was performed to directly evaluate the induction of specific 
cytotoxic T cells in immunized mice. Naïve BALB/c mice (1 mouse per 3 recipient mice) 
were sacrificed and spleens were collected. The spleens were flushed with erythrocyte lysis 
buffer and erythrocytes were lysed at room temperature for 5-10 min. Cells were filtered 
through a 30 µm Nylon mesh (BD Biosciences, Erembodegem, Belgium), collected in 
50 ml Falcon tubes and the tube was filled with complete IMDM before centrifuging at 
1000 rpm for 10 min. Cells were resuspended in 50 ml complete IMDM and counted. The 
cell suspension was divided into two equal volumes. One half served as control cells and 
an equal volume of medium was added to the cells. The other half was sensitized with 
LLO91-99 peptide at an end concentration of 1 µg ml-1. The peptide was added to the cells in 
an equal volume of complete IMDM. Both control and sensitized cells were incubated at 
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37°C for 45 min. Cells were then washed twice with PBS. Subsequently, LLO-sensitized 
cells were stained with 5 µm CFSE at 5 × 107 cells per ml CFSE solution. Control cells 
were similarly stained but with 0,5 µm CFSE. Cells were incubated at 37°C for 10 min, 
25 ml complete IMDM was added and a last incubation step for 5 min on ice was 
performed. Cells were again washed twice with PBS and both populations were pooled and 
adjusted to a concentration of 1-2 × 108 ml-1. Each immunized mouse was injected with 
100 µl i.v.  
16-18 h after injection mice were sacrificed and 200 µl heart blood was collected in a 
syringe containing 100 µl Heparin (Liquemin, Roche Pharma, Reinach, Switzerland, 1:100 
diluted in PBS). The blood/heparin mix was diluted with 800 µl 5 mM EDTA in PBS and 
2 ml erythrocyte lysis buffer and incubated at room temperature for 5 min. The suspension 
was centrifuged at 1000 rpm for 5 min and the pellet was again treated with 2 ml 
erythrocyte lysis buffer and incubated at room temperature for 5 min. Then, the cells were 
washed twice with 2 ml PBS and resuspended in 200 µl FACS buffer and finally analyzed 
by flow cytometry. The ratios of control cells (CFSElow) and LLO91-99-sensitized cells 
(CFSEhigh) in uninfected mice should be 50:50 (in percent). When a cytotoxic reaction 
occurs, sensitized cells are killed and therefore the ratio will change. Specific cytotoxic 
killing can thus be determined. 
2.14 Infection of tumor-bearing mice  
To establish a subcutaneous tumor in BALB/c mice, CT26 or TS/A cells were harvested by 
trypsin treatment, washed once with PBS and resuspended in PBS to obtain a single cell 
suspension of 1-2 × 107 ml-1. 50 µl were injected s.c. into each mouse. Mice bearing 
tumors of 5 - 8 mm in diameter (approximately at day 10 after tumor transplantation) were 
intravenously injected with 5 x 105 cfu of bacteria suspended in PBS. At different time 
points post-infection, L-arabinose dissolved in PBS was administered i.p. to mice. At 
various time points after injection, mice were sacrificed and tumor, spleen and liver were 
transferred into 3 ml if ice-cold PBS. Tissues were disrupted using a Polytron PT3000 
homogenizer. To analyze colonization, 500 µl homogenate was diluted with 500 µl PBS 
containing 0,25 % (v/v) Triton X-100 and serial dilutions were plated with or without 
antibiotics. To measure luciferase expression, 500 µl homogenate were mixed with an 
equal volume of lysis buffer (50 mM Tris-HCl pH 8,3, 4 mM DTT, 20% v/v glycerol, 
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2% v/v Triton-X, 2 mg ml-1 lysozyme) and the mixture was incubated at room temperature 
with shaking for 10 min. Luciferase activity of the supernatants was determined using the 
Luciferase Assay System according to the manufacturer’s instructions. 
2.15 Non-invasive in vivo imaging 
BALB/c mice were immunized intragastrically with 2 x 109 cfu of SL7207 harboring the 
luxCDABE expression plasmid pAEN102. Mice were anaesthetized with isoflurane using 
the XGI-8 gas anaesthesia system (Xenogen, Hopkinton, USA). Images were obtained at 
consecutive time points thereafter using the IVIS-200 system (Xenogen) according to 
instructions of the manufacturer. The software Living image 2.6 (Xenogen) was used for 
image analysis and quantification of emission intensities. 
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3 Results 
Thus far, optimization of Salmonella as delivery vector for proteins or expression plasmids 
with regard to stability of the recombinant phenotype included chromosomal integration of 
the gene of interest or the use of low-copy number plasmids in conjunction with balanced 
lethal systems (Kotton and Hohmann 2004). In the present work, as an alternative, a 
system for inducible amplification of expression plasmids was developed in the 
S.typhimurium vaccine strain SL7207. To allow control of the copy number, expression 
plasmids were constructed that contain two origins of replication. The first replicon 
ensures the minimal-copy state under non-inducing conditions (e.g. the inoculum). The 
second, medium-copy replicon is derived from the broad host-range plasmid RK2. It is 
responsible for conditional amplification of the expression plasmid (Wild et al. 2002). 
Replication via the RK2-derived origin of replication oriV depends on the protein TrfA, 
which is essential for replication initiation. TrfA binds in the monomeric form to the host 
initiator protein DnaA and to direct repeats (iterons) at oriV (Kongsuwan et al. 2006). 
Expression of the trfA gene is tightly controlled by a transcriptional linkage to Salmonella- 
specific in vivo inducible promoters or the L-arabinose inducible promoter PBAD, 
respectively. Upon induction, the promoters drive the expression of the replication protein 
TrfA that in turn activates the second replicon and thereby mediates amplified plasmid 
replication.  
3.1 Establishment of an in vivo inducible plasmid 
amplification system 
3.1.1 Characterization of in vivo inducible promoters in 
S. typhimurium SL7207 
First, in vivo inducible promoters were used to initiate plasmid amplification upon vaccine 
administration. As a prerequisite for tight control, suitable promoters should provide low 
background activity under non-inducing conditions coupled with a strong expression once 
being activated. Therefore, three previously identified in vivo inducible promoters PphoN, 
Pstm1630 and PsifA (Rollenhagen et al. 2004) were considered. First, they were characterized 
in SL7207, an attenuated strain of S. typhimurium that is commonly used as carrier for 
heterologous antigens and expression plasmids (Hoiseth and Stocker 1981). Promoter PphoN 
drives the PhoP-activated expression of phoN, a periplasmic non-specific acid phophatase 
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(Kasahara et al. 1991). Promoter PsifA regulates the expression of the SPI2-TTSS effector 
SifA (Brown et al. 2006) and promoter Pstm1630 drives the expression of a putative inner 
membrane protein within SPI2. These promoters were chosen because they share the 
common feature to be activated within intracellular compartments of host cells. Thus, they 
have a high potential to mediate the amplification of expression plasmids upon entry of 
Salmonella into APC of lymphoid tissues.  
Fragments containing the promoter regions of phoN, stm1630 and sifA were cloned 
upstream of gfpmut2 and integrated as a single copy into the Tn7-specific integration site 
of the Salmonella chromosome (see Fig. 2.8). This GFP variant is stable and accumulates 
in cells rendering the detection of low promoter activity feasible. The intracellular 
conditions leading to activation of the promoters in vivo can be mimicked in vitro by 
growing the bacteria in defined minimal media containing low amounts of divalent cations 
(Deiwick et al. 1999). Accordingly, to analyze reporter expression, the chromosomal 
integration derivatives were grown in induction medium, an acidic minimal medium 
without Ca2+ and low Mg2+ levels. Under inducing conditions, all strains bearing 
chromosomally integrated constructs expressed GFP in detectable amounts (Fig. 3.1). PsifA 
showed the strongest induction (median fluorescence intensity MFI 5,5) in comparison to 
PphoN (MFI 4) and Pstm1630 (MFI 3,9). Importantly, for PsifA, almost no background was 
detectable when grown in LB medium compared to the parental strain SL7207. In contrast, 
slight activation of PphoN and Pstm1630 during growth in LB medium could be observed. 
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Fig. 3.1: Flow cytometric detection of GFP expression in vitro. Thick lines represent strains 
SL7207::AEN45.1 (PphoN-gfp), SL7207::AEN45.2 (Pstm1630-gfp) and SL7207::45.3 (PsifA-gfp) grown under 
non-inducing conditions (LB), dashed lines represent strains grown under inducing conditions (IM). The 
shaded curve represents background fluorescence of the parental strain SL7207. 
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3.1.2 Construction of strains with inducible plasmid amplification 
Next, the promoters were fused to trfA in order to amplify expression plasmids. TrfA 
cassettes were chromosomally integrated via Tn7-mediated transposition. Strains 
SL7207::AEN47.1-3 are shown in Fig. 2.8. Plasmid pAEN35 was cloned as reporter 
construct for plasmid amplification. This plasmid is equipped with the F plasmid derived 
single-copy maintenance system oriS-repE-parABC as well as the second origin of 
replication oriV (Fig. 3.2). Moreover, pAEN35 harbors gfp_ova under control of the 
ß-lactamase promoter of E. coli Pbla. This weak promoter was chosen to obtain a sensitive 
method for detection of plasmid amplification via increased reporter expression. 
Furthermore, the instable GFP_ova variant was chosen as reporter in order to prevent 
excessive GFP accumulation thus impairing Salmonella virulence (Wendland and Bumann 
2002). 
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Fig. 3.2: Construction of SL7207 strains with inducible plasmid amplification. The bacteria 
carry a gfp_ova expression plasmid, which is maintained as single copy due to F plasmid elements. Upon 
promoter activation, the chromosomally integrated replication protein TrfA is expressed and mediates 
amplified replication from the second replicon, oriV. 
Strains SL7207::AEN 47.1-3 were transformed with pAEN35, which is maintained as 
single copy when the promoters are not active. Upon induction of the oriV/trfA 
amplification system plasmid amplification should start. As expected, the copy number of 
plasmid pAEN35 increased in all strains when grown under inducing conditions compared 
to growth in standard medium (Fig. 3.3). The strain PsifA-trfA induced the strongest 
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amplification with a low background under non-inducing conditions (from one to fifty 
plasmid copies). 
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Fig. 3.3:  In vitro inducible plasmid amplification. (A) Copy number of pAEN35 in strains 
SL7207::AEN47.1 (PphoN-trfA), SL7207::AEN47.2 (Pstm1630-trfA) and SL7207::47.3 (PsifA-trfA) grown under 
non-inducing conditions (LB, black bars) and inducing conditions (IM, open bars). (B) Plasmid preparations 
from the different strains. A total of 2 × 109 transformants were used for plasmid preparations from strains 
grown in LB and 2 × 107 for IM, respectively. Plasmids were digested with PstI to facilitate comparison on 
the agarose gel. M indicates the size marker. 
The strains were further analyzed in culture for reporter gene expression via flow 
cytometry. Amplification of pAEN35 in PsifA-trfA resulted in an increase of gfp_ova 
expression whereas almost no fluorescence could be detected in standard growth medium. 
This is also obvious when compared to the parental strain transformed with the same 
plasmid (Fig. 3.4 A). In contrast, numbers of expression plasmid and reporter expression 
were higher in strain PphoN-trfA under non-inducing conditions compared to strain PsifA-trfA, 
demonstrating the higher background activity of this promoter that could be already 
observed (see Fig. 3.1). Compared to PphoN and PsifA, the plasmid amplification induced by 
Pstm1630 was significantly lower.  
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Fig. 3.4: In vitro and in vivo inducible plasmid amplification. Strains SL7207::AEN47.1 
(PphoN-trfA), SL7207::AEN47.2 (Pstm1630-trfA) and SL7207::47.3 (PsifA-trfA) harboring pAEN35 were used. 
(A) Flow cytometric detection of in vitro GFP expression. The shaded curve represents background 
fluorescence of the parental strain SL7207 transformed with pAEN35. (B) GFP expression of strains 24 h 
after infection of J774-A.1 mouse macrophages quantified by two color flow cytometry. (C) In vivo GFP 
expression of strains measured by two color flow cytometry. Mice were infected i.v. with 5 × 106 cfu; 2 d p.i. 
spleens were removed and analyzed. In each case, thick lines represent strains grown under non-inducing 
conditions (LB), dashed lines represent strains grown under inducing conditions (IM, macrophages, spleen). 
The quantitation of GFP in infected host cells is normally hampered by strongly 
autofluorescing tissue fragments, which significantly decrease the sensitivity of detection. 
Therefore, two color flow cytometry was used to quantify the GFP expression of 
Salmonella after infection of the macrophage cell line J774-A1 and in spleens of infected 
mice (Bumann 2002). This method allows spectral distinction between GFP fluorescence 
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and background autofluorescence, resulting in lower detection thresholds for Salmonella 
GFP expression in infected tissues.  
First, J774-A1 mouse macrophages were infected with strains SL7207::AEN47.1-3 
harboring pAEN35, lysed 24 h thereafter and cellular lysates were analyzed by two color 
flow cytometry. As shown in Fig. 3.4 B, all three chromosomal constructs induced levels 
of GFP expression that were above the background fluorescence of cellular debris 
indicating a successful amplification of the expression plasmids.  
Next, amplification of GFP_ova expression plasmids was analyzed in vivo. Mice were 
infected intravenously with the recombinant strains and two days later spleen homogenates 
were submitted to two color flow cytometry. Again all three strains induced plasmid 
amplification leading to enhanced levels of the reporter compared to strains grown under 
noninducing conditions (Fig. 3.4 C). Moreover, no bacteria expressing GFP above the 
background fluorescence of cellular debris could be detected in mice that were infected 
with parental SL7207 carrying the expression plasmid (data not shown). As can be seen in 
Fig. 3.4 B and Fig. 3.4 C, Pstm1630-trfA exhibits similar levels of induced GFP expression as 
PsifA and PphoN, which is in contradiction to the data obtained in induction medium. 
Probably, bacterial subpopulations with lower GFP expression levels were not detected due 
to interfering host cell autofluorescence in this case.  
Taken together, the data clearly show that expression plasmids can be amplified in 
bacterial culture, in J774-A1 mouse macrophages and in vivo using the novel system. 
However, it appears that PsifA is the most appropriate promoter for the development of a 
vaccine strain, since it combines a strong inducible amplification in infected tissues with a 
low background in the uninduced state. 
3.1.3 Simultaneous amplification of plasmid replication and 
antigen expression 
In order to further increase antigen expression, a system for simultaneous amplification of 
plasmid replication and protein expression was established. Therefore, the inducible 
promoter PsifA was used in parallel for the amplification of expression plasmids and in 
addition directly for antigen expression (Fig. 3.5). In doing so, enhanced levels of antigen 
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expression were expected. Additionally, the background fluorescence under non-inducing 
conditions should be further decreased using PsifA-gfp_ova instead of Pbla-gfp_ova.  
The use of low-copy expression vectors derived from plasmids pSC101, pMB1 or p15A 
had been described for Salmonella vaccines (Panthel et al. 2005, Bauer et al. 2005, Kotton 
et al. 2006). Such plasmids are maintained at 5-20 copies per cell imposing a low 
metabolic burden on transformed bacteria. To increase the starting copy number for 
amplification from 1 to 5-20, plasmids were generated harboring these different low-copy 
number replicons (ori X in Fig. 3.5). 
trfAPsifA
pAEN_
CmR
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gfp_ova
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S. typhimurium SL7207
 
Fig. 3.5: Strategy for simultaneous amplification of plasmid replication and antigen expression 
using the in vivo inducible promoter PsifA. First, once activated, the promoter drives the expression of 
gfp_ova. The reporter is encoded on expression plasmids that are maintained at different minimal-copy 
numbers depending on the ori X. Second, once activated, the promoter induces expression of TrfA, which 
mediates amplified replication from the second replicon, oriV. 
The parental strain SL7207 and the chromosomal integration derivative PsifA-trfA were 
transformed with these new plasmids and tested for antigen expression in vitro. Detectable 
antigen expression was induced by PsifA in the parental strain SL7207 harboring the 
plasmid that is maintained as single copy due to the F plasmid replicon (Fig. 3.6 A). 
Enhanced antigen expression could be observed in induction medium with the strain 
SL7207::PsifA-trfA. This is due to amplification of the expression plasmid in addition to 
induced expression. Importantly, this expression plasmid was amplified up to 50 copies in 
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vitro like pAEN35, indicating that inducible expression of the antigen does not interfere 
with inducible plasmid amplification.  
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Fig. 3.6: Simultaneous amplification of plasmid replication and GFP_ova expression in vitro 
under control of PsifA. Strains SL7207 or SL7207::PsifA-trfA harboring expression plasmids pAEN51 (A), 
pAEN61 (B), pAEN108 (C) or pAEN109 (D) were grown under non-inducing conditions (LB, thick lines) or 
inducing conditions (IM, dashed lines), analyzed by flow cytometry and the copy number was determined. 
Exchanging the F plasmid replicon with other low-copy number replicons resulted in all 
cases in higher antigen expression in the parental strain SL7207 under inducing conditions 
(Fig. 3.6). Thereby, GFP_ova expression increased proportionally with the copy number of 
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the plasmids as expected. However, when strain SL7207::PsifA-trfA was transformed with 
the indicated expression plasmids, different effects could be observed. In case of the 
pSC101 and p15A ori, a copy number of about 100 molecules in each bacterial cell could 
be determined in induction medium. This was associated with high GFP expression 
(Fig. 3.6 B and D). In contrast, the plasmid harboring the pMB1 ori did not show enhanced 
antigen expression and significant increase of copy number in SL7207::PsifA-trfA under 
inducing conditions (Fig. 3.6 C). It is unclear why the pMB1 containing plasmid could not 
be amplified. Obviously, some interference of replication from the different origin of 
replications pMB1 and oriV takes place. 
Taken together, an increased conditional antigen level could be achieved on the one hand 
by placing plasmid amplification and protein expression under simultaneous control of the 
in vivo inducible promoter PsifA. A higher copy number could be achieved in some cases 
under inducing conditions by exchanging the origin of replication that determines the 
initial minimal copy number. This result was rather unexpected, since the second origin of 
replication oriV and the replication protein TrfA mediate the plasmid amplification. 
Therefore, its magnitude should be independent of the basal uninduced copy number.  
The constructs pAEN51 and pAEN61, containing the F plasmid and pSC101 replicon, 
were chosen for further experiments, since they combine a very low copy number (single 
copy and 5 copies, respectively) and low antigen expression under non-inducing conditions 
with strong inducible plasmid amplification and antigen expression in vitro.  
Hence, SL7207::PsifA-trfA carrying pAEN51 and pAEN61 were used to infect mice 
intravenously and two days later spleen homogenates were analyzed for GFP expression 
via two color flow cytometry. Both constructs exhibited a strong antigen expression in 
spleens of infected mice (Fig. 3.7). The higher copy number of induced pAEN61 could be 
confirmed, since the GFP expression level of bacteria carrying this construct was higher 
(MFI 542) compared to plasmid pAEN51 (MFI 457).  
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Fig. 3.7: Simultaneous amplification of plasmid replication and antigen expression in vivo 
under control of PsifA. GFP expression of strain SL7207::AEN47.3 (SL7207::PsifA-trfA) harboring plasmid 
pAEN51 (A) and plasmid pAEN61 (B) measured by two color flow cytometry. Mice were infected i.v. with 
5 × 106 cfu of the indicated strains. 2 d p.i. spleens were removed and analyzed. Thick lines represent 
bacteria grown under non-inducing conditions (LB); dashed lines represent bacteria grown in vivo. 
3.1.4 Colonization of mice by strains with inducible plasmid 
amplification 
To test whether the chromosomal integration of the trfA gene influences the invasion 
efficiency, mice were infected orally with the parental strain SL7207 or the plasmidless 
recombinant strain SL7207::AEN47.3 harboring a PsifA-trfA cassette integrated into the 
chromosome. Similar bacterial numbers could be isolated from PP and mesenteric lymph 
nodes (MLN) at different time points after infection with both strains (Fig. 3.8). 
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Fig. 3.8:  Comparison of colonization efficiency of the parental strain SL7207 and the 
chromosomal integration derivative SL7207::PsifA-trfA. Bacterial numbers in PP (A) and MLN (B) after 
oral administration of 1 × 109 cfu of SL7207 or SL7207::PsifA-trfA. Values represent the average for three 
mice per group (mean + s.d.). 
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Besides the in vivo antigen expression level, colonization capability and stability of the 
vector system are important parameters for vaccination efficiency. To evaluate the 
PsifA-trfA strains with inducible plasmid amplification in this respect, mice were infected 
orally and then bacterial numbers and plasmid stability were determined in PP, MLN and 
spleen at different time points. Additionally, these strains were compared with the parental 
strain SL7207 without plasmid or transformed with the same PsifA-gfp_ova expression 
plasmids.  
As seen in Fig. 3.9 A, the parental strain SL7207 exponentially proliferates in the PP until 
day 7 p.i.. A similar kinetic with about 10-fold lower numbers could be observed in MLN 
(Fig. 3.9 B). Bacterial numbers in spleen were similar to those observed in MLN at day 7 
p.i. (data not shown). Despite lower bacterial counts at day 1 p.i., Salmonella without 
chromosomal integration carrying only the expression plasmids had no major colonization 
disadvantages in PP and MLN compared to SL7207. This confirmed that expression 
plasmids with the F plasmid and pSC101 replicon impose no metabolic burden upon the 
carrier when maintained in one or five copies, respectively. In concordance, the plasmids 
were present throughout the entire observation period (Fig. 3.10 A and B). The PsifA-trfA 
strains that amplified the expression plasmids exhibited comparable bacterial numbers to 
plasmid carriers without PsifA-trfA integration at day 1 p.i.. However, their numbers 
declined throughout the infection (Fig. 3.9 A and B). This could be attributed to plasmid 
loss within 7 days p.i. (Fig. 3.10. A and B), since the values in Fig. 3.9 A and B were 
determined by plating with antibiotic selection.  
That the induced amplification would eventually lead to plasmid loss was not unexpected. 
Again not surprisingly, the pSC101 plasmid, which is amplified twice as high was lost 
more rapidly than the one with the F plasmid replicon.  
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Fig. 3.9: Bacterial colonization after oral infection of mice. Mice were infected with 5 × 108 cfu 
of SL7207 or recombinant GFP_ova expressing SL7207. Colonization of PP (A) and MLN (B) as determined 
from plating with antibiotics. Values represent the average for three mice per data point (mean + s.d.). For 
clarity of the figure, plasmid constructs are indicated with the first origin of replication only: F = pAEN51; 
pSC101 = pAEN61. Strains with inducible amplification of the expression plasmid are indicated as PsifA-trfA. 
Experiment was performed twice with similar results. 
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Fig. 3.10: Plasmid stability after oral infection of mice. Mice were infected with 5 × 108 cfu of 
recombinant GFP_ova expressing SL7207.Stability of PsifA-gfp_ova expression plasmids in PP (A) and MLN 
(B). Values represent the average for three mice per data point (mean + s.d.). For clarity of the figure, 
plasmid constructs are indicated with the first origin of replication only: F = pAEN51; pSC101 = pAEN61. 
Strains with inducible amplification of the expression plasmid are indicated as PsifA-trfA. Experiment was 
performed twice with similar results. 
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3.1.5 Immunization of mice 
The colonization studies showed that the novel Salmonella strains with inducible plasmid 
amplification stably retained expression plasmids in a multi-copy state for at least three 
days in vivo. This represents an important improvement in comparison to high-copy 
number systems in which no Salmonella carrying expression plasmids could be detected in 
murine tissues after oral infection due to a very low stability (Darji et al. 1997, Dunstan et 
al. 2003, Bauer et al. 2005). Hence, it should be tested, whether this results in sufficient 
expression of the model antigens OVA323-339 and LLO to trigger specific CD4+ and CD8+ T 
cells.  
3.1.5.1 Generation of CD4+ T cell responses 
GFP_ova had been used as reporter to measure in vivo inducible plasmid amplification 
coupled with antigen expression via flow cytometry. This gene is a fusion of the gfp 
variant mut2 and a 25-amino-acid-fragment of ovalbumin. It contains a dominant MHC 
class II (H-2d) presented 17-mer T cell epitope together with the 4 adjacent amino acids on 
both the N and the C termini (Bumann 2001a). Therefore, GFP_ova is a suitable antigen to 
analyze the induction of Ova-specific CD4+ T cells following immunisation with 
recombinant Salmonella. A widely used transgenic T cell receptor (tgTCR) adoptive 
transfer model (Pape et al. 1997) was used for analysis. In this system, a few million CD4+ 
T cells from DO11.10 mice, which are transgenic for a TCR that recognizes the ovalbumin 
epitope (amino acids 323 to 339) bound to I-Ad MHC class II molecules, are transferred 
into syngeneic BALB/c mice. In such chimeric mice, the small fraction of transgenic T 
cells can be traced with the clonotypic monoclonal antibody KJ1-26. Transgenic T cells 
were additionally labeled with the fluorescent dye CFSE prior to the adoptive transfer in 
order to characterize their in vivo division via flow cytometry. Proliferation of cells stained 
with CFSE can be followed as the dye is diluted upon cell division and the fluorescence 
intensity accordingly decreases.  
In a pilot experiment, chimeric mice were immunized intragastrically and intravenously 
with SL7207::PsifA-trfA harboring PsifA-gfp_ova expression plasmid pAEN51 with the F 
plasmid replicon one day after the adoptive transfer. Control mice received SL7207 
without any expression plasmid or ovalbumin orally. After oral administration of GFP_ova 
expressing SL7207 to chimeric mice, 12% of the ovalbumin-specific T cells in the spleen 
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lost part of their CFSE fluorescence (Fig. 3.11 C), indicating in vivo division. In contrast, 
only 5% dividing transgenic T cells could be observed after oral immunization with the 
negative control SL7207 (Fig. 3.11 B). Most of the cells had divided in the positive control 
using orally administered ovalbumin (Fig. 3.11 A). After i.v. administration of a lower 
dose of GFP_ova expressing SL7207 to chimeric mice, more dividing antigen-specific T 
cells could be detected in comparison to oral administration (Fig. 3.11 D). This can be 
attributed to a stronger colonization of the spleen after intravenous administration and was 
also observed in the MLN (data not shown). Since the in vivo division of transgenic T cells 
was stronger in case of intravenous administration of recombinant Salmonella, this route of 
immunization was chosen for further experiments to assess the effect of plasmid 
amplification on the generation of CD4+ T cell responses. 
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Fig. 3.11: Proliferation of Ova-specific T cells. Fluorescence of CFSE-labeled Ova323-339-specific T 
cells 7 days after oral immunization with 15 mg ovalbumin (A), 1 × 109 cfu of SL7207 (B), and 1 × 109 cfu 
of SL7207::PsifA-trfA[F:PsifA-gfp_ova] (C) or after i.v. immunization with 5 × 105 cfu of 
SL7207::PsifA-trfA[F:PsifA-gfp_ova] (D). Spleen cells of two mice per group were pooled and histograms are 
gated on CD4+ and tgTCR positive lymphocytes. Experiment was performed once. 
Next, chimeric mice were immunized intravenously with 5 × 105 cfu SL7207::PsifA-trfA 
harboring PsifA-gfp_ova expression plasmids pAEN51 (F plasmid replicon) and pAEN61 
(pSC101 replicon) one day after the adoptive transfer. These strains were compared with 
the parental strain SL7207 and SL7207 transformed with the same PsifA-gfp_ova expression 
plasmids. As positive control, 15 mg ovalbumin were administered orally. Spleen cells as 
well as lymphocytes from mesenteric lymph nodes were tested for proliferation of antigen-
specific helper T cells via flow cytometry 7 d p.i..  
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Fig. 3.12: Plasmid amplification leads to enhanced in vivo division of CFSE-labeled 
Ova323-339-specific T cells. Chimeric mice were immunized i.v. with 5 × 105 cfu of the indicated strains or 
orally with 15 mg ovalbumin. 7 d p.i., antigen-specific T cells were analyzed via flow cytometry. 
(A) Representative histograms for MLN for one mouse per group gated on CD4+ and tgTCR positive 
lymphocytes. Number of cell divisions per 1000 tg T cells and percentages of cells with low fluorescence in 
MLN (B) and spleen (C). Unless otherwise indicated, averages for three mice per group (mean + s.d.) are 
shown (* p<0,05; ** p<0,001). Plasmid constructs are indicated with the first origin of replication only: F = 
pAEN51; pSC101 = pAEN61. Strains with inducible amplification of the expression plasmid are indicated as 
PsifA-trfA. Experiment was performed twice with similar results. 
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As seen in Fig. 3.12 A, the fluorescence of CFSE labeled transgenic T cells decreased 
stronger in case of strains with inducible plasmid amplification and more cell divisions 
occurred apparently. This was confirmed when the number of cell divisions per 1000 
specific T cells and the percentage of cells with low fluorescence intensity was calculated. 
All strains harboring PsifA-gfp_ova expression plasmids exhibited an inidicative decrease in 
fluorescence in spleen and MLN compared to the negative control (Fig. 3.12 B and C). 
Additionally, the number of cell divisions and percentage of CFSElow-cells in spleen was 
significantly higher when the recombinant strains were able to amplify the expression 
plasmids in vivo (Fig. 3.12 C). Interestingly, no difference in the generation of the T helper 
cell response could be observed between the F plasmid and the pSC101 plasmid, although 
the latter is amplified twice as high. Probably, the higher stability of the system with the F 
plasmid replicon compensated the lower final copy number. 
Taken together, in vivo amplification of low-copy number expression plasmids in 
Salmonella vectors leads to stronger CD4+ T cell responses after intravenous 
administration. This remains to be confirmed in an oral immunization scheme. 
3.1.5.2 Generation of cytotoxic T cells 
Thus far, the particular nature of the antigen only tested for induction of CD4+ T helper 
cells. In order to also analyze the CD8+ T cell response, a part of the listeriolysin O (hly) 
gene (amino acids 49-361) was placed under control of PsifA and incorporated into 
amplifiable plasmids with the F plasmid or pSC101 replicon, generating plasmids pAEN98 
or pAEN95, respectively (see Fig. 2.7). The antigenic fragment encodes a non-hemolytic 
variant of the pore-forming toxin LLO of L. monocytogenes that contains the MHC class I 
(H-2Kd) restricted T cell epitope LLO91-99 (Pamer et al. 1991). This antigen is therefore 
suitable to measure the induction of CD8+ T cell responses.  
To evaluate whether exchange of the antigen altered the pattern of plasmid amplification 
and antigen expression, strains SL7207 and SL7207::PsifA-trfA carrying pAEN95 or 
pAEN98 were grown in LB and induction medium and submitted to Western Blot analysis. 
Using SL7207 as carrier of the plasmids, protein expression was upregulated in induction 
medium due to the conditional promoter PsifA (Fig. 3.13). A higher antigen expression 
could be observed when the plasmids were simultaneously amplified in strain 
SL7207::PsifA-trfA. Indeed, the LLO49-361 containing plasmids were approximately 
3 Results 
 
81 
amplified up to 50 (F plasmid replicon) and 100 (pSC101 replicon) copies (data not shown) 
confirming the data obtained with gfp_ova as antigen.  
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Fig. 3.13: Antigen expression and plasmid amplification with LLO49-361 as antigen. Whole lysates 
of strains SL7207 and SL7207::PsifA-trfA grown under non-inducing (LB) and inducing conditions (IM) were 
analyzed by Western Blot using a polyclonal antibody to LLO. The bacteria were transformed with PsifA-LLO 
encoding amplifiable plasmids, which carry the F plasmid or pSC101 replicon to maintain the minimal-copy 
state.  
To test whether the stability of the amplified plasmids could be influenced by the choice of 
antigen, the colonization abilities of strains expressing LLO49-361 were also characterized. 
This had no influence on colonization efficiency and plasmid stability (data not shown).  
Then, it was tested whether in vivo inducible plasmid amplification augments the 
generation of cytotoxic T cells. To this end, BALB/c mice were immunized orally with 
three doses of 1 × 109 cfu recombinant Salmonella expressing LLO49-361 in 14 day intervals 
and the cytotoxic responses measured by an in vivo killer assay 10 d after the last 
immunization. Fig. 3.14 A represents a typical histogram. In naïve control mice, no 
cytotoxic reaction occurs such that untreated (low CFSE) and LLO91-99 sensitized cells 
(high CFSE) remain at their initial 50:50 relationship. In positive control mice immunized 
once with Listeria monocytogenes, LLO91-99 sensitized cells are killed, which can be 
calculated as specific killing (Fig. 3.14 A). In the group immunized with SL7207::PsifA-trfA 
harboring PsifA-LLO expression plasmid pAEN98 (F plasmid replicon), one mouse out of 
three exhibited cytotoxic activity (28% specific killing). Both mice immunized with 
SL7207::PsifA-trfA harboring PsifA-LLO expression plasmid pAEN95 (pSC101 plasmid 
replicon) mounted a specific cytotoxic T cell response (Fig. 3.14 B). However, 
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reproduction of these results failed. In such experiments, mice were immunized with 
SL7207 and SL7207::PsifA-trfA carrying the PsifA-LLO expression plasmids in order to 
assess the influence of plasmid amplification. No specific killing could be detected after 
three oral immunizations. Likewise, mice immunized thrice i.v. with 0,5-1 × 105 cfu of the 
same recombinant strains did not mount a cytotoxic response against the antigen. 
Obviously, the high antigen expression induced in the recombinant Salmonella strains is 
not sufficient to circumvent the problem of antigen delivery to the cytosol of infected cells 
and subsequent MHC class I presentation.  
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Fig. 3.14: In vivo cytotoxicity assay after immunization with LLO49-361 expressing Salmonella. 
(A) Representative histograms for naïve control and Listeria-immunized mice and formula used for 
calculating specific killing. (B) Specific killing determined in individual mice that received a single sublethal 
dose of Listeria or three doses of recombinant Salmonella. Plasmid constructs are indicated with the first 
origin of replication only: F = pAEN98; pSC101 = pAEN95. PsifA-trfA indicates strains with inducible 
amplification of the expression plasmids.  
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3.1.6 Simultaneous in vivo inducible plasmid amplification and 
remote control of bacterial lysis by L-arabinose 
The Salmonella-mediated delivery of antigens or DNA vaccines requires liberation of the 
proteins or plasmids after invasion of APC. A system for programmed lysis of the bacterial 
carrier might be suitable for such a purpose. Therefore, the lysin gene E of the 
bacteriophage фX174 was placed under control of the L-arabinose inducible promoter PBAD. 
It had been shown before that already 100 molecules of the lysin encoded by gene E lead 
to loss of bacterial viability (Maratea et al. 1985). The construct was integrated as a single 
copy into the chromosome of SL7207 together with the fragment PsifA-trfA for 
amplification (strain SL7207::AEN106 in Fig. 2.8). This strain should mediate plasmid 
amplification and in addition, be prone to L-arabinose inducible lysis (Fig. 3.15).  
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Fig. 3.15: Strategy for simultaneous in vivo inducible plasmid amplification and remote control 
of bacterial lysis by L-arabinose. Upon activation of PsifA, the chromosomally integrated replication protein 
TrfA is expressed and mediates amplification of pAEN51 from the second replicon, oriV. Additionally, the 
strain SL7207::AEN106 harbors a chromosomal cassette encoding lysin gene E under control of the 
L-arabinose inducible promoter PBAD. 
To test whether the additional lysis cassette interferes with plasmid amplification, strain 
SL7207::AEN106 was transformed with plasmid pAEN51 and GFP expression was 
analyzed in comparison to SL7207::PsifA-trfA. No differences in the ability to mediate 
plasmid amplification and antigen expression were observed between the two strains in the 
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absence of L-arabinose (Fig. 3.16 A). This indicates that the integration of the lysis 
cassette does not affect the expression of the replication protein TrfA.  
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Fig. 3.16: Simultaneous inducible plasmid amplification and remote control of bacterial lysis by 
L-arabinose in culture. (A) GFP expression of indicated chromosomal integration derivatives transformed 
with plasmid pAEN51 grown in LB (shaded curve) or induction medium (thick lines) in the absence of 
L-arabinose. (B) SL7207::AEN106[pAEN51] was grown in LB in the absence or presence of 0,1% 
L-arabinose for 4 h and subjected to live/dead staining and subsequent flow cytometric analysis. Comparable 
results could be obtained with strains transformed with pAEN61 (data not shown). 
However, upon addition of the inducer, visible lysis occurred in cultures of strain 
SL7207::AEN106 containing chromosomally integrated PBAD-gene E. This could be 
confirmed by applying live/dead staining after culturing the strain in the absence and 
presence of L-arabinose (Fig. 3.16 B). The assay is based on staining the bacterial DNA 
with the membrane-permeable dye thiazole orange (TO) and the membrane-impermeable 
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dye propidium iodide (PI). Without inducer, bacteria were mainly stained by TO and thus 
were viable, whereas bacteria became PI positive after adding L-arabinose since the 
membranes were damaged by induced gene E. In addition, an unstained bacterial 
population appeared after L-arabinose induced lysis. This probably reflected bacteria that 
had already released their content into the surrounding media. Taking together, an 
additional lysis cassette did not interfere with tight control of plasmid amplification and 
antigen expression but allowed remote control of bacterial viability by an easily available 
inducer. It remains to be established whether such a vaccine strain with in vivo amplifiable 
plasmid replication and antigen expression augments the generation of CD4+ T-helper cell 
responses upon lysis of the bacterial carrier strain.  
3.1.7 Non-invasive in vivo imaging of PsifA induction 
A recent study described the activation of SPI-2 promoters PsseA, PspiC and PssaG already in 
the murine intestine during initial stages of Salmonella pathogenesis (Brown et al. 2005). 
This is contradictory to the established model that argues for exclusive intracellular 
expression of SPI-2. Activation of PsifA prior to penetration of the intestinal epithelium 
could lead to impaired invasion efficiency of strains carrying the chromosomal integration 
PsifA-trfA and/or PsifA expression plasmids. However, the promoter PsifA was not tested by 
this group. Therefore, this matter was addressed using bioluminescence in vivo imaging. 
The amplifiable plasmid pAEN102 was constructed that contains the lux operon of the 
bacterium Photorhabdus luminescens (Meighen and Szittner 1992) as reporter (Fig. 3.17). 
Expression of this reporter results in continuous light emission without the need of 
exogenous substrate and allows simple monitoring of bacteria in live mice (Contag et al. 
1995).  
The parental strain SL7207 and the chromosomal integration derivative PsifA-trfA were 
transformed with plasmid pAEN102 and tested for light emission in vitro. As expected, in 
induction medium, strain PsifA-trfA generated more bioluminescence than strain SL7207 
due to amplification of the expression plasmid (data not shown). Importantly, both strains 
exhibited similar levels of background light activity in LB medium (data not shown). This 
confirmed again the tight control of PsifA under non-inducing conditions.  
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To follow the in vivo induction of PsifA, mice were infected orally with SL7207 or PsifA-trfA 
carrying plasmid pAEN102 and monitored for 4 h using the supercooled CCD camera 
system IVIS-200 (Xenogen). As control, recombinant SL7207 harboring plasmid pSL1 
(Winson et al. 1998) were administered. Plasmid pSL1 offers weak constitutive expression 
of the lux genes. Already 30 min after oral administration of recombinant PsifA-trfA, a 
strong bioluminescence signal was detected in the gut region (Fig. 3.18 A). In contrast, 
SL7207 harboring pAEN102 emitted light of lower intensity (Fig. 3.18 A and B). Such 
difference can only be attributed to plasmid amplification induced by activated PsifA. This 
clearly argues for activation of the promoter in the gut lumen prior to breaching of the 
intestinal barrier.  
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Fig. 3.17: Strategy for non-invasive in vivo imaging of PsifA induction. Upon activation of PsifA, the 
promoter drives the expression of the lux operon. The reporter is encoded on pAEN102 which is maintained 
at 5 copies per bacterial cell. Amplified replication of pAEN102 from oriV is mediated by TrfA, whose 
expression is also activated by PsifA. 
In all strains, light emission diminished from 30 min to 4 h p.i. (Fig. 3.18 A and B). This 
might be due to a change in the localization of the bacteria relative to the surface of the 
mouse. Alternatively, bacterial shedding after movement through the intestinal tract via 
feces could be the reason.  
Activation of PsifA very early in the intestine most likely lowers the invasion efficiency of 
recombinant Salmonella. However, when mice infected with PsifA-trfA carrying plasmid 
pAEN102 were sacrificed 5 h p.i., ex vivo images of the intestine revealed weak 
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bioluminescence signals localized to areas of the PP (data not shown). This indicates that 
some bacteria are able to penetrate the intestine and reach immune inductive sites of 
lymphoid tissues as already shown in the colonization studies. Nevertheless, this 
demonstrates the need to explore also alternative promoters for plasmid amplification, like 
promoters that are controllable by external inducers. 
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Fig. 3.18: Non-invasive in vivo imaging of bacterial bioluminescence. Mice were infected orally 
with 2 × 109 cfu of S. typhimurium harboring either the inducible PsifA-lux expression plasmid pAEN102 or 
plasmid pSL1 with constitutive lux expression. The strain with inducible amplification of the expression 
plasmid is indicated as PsifA-trfA. (A) Images of individual anaesthetized mice were acquired at indicated time 
points. (B) The intensity of bioluminescence emission was quantified for all mice of each group. Values 
represent the average for three mice per data point (mean + s.d.). 
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3.2 Remote control of plasmid amplification by L-arabinose 
The use of in vivo inducible promoters as mediators for plasmid amplification was 
considered suitable for immunizations. An alternative application might be the use of 
Salmonella that colonize tumors for therapy. Thus, it might be advantageous to control 
bacteria at a defined time in vivo by administration of an inducer. For that purpose, it was 
decided to concentrate on the L-arabinose inducible promoter PBAD and regulator AraC 
from the arabinose operon of Escherichia coli, which was applied already before for 
induced bacterial lysis. The araC-PBAD system is often used for controlled gene expression 
in E. coli and other bacteria, as it offers regulatable control in the presence and tight 
control in the absence of inducer (Guzman et al. 1995). Therefore, plasmid amplification 
was placed under control of PBAD and the amplification system was characterized in 
medium, in cell culture and subsequently in vivo in a mouse tumor model. 
3.2.1 Amplification of a single copy plasmid controlled by plasmid-
encoded PBAD 
Expression plasmids pAEN9 (see Fig. 2.1) and pAEN38 were constructed to investigate 
the induction of plasmid amplification under remote control. These plasmids are equipped 
with the F plasmid derived single-copy maintenance system oriS-repE-parABC and a 
second replicon based on the origin of replication oriV and the replication protein TrfA, 
whose expression is controlled by PBAD. Moreover, the plasmids encode reporter genes 
gfp_ova (pAEN9) and firefly luciferase (pAEN38) under control of the weak constitutive 
promoter Pbla. S. typhimurium SL7207 was transformed with these vectors and cultures of 
such transformants were induced with different concentrations of L-arabinose for 4 h. As 
expected, without addition of L-arabinose, the plasmids were present at a single copy state 
(Fig. 3.19 A). Both reporter plasmids were amplified to comparable numbers depending on 
the concentration of L-arabinose in the growth medium. In concordance, plasmid 
amplification resulted in strong induction of GFP_ova and luciferase expression (Fig. 3.19 
B and C).  
3 Results 
 
89 
A
GFP expression
B
10
100
10
101 102
10
103
10
104
Fr
eq
u
en
cy 0%
0,01%
0,05%
0,1%
0
20
40
60
80
100
120
0 0,01 0,05 0,1 0,25
Pl
as
m
id
 
co
py
/c
fu
gfp_ova
luc
L-arabinose [%]
C
RL
U/
10
5
c
fu
100
101
102
103
104
105
0 0,01 0,05 0,1 0,25
L-arabinose [%]
 
Fig. 3.19: Plasmid amplification of reporter plasmids after induction with L-arabinose in 
bacterial cultures. (A) SL7207 harboring pAEN9 (gfp_ova) or pAEN38 (luc) were induced with different 
concentrations of L-arabinose in LB medium and plasmid copy/cfu were determined 4 h after induction. (B) 
Bacteria harboring pAEN9 were induced as in a) and GFP expression was analyzed by flow cytometry. (C) 
Bacteria harboring pAEN38 were induced as in a) and enzymatic activity of luciferase was determined from 
lysates and calculated as relative light units (RLU) per 105 cfu. 
Subsequently, induced plasmid amplification was tested when Salmonella resided inside 
host cells. In case of the reporter GFP, plasmid pAEN17 was employed. This vector 
encodes the stable variant gfpmut2 instead of degradable gfp_ova in order to allow 
accumulation of the reporter within the bacteria. Thereby, the sensitivity of detection via 
two color flow cytometry is enhanced. S. typhimurium SL7207 was transformed with 
expression plasmids pAEN17 and pAEN38 and J774-A1 mouse macrophages were 
infected with the transformants. Extracellular bacteria were killed with gentamycin and 3 h 
p.i. L-arabinose was added to the cultures at different concentrations. After incubation for 
4 h, cells were lysed and bacteria analyzed for reporter gene expression. As shown in 
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Fig. 3.20 A and B, increasing concentrations of L-arabinose led to increased bacterial 
expression of the reporters, indicating a successful amplification of the expression 
plasmids. Furthermore, the number of GFP-expressing Salmonella above the background 
autofluorescence increased with rising concentrations of L-arabinose. 
Fr
e
qu
en
c
y
A B 30
0
0,05
0,1
0,15
0,2
0,25
0,3
0 0,07 0,7 7
L-arabinose [%]
RL
U/
cf
u
100 101 102 103 104
0%
0,07%
0,7%
7%
GFP expression
 
Fig. 3.20: Plasmid amplification of reporter plasmids after induction with L-arabinose after 
infection of mouse macrophages. SL7207 harboring pAEN17 (gfp) or pAEN38 (luc) were used to infect 
J774-A1 macrophages. 3 h p.i., L-arabinose at indicated final concentrations was added. (A) Bacterial GFP 
expression in cellular lysates was measured by two color flow cytometry 4 h after induction. (B) Luciferase 
expression by intracellular bacteria was determined as relative light units (RLU) per cfu 4 h after induction. 
Having established that L-arabinose reaches bacteria residing in phagosomal compartments 
of macrophages, it was tested whether plasmid amplification could be also induced in vivo. 
Mice were infected intravenously with S. typhimurium SL7207 carrying the amplifiable 
GFP expression plasmid pAEN17 or luciferase expression plasmid pAEN38, respectively. 
Three days later, different amounts of L-arabinose were injected intraperitoneally and 6 h 
later reporter gene expression was determined in bacteria recovered from lysed spleen cells. 
Administration of L-arabinose resulted in increasing numbers of GFP-expressing 
Salmonella and increasing values of the median GFP fluorescence intensity with rising 
concentrations of the inducer (Fig. 3.21 A). Likewise, a strong induction of bacterial 
luciferase expression could be observed in spleens from infected mice after L-arabinose 
injection (Fig. 3.21 B). Based on these results, it was decided to administer the highest 
amount of L-arabinose (120 mg) and to concentrate on luciferase as reporter for the 
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experiments with tumor-targeted Salmonella. In contrast to GFP, the use of luciferase as 
reporter is not hampered by high background activity of mammalian cells and tissues. 
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Fig. 3.21: Plasmid amplification of reporter plasmids after induction with L-arabinose after 
colonization of spleen. Mice were infected with 2 × 106 SL7207 harboring pAEN17 (gfp) or pAEN38 (luc). 
3 d p.i., L-arabinose at indicated amounts was injected i.p.. (A) Bacterial GFP expression in splenic lysates 
was measured by two color flow cytometry 6 h after induction. Histograms represent individual mice. (B) 
Luciferase expression by intracellular bacteria was determined as relative light units (RLU) per cfu 6 h after 
induction. Bars represent individual mice.  
3.2.2 Amplification of a single copy plasmid controlled by 
chromosomally integrated PBAD 
Thus far, the expression plasmids contained the replication elements of the F plasmid for 
single-copy maintenance and the PBAD-trfA/oriV replicon for L-arabinose inducible plasmid 
amplification. For that reason, the size and complexity of those plasmids is rather large, 
which might impair plasmid stability in vivo. In order to reduce the plasmid size, the 
PBAD-trfA cassette was integrated into the Salmonella chromosome generating the strain 
SL7207::AEN46 (see Fig. 2.8). This strain was transformed with the minimal plasmid 
pAEN35 that lacks the PBAD-trfA cassette and harbors gfp_ova under control of the 
promoter Pbla. Cultures of such transformants were induced with different concentrations 
of L-arabinose for 4 h. Although the copy number of pAEN35 increased with rising 
concentrations of the sugar, it was amplified to a lesser extent compared to plasmid 
pAEN9 (Fig. 3.22 B vs. Fig. 3.19 A). Likewise, a lower induction of GFP_ova expression 
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could be observed (Fig. 3.22 B vs. Fig. 3.19 B). Obviously, chromosomal expression of the 
replication protein TrfA under control of PBAD was not sufficient for amplification to higher 
copy numbers. This was also confirmed when strain SL7207::AEN44 (see Fig. 2.8), a 
chromosomal integration derivative of PBAD-gfp, was tested for reporter gene expression 
after L-arabinose induction in vitro. Only a slight increase of fluorescence intensity could 
be observed under inducing conditions (Fig. 3.22 A), showing that PBAD is a weaker 
promoter compared to the in vivo inducible promoters tested in the first part of this work 
(see Fig. 3.1).  
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Fig. 3.22: Gene expression from chromosomally located PBAD is not sufficient for strong plasmid 
amplification. (A) Flow cytometric detection of in vitro GFP expression of SL7207::AEN44 (PBAD-gfp) 
grown for 4 h under non-inducing conditions (LB w/o L-arabinose, shaded curve) and inducing conditions 
(LB with 0,1% L-arabinose, black lines) (B) SL7207::AEN46 (PBAD-trfA) harboring pAEN35 was induced 
with different concentrations of L-arabinose in LB medium and plasmid copy/cfu and GFP expression were 
determined 4 h after induction. 
Taking together, a reduction of plasmid size (11,3 kb vs. 8,4 kb) was achieved by 
removing the PBAD-trfA cassette from plasmid pAEN9. However, the minimal plasmid 
pAEN35 could only be amplified from 1 to 8 copies by chromosomally integrated 
PBAD-trfA. Therefore, it was decided to control plasmid amplification by plasmid-encoded 
PBAD-trfA in further experiments.  
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3.2.3 Remote control of simultaneous amplification of plasmid 
replication and protein expression 
The same strategy for the enhancement of copy number and gene expression described in 
section 3.1.3 was also employed for remote control by L-arabinose. The luciferase 
expression plasmid pAEN59 (see Fig. 2.2) was constructed, which is derived from plasmid 
pAEN38 but harbors the pSC101 replicon instead of the F plasmid replicon to maintain the 
minimal-copy state. Transformants of SL7207 carrying these plasmids were induced in 
vitro with different concentrations of L-arabinose for 4 h. Amplification of pAEN59 
resulted in approximately five times higher copy number than pAEN38 (Fig. 3.23 A). 
Consequently, a higher luciferase expression could be achieved (Fig. 3.23 B). Importantly, 
both plasmids were stably propagated without antibiotic selection in vitro (data not shown).  
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Fig. 3.23: In vitro plasmid amplification of luciferase expression plasmids with different minimal 
copy replicons after induction with L-arabinose. (A) SL7207 harboring pAEN38 (F plasmid replicon) or 
pAEN59 (pSC101 replicon) were induced with different concentrations of L-arabinose in LB medium and 
plasmid copy/cfu were determined 4 h after induction. (B) Bacteria were induced as in a) and enzymatic 
activity of luciferase was determined from lysates and calculated as relative light units (RLU) per 105 cfu. 
As an additional way to enhance reporter gene expression, luciferase expression was 
placed under control of PBAD instead of the weak constitutive Pbla promoter resulting in 
plasmid pAEN64 (see Fig. 2.3). SL7207 was transformed with this plasmid and the 
transformants were induced for 4 h with different concentrations of L-arabinose. As 
expected, simultaneous induction of plasmid amplification and protein expression by PBAD 
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resulted in increased luciferase expression compared to the combination of L-arabinose 
inducible plasmid amplification and constitutive luciferase expression (Fig. 3.24). 
Moreover, a lower background expression was observed under non-inducing conditions. 
Additionally, plasmid pAEN110 was constructed, which is a derivative of pAEN64 lacking 
the PBAD-trfA cassette. This plasmid is not amplifiable by L-arabinose and the measured 
luciferase expression can be attributed entirely to protein expression driven by PBAD. 
Consequently, luciferase expression is reduced by 1 log in bacteria carrying pAEN110 
instead of pAEN64 (Fig. 3.24). This points out that plasmid amplification contributed 
indeed to the strong luciferase expression.  
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Fig. 3.24: Simultaneous plasmid amplification and protein expression by L-arabinose. SL7207 
harboring pAEN59 (PBAD-trfA/Pbla-luc), pAEN64 (PBAD-trfA/PBAD-luc) and pAEN110 (-/PBAD-luc) were 
induced with different concentrations of L-arabinose in LB medium and enzymatic activity of luciferase was 
determined from lysates and calculated as relative light units (RLU) per 105 cfu. Values represent the average 
for three cultures per data point (mean + s.d.). 
In summary, a higher copy number could be achieved under inducing conditions by 
exchanging the origin of replication that determines the initial minimal-copy number. 
Furthermore, simultaneous control of protein expression and plasmid amplification by PBAD 
resulted in higher reporter gene expression and lower background. 
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3.2.4 Remote control of plasmid amplification in tumor-colonizing 
SL7207 
Before testing the control of plasmid amplification in tumor-colonizing S. typhimurium 
SL7207 in vivo, it was important to determine how L-arabinose accumulates in the 
circulation of mice to induce the PBAD promoter. Therefore, 120 mg L-arabinose were 
injected intraperitoneally and the concentration of the sugar was determined. Fig. 3.25 
shows that a high but transient concentration of L-arabinose could be found in the blood of 
mice. This concentration should be sufficient to induce bacterial gene expression under the 
control of PBAD. The decrease after 4-6 h is probably due to degradation by host enzymes 
(Seri et al. 1996). 
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Fig. 3.25: Accumulation of L-arabinose after intraperitoneal administration of 120 mg sugar. 
Concentration of L-arabinose in blood plasma was measured at consecutive time points. Values represent the 
average for three mice per data point (mean + s.d.); experiment was performed three times with similar 
results. 
Then, SL7207 carrying the amplifiable Pbla-luciferase expression plasmid pAEN38 were 
injected intravenously into mice bearing a subcutaneous CT26 tumor of 5-8 mm diameter. 
Seven days later, L-arabinose was injected intraperitoneally and colonization as well as 
bacterial luciferase expression was determined in tumor, liver and spleen. In individual 
mice, a 10-100 fold enrichment of bacteria in tumors was observed (Fig. 3.26 A). This was 
not as dramatic as previously observed with other S. typhimurium strains (Bermudes et al. 
2002) and might be due to the strain SL7207 used here, which was not particularly 
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optimized for tumor-targeting. The accumulation ratio was rather variable during all tumor 
experiments, although all tumors were colonized. Moreover, the accumulation ratio did not 
increase from 7 to 14 days after injection of the bacteria (data not shown). Administration 
of L-arabinose resulted in increased reporter expression in bacteria from all three tissues 
(Fig. 3.26 B). This is due to induction of plasmid amplification by PBAD. Interestingly, 
without induction, a higher plasmid stability was observed in tumors (94 +/- 6%) compared 
to liver (62 +/- 8%) and spleen (60 +/- 11%) (Fig. 3.26 C).  
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Fig. 3.26: L-arabinose induced plasmid amplification in tumor-bearing BALB/c mice. 7 d p.i. of 
5 × 105 SL7207 carrying pAEN38, groups of mice were injected intraperitoneally with 0 and 120 mg of 
L-arabinose for 6 h. (A) Colonization of host tissue as determined from plating of tissue homogenates. 
(B) Bacterial luciferase expression was determined in tissue lysates and calculated as relative light units 
(RLU) per CFU. (C) Stability of pAEN38 in recombinant SL7207. Values represent the average for three 
mice per data point (mean + s.d.); experiment was performed twice with similar results. 
Although plasmid pAEN38 was stably retained in SL7207 in vitro, it was not fully stable 
in vivo (values ranged from 2-80% plasmid stability 14 d after bacterial injection, data not 
shown). Therefore, experiments were also performed with SL7207 carrying pAEN59, 
which harbors the pSC101 replicon instead of the F plasmid replicon. In this case, a similar 
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bacterial colonization could be observed and the plasmid was stably retained in 
approximately 100% and 70% of the bacteria 7 days and 14 days after injection, 
respectively (data not shown).  
100
101
102
103
104
105
106
107
108
0 3 6 12 24
Time [h]
Cf
u
/o
rg
an
0
20
40
60
80
100
120
140
0 3 6 12 24
Time [h]
Pl
as
m
id
 
st
ab
ili
ty
[%
]
0
5
10
15
20
25
30
35
40
45
50
0 3 6 12 24
Time [h]
RL
U/
cf
u
spleen
liver
tumor
A B
C
 
Fig. 3.27: Time course of plasmid amplification after injection of L-arabinose into tumor-
bearing BALB/c mice. 3 d p.i. of 5 × 105 SL7207 carrying pAEN59, groups of mice were injected 
intraperitoneally with 120 mg of L-arabinose. (A) Colonization of host tissue as determined from plating of 
tissue homogenates at consecutive time points. (B) Kinetics of bacterial luciferase expression as indicator for 
L-arabinose induced plasmid amplification. Luciferase activity was determined in tissue lysates and 
calculated as relative light units (RLU) per CFU. (C) Stability of pAEN59 in recombinant SL7207 during the 
course of induction. Graphs summarize two independent experiments with three mice for each data point 
(mean + s.d.).  
To see how the transient accumulation of L-arabinose in blood influences the induction of 
plasmid amplification, luciferase activity had to be determined at consecutive time points 
during the course of induction. Therefore, SL7207 carrying the amplifiable Pbla-luciferase 
expression plasmid pAEN59 were injected intravenously into mice bearing a subcutaneous 
CT26 tumor of 5-8 mm in diameter. Three days later, 120 mg L-arabinose were injected 
intraperitoneally and colonization, bacterial luciferase expression and plasmid stability 
3 Results 
 
98 
were determined in tumor, liver and spleen. At least a 10-fold enrichment of bacteria in 
tumors was observed (Fig. 3.27 A). The bacterial accumulation in tumors was rather 
variable leading to high standard deviations during measurement of the time course of 
luciferase activity per CFU (Fig. 3.27 B). Nevertheless, it is obvious that the maximal 
plasmid copy number was reached within 6–12 h after administration of L-arabinose. 
Plasmid amplification seemed to result in partial plasmid loss, since the plasmid stability 
decreased during the course of induction (Fig. 3.27 C). 
Expression of genes under control of PBAD is short-lived in vivo, since the inducer only 
transiently accumulates in the tissues (Loessner et al. 2007). However, a repeated induction 
of plasmid amplification and protein expression by L-arabinose should be possible. To test 
this hypothesis, tumor-bearing mice were infected intravenously with SL7207 carrying the 
amplifiable PBAD-luciferase expression plasmid pAEN64 (pSC101 replicon) and repeatedly 
induced i.p. with 120 mg L-arabinose (Fig. 3.28). Twelve hours after each induction time 
point, colonization, bacterial luciferase expression and plasmid stability were determined 
in tumor, liver and spleen. 
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Fig. 3.28: Scheme of repeated induction of plasmid amplification and protein expression by 
L-arabinose in recombinant Salmonella in vivo. Tumor-bearing BALB/c mice were infected i.v. with 
SL7207[pAEN64]. 3 d p.i., groups of mice were injected i.p. with 0 mg (w/o) or 120 mg L-arabinose and 
analyzed for tissue colonization, luciferase expression and plasmid stability 12 h later. Another group of mice 
that received L-arabinose was again injected i.p. with 0 mg (w/o) or 120 mg L-arabinose 36 h after the 1st 
induction and assayed 12 h later. This procedure was repeated 36 h after the 2nd induction.  
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Again, recombinant SL7207 preferentially colonized tumors (Fig. 3.29 A) compared to 
spleen (Fig. 3.29 B) and liver (data not shown). Repeated induction of plasmid 
amplification and protein expression resulted in plasmid loss and accordingly declining 
CFU, since displayed values were determined from plating with antibiotic selection. At 
each induction time point, administration of L-arabinose resulted in higher luciferase 
expression in bacteria from tumor (Fig. 3.29 A), spleen (Fig. 3.29 B) and liver (data not 
shown). The induction factor appeared higher in tumor than in spleen; a phenomenon that 
had been described and can be attributed to the extracellular location of Salmonella within 
tumors (Loessner et al. 2007). Interestingly, the luciferase activity per cfu increased from 
the 1st to the 2nd induction. This might be due to an additional increase of the plasmid copy 
number in bacteria, which were not completely induced before. Alternatively, plasmid 
amplification and protein expression were activated in a portion of bacteria that was not 
induced at the first administration. Subsaturating inducer concentrations inside tissues 
could result in gene activation in one but not the other bacterium, a phenomenon called 
“all-or-nothing” induction of the PBAD promoter (Siegele and Hu 1997).  
Similar observations were made when this experiment was performed with SL7207 
carrying amplifiable Pbla-luciferase expression plasmid pAEN59 or the non-amplifiable 
PBAD-luciferase expression plasmid pAEN110 (data not shown). In concordance with the in 
vitro data (Fig. 3.24), a lower luciferase activity was determined in both cases compared to 
SL7207 carrying pAEN64 (data not shown). In summary, it is possible to repeatedly 
induce plasmid amplification and protein expression with L-arabinose after bacterial 
colonization of the mammalian host. 
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Fig. 3.29: Repeated induction of simultaneous plasmid amplification and protein expression by 
L-arabinose in tumor-bearing BALB/c mice. Mice were infected with SL7207[pAEN64] and repeatedly 
induced by L-arabinose as described in Fig. 3.28. 12 h after each induction, colonization, bacterial luciferase 
expression and plasmid stability was determined in tumor (A) and spleen (B). Values represent the average 
for three mice per data point (mean + s.d.). 
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4 Discussion 
Over the years, Salmonella vaccine strains expressing heterologous antigens or delivering 
expression plasmids have been used to raise immune responses against a broad range of 
pathogens as well as to induce antitumor immunity in animal models and to some extent 
also in humans and non-human primates (reviewed by Garmory et al. 2002 and Loessner 
and Weiss 2004). One of the conclusions of such trials was that it is of utmost importance 
to express the heterologous antigens at sufficient levels. This requires that the eukaryotic or 
prokaryotic expression plasmids are stably retained in the bacterial carrier. Therefore, for 
the construction of efficient vaccine strains, it is critical to reduce the interference of 
antigen expression or plasmid load with the viability and fitness of the bacterial carrier. In 
case of mucosal application, the vaccine strain must also retain its potential to breach the 
gastrointestinal barrier to reach inductive sites of the immune system (Hansen-Wester and 
Hensel 2001). 
4.1 Establishment of an in vivo inducible plasmid 
amplification system 
In the first part of this work, an in vivo inducible plasmid amplification system was 
developed to reduce the metabolic burden of the vaccine carrier especially in the early 
phase of host colonization. To construct such vaccine strains with a minimal heterologous 
load, the plasmids contained the replicon of the F plasmid. For inducible plasmid 
amplification, this was combined with a second RK2-derived origin of replication, oriV. In 
addition, the RK2-derived replication protein TrfA that is responsible for induction of 
replication via oriV was fused to particular in vivo inducible promoters and then 
chromosomally integrated. Such recombinant strains were used to amplify a GFP_ova 
expression plasmid. 
As promoters, three previously identified inducible promoters were employed that were 
known to be activated during intracellular replication of Salmonella within professional 
APC (Rollenhagen et al. 2004). Chromosomally integrated constructs of the reporter gene 
GFP driven by the promoters PsifA, Pstm1630 and PphoN confirmed their function in the vaccine 
strain S. typhimurium SL7207. The three chromosomal constructs responded to defined in 
vitro inducing conditions. Under these conditions PsifA performed best as it showed the 
highest up-regulation combined with low background. Similar findings had been made 
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previously in S. typhimurium strain SL1344 using a pBR322-derived gfp-ova reporter 
plasmid. In this setting, PsifA exhibited a twofold higher in vivo expression level compared 
to Pstm1630 and PphoN (Rollenhagen et al. 2004).  
The initiation protein TrfA mediates assembly of the replication complex at oriV in a 
monomeric form (Toukdarian et al. 1996). Once a plasmid in the bacterial cell is at or 
above is characteristic copy number, dimeric TrfA takes over the copy number control by 
coupling oriV-bound TrfA monomers (Toukdarian and Helinski 1998). This “handcuffed” 
complex prevents DNA replication by making it inaccessible for other components of the 
replication machinery. In the present study, a copy-up trfA gene derived from pETcoco-1 
(Wild and Szybalski 2004) was used. It was found to have reduced ability to form coupled 
complexes (Blasina et al. 1996). This might explain why the expression plasmids could be 
amplified in vitro up to 50 copies per bacterial cell when the promoters PsifA and PphoN were 
used to drive trfA transcription.  
In infected macrophages and in spleen cells from infected mice, the three promoters 
showed similar levels of GFP_ova expression as indicator for successful plasmid 
amplification. As an explanation for the discrepancy between bacterial culture and 
presence in host cells, bacterial subpopulations with low GFP expression levels might 
escape detection due to interfering host-cell autofluorescence. Thus, many bacteria 
containing Pstm1630-constructs might not be analyzed. Alternatively, environmental stimuli 
imposed by the phagosomal compartment of host cells might have a different impact on 
promoter activity than induction medium. Nevertheless, PsifA had clearly the most attractive 
induction properties for an in vivo inducible plasmid amplification system; i.e. low in vitro 
background and high in vivo activity.  
As a second step, enhanced antigen expression levels and lower background was achieved 
by using PsifA for simultaneous regulation of plasmid amplification and reporter gene 
expression. Interestingly, the strong transcription of GFP_ova observed here did not 
interfere with amplified replication of the expression plasmid. Transcription from strong 
promoters had been shown before to interfere with plasmid replication (Stueber and Bujard 
1982).  
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When the F plasmid replicon was exchanged with the alternative low-copy number 
replicons pSC101 and p15A, GFP_ova expression plasmids could be amplified from 5-10 
to 100 copies. The twofold higher maximum copy numbers of the pSC101/p15A 
containing vector compared to the oriS containing vector was unexpected. Theoretically, 
the copy number driven by TrfA and oriV should reach a maximum independent of the 
vector base. In addition, the plasmids were propagated in the same recombinant strain with 
chromosomally integrated PsifA-trfA. Thus, the same amount of the initiator protein should 
have been available for amplification of all the plasmids. Therefore, it is likely that the 
different plasmid backbone or the reduced plasmid size lead to a higher characteristic copy 
number under inducing conditions.  
In this context, another unexpected finding was that no significant plasmid amplification 
was observed in induction medium when strain PsifA-trfA carried an expression plasmid 
based on the low-copy number replicon pMB1. This effect might be attributed to 
interfering GFP_ova transcription in this combination, although antigen expression was 
apparently reduced in this case. An alternative explanation for this phenomenon might be 
that replication from origins of replications like pMB1 interferes with oriV. From these 
data, two replicons, either of the F plasmid or pSC101, were selected for further in vivo 
application.  
Recombinant strains transformed with amplifiable plasmids based on the F plasmid and 
pSC101 replicon were therefore tested in colonization studies and compared with control 
strains. The colonization capabilities of such strains differed depending on their ability to 
amplify the PsifA-gfp_ova expression plasmid. Whereas SL7207 carrying only the 
amplifiable plasmid showed no colonization defect and plasmids were stably retained for 
more than 7 days after oral immunization, SL7207 bearing amplifying PsifA-trfA exhibited 
plasmid loss and impaired tissue replication. Lower bacterial numbers were observed with 
both recombinant strains compared to parental strain SL7207 already 1 day p.i.. This 
indicates either impaired invasion efficiency or impaired survival/replication in host cells. 
The latter could be due to high protein expression induced by PsifA once the bacteria reside 
within host cells.  
Non-invasive in vivo imaging pinpointed at an explanation for the inferior performance of 
bacteria carrying amplifiable plasmids. Activation of PsifA and plasmid amplification takes 
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place already in the intestine and hence precedes penetration of the intestinal barrier. This 
is consistent with a study describing the expression from SPI-2 promoters PsseA, PspiC and 
PssaG in the gut within 15 min after application (Brown et al. 2005). The early activation of 
PsifA obviously results in high antigen expression and contributes very likely to the 
impaired invasion efficiency observed in the colonization studies. 
As one would predict, the colonization defect is enhanced in case of the plasmid containing 
the pSC101 replicon. This plasmid is lost faster than the oriS-containing plasmid in strain 
PsifA-trfA, which is most likely a result of the higher amplification.  
It has previously been observed that fluorescent proteins like GFP can lower the fitness of 
bacterial pathogens (Knodler et al. 2005). Since the same effects were observed using 
LLO49-361 instead of GFP, the choice of antigen seems to have no impact on the 
colonization performance. Rather the nature of the plasmid components appears decisive. 
Consistently, chromosomal insertion of the promoter-trfA fusion did not detectably 
influence the colonization capability of the carrier strain. 
Amplified plasmids are retained in carrier bacteria at high percentages for at least three 
days despite of the metabolic burden imposed. Thus, high antigen expression should be 
encountered during this time. To relate high antigen expression with the induction of a 
specific T cell response, a chimeric mouse model was used in which transgenic T cells 
recognizing the epitope of GFP_ova were adoptively transferred into syngeneic, non-
transgenic mice (Pape et al. 1997). Oral administration of 1 × 109 SL7207::PsifA-trfA 
harboring a PsifA-gfp_ova expression plasmid resulted in a higher stimulation of T cell 
proliferation compared to the control parental strain. However, a stronger antigen-specific 
T cell response was observed with intravenous immunization using 5 × 105 cfu of the same 
strain. Therefore, this route of administration was considered more appropriate to assess 
the effect of plasmid amplification on the generation of CD4+ T cell responses.  
Consistently, stronger immune responses could be observed when the recombinant strains 
were able to amplify the expression plasmids in vivo. Obviously, high antigen expression 
due to plasmid amplification in SL7207::PsifA-trfA compensates for the lower stability of 
such plasmids. On the other hand, twofold higher amplification of the pSC101 containing 
plasmid did not lead to stronger T helper cell responses in comparison to the F factor-
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containing plasmid. This suggests that prolonged antigen expression due to higher stability 
of the vector system counterbalances the higher antigen expression in this case. Possibly, a 
specific optimum of in vivo expression levels for every antigen might exist depending on 
its influence on colonization, stability and immunogenicity.  
The superior efficacy of the plasmid amplification system in the generation of CD4+ T cell 
responses remains to be confirmed in an oral immunization scheme. This could be 
achieved by administering higher doses of recombinant Salmonella. Indeed, 1 × 109 cfu is 
a rather low dose compared to what has been used in other studies with S. typhimurium 
vaccine vectors (4-5 × 109 cfu) (McKelvie et al. 2004, Husseiny and Hensel 2005). In 
addition, Husseiny and Hensel observed that intracellular antigen expression under control 
of the SPI-2 promoter PsseA was less efficient in strain SL7207 compared to an attenuated 
strain deficient in the SPI-2 translocation system. Using the aroA attenuated carrier strain, 
regulated Ova expression on a low-copy number plasmid did not result in a significant 
stimulation of Ova-specific T cell proliferation (Husseiny and Hensel 2005). Future work 
should therefore be directed to the comparison of different attenuated strains of 
S. typhimurium harboring the novel plasmid amplification system. The use of carriers with 
other attenuations might enhance antigen expression to cognate T cells. On this score, 
strategies for secretion (Hess et al. 1996) or surface display (Kramer et al. 2003) of the 
antigen instead of cytoplasmic expression might be advantageous.  
An alternative strategy to increase antigen presentation via MHC class II and to induce 
CD4+ T cell responses was pursued in this work. Chromosomal integration of the 
PBAD-gene E lysis cassette next to the PsifA-trfA fragment generated a vaccine strain, which 
allows induction of programmed lysis upon application of L-arabinose. In addition, 
plasmid amplification was mediated in vitro. It remains to be established, whether in vivo 
lysis of the carrier in the phagosomal compartment of APC augments MHC class II-
dependent immune responses.  
The suitability of the in vivo inducible plasmid amplification system for the generation of 
cytotoxic T cells was evaluated using the model antigen LLO. Independent of the route of 
immunization, the recombinant Salmonella strains failed to elicit in vivo cytotoxicity. This 
strongly suggests a detrimental effect of the intracellular antigen localization, which can 
not be compensated by high antigen amounts expressed in the plasmid amplifying strains. 
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Thus, in order to raise protective CD8+ T cell responses, the vaccine strain needs to be 
improved regarding the feeding of antigen into the MHC class I antigen processing and 
presentation pathway. In this respect, the use of SPI-2 type III effector proteins to act as 
carrier molecules for heterologous antigens seems very attractive. Exemplarily, fusion of 
the model antigen p60 of L. monocytogenes to SPI-2 effectors SifA and SspH2 under 
control of their native promoters and expression from medium-copy number plasmids led 
to translocation of chimeric p60 proteins into Salmonella-infected APC and in turn to 
CD8+ T cell priming (Panthel et al. 2005). Interestingly, mice immunized with Salmonella 
expressing chimeric SifA/p60 proteins from low-copy number vectors did not mount 
measurable immune responses in this study. Thus, the application of in vivo inducible 
plasmid amplification under control of PsifA might be advantageous in this setting. Hence, 
plasmid amplification and heterologous protein expression would start at the same time as 
expression of the cognate TTSS since both are specifically controlled via the same 
environmental conditions. However, the nature of the attenuating mutation in the 
Salmonella carrier strain has to be considered also for this improvement strategy. Notably, 
a reduced expression of SPI-2 fusion constructs was observed in a S. typhimurium aroA 
strain in comparison to strains deficient in htrA, purD, galE or htrA/purD (Husseiny et al. 
2007).  
Taken together, this is the first study that demonstrates the in vivo inducible amplification 
of expression plasmids in a Salmonella vaccine strain. Simultaneous regulation of plasmid 
amplification and antigen expression for Salmonella-mediated protein delivery has several 
advantages to in vivo regulated antigen expression alone. First, expression of the 
heterologous antigen is presumably minimal during fermentation, eliminating any 
metabolic burden during vaccine manufacture. The transformants carrying the expression 
plasmids are stable per se abrogating the need for antibiotics in the growth medium during 
production. Second, dual control reduces the background antigen expression. This might 
also allow the expression of heterologous antigens that may be deleterious to Salmonella 
carrier strains in conventional expression systems. Thus, this approach appears to be very 
promising for heterologous protein delivery when supplemented with appropriate antigen 
presentation strategies and in combination with the right attenuation of the carrier. Future 
work might also investigate the potential of other intracellular activated promoters.  
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Moreover, the in vivo inducible plasmid amplification system is particularly suited for the 
amplification of DNA vaccines carried by the bacterial vector upon infection of immune 
cells. Within the framework of this thesis, the system was not evaluated in this respect. 
However, the amplifiable plasmids could be easily modified for this purpose by 
exchanging PsifA with a eukaryotic promoter.  
The induction of uncontrolled plasmid replication, so-called runaway replication, might 
also be an interesting strategy for Salmonella-mediated DNA vaccination. Runaway 
replication leads to an exponential increase in the concentration of plasmid DNA until the 
cells eventually die (Larsen et al. 1984). Such loss of copy number control could be 
achieved in our system using a combination of two characterized copy-up TrfA mutations. 
The double mutant TrfA protein has been shown to be defective in coupling replication 
origins while being able to bind to oriV, thus initiating runaway replication (Blasina et al. 
1996). It remains to be tested whether chromosomal expression of the double mutant TrfA 
under control of PsifA results in uncontrolled plasmid amplification and whether this 
subsequently augments the DNA transfer. 
4.2 Remote control of plasmid amplification by L-arabinose 
The deliberate induction of plasmid amplification in vivo is an alternative to the use of 
Salmonella-specific in vivo inducible promoters. This strategy appears to be especially 
promising for tumor therapy. It allows temporal control of the carrier in order to increase 
specificity, e.g. by administration of the inducer after completion of migration of the 
bacteria into the tumor. As demonstrated in this work, use of the monosaccharide 
L-arabinose in combination with the corresponding molecular switch PBAD is highly 
suitable for that purpose. L-arabinose seems to fulfill all criteria of a versatile inducer. It is 
a biocompatible food component and is suggested for clinical use in other contexts. 
Furthermore, it is non-toxic and non-immunogenic to the host and readily available at low 
cost.  
The conditional amplification of reporter plasmids under control of L-arabinose was shown 
to be tightly regulated in vitro. Without addition of the inducer, plasmids were present in a 
characteristic minimal-copy number state (1-5 copies). This stringent control of plasmid 
amplification is an important property since it leads to high in vitro stability. Depending on 
the respective first origin of replication, the copy number could be regulated to about 
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80-100 (F factor) or 250 (pSC101 replicon) copies upon induction. Thereby the trfA gene 
is also amplified due to the episomal location of the PBAD-trfA cassette. This seems to 
augment the amplification effect, since chromosomal expression of trfA under control of 
PBAD resulted only in 8-fold amplification.  
In contrast, up to 30-fold amplification of low-copy bacterial artificial chromosomes 
(BACs) was observed in E. coli DH10B carrying a chromosomally integrated PBAD-trfA 
cassette (Wild et al. 2002). This difference might likely be due to the different carriers used, 
i.e. S. typhimurium SL7207 vs. E. coli DH10B. 
The copy number of the reporter plasmids and in concordance GFP or luciferase 
expression increased over a wide range of inducer concentrations in vitro and in vivo. 
L-arabinose not only reaches Salmonella that reside in the phagosomal compartments of 
infected J774-A1 macrophages but also reaches bacterial niches in tumor, spleen and liver 
of infected mice. After systemic administration of L-arabinose the sugar only transiently 
circulates in the blood of mice and is degraded by host enzymes (Seri et al. 1996). 
Nevertheless, this leads to L-arabinose concentrations high enough to induce a short-lived 
expression of genes under control of PBAD (Loessner et al. 2007). Interestingly, the level of 
constitutive luciferase expression as indicator for plasmid amplification is still rather high 
24 h after administration of the inducer, although L-arabinose is completely degraded 7 h 
after injection. This can be explained by low proliferation rates of such bacteria, since the 
copy number of amplified plasmids will only decrease when the bacteria divide. 
Within the course of induction, plasmid amplification apparently leads to plasmid loss in 
vivo. However, unless induced, amplifiable plasmids harboring the pSC101 replicon are 
stably retained in vivo for two weeks. The reason for this higher stability in comparison to 
amplifiable plasmids harboring the F replicon is unclear. It might be due the reduced 
plasmid size (12,2 kb vs. 9,2 kb). However, this property as well as the higher copy 
number after induction render pSC101 based constructs more suitable than the plasmids 
containing the F replicon.  
Dual control of reporter gene expression and plasmid amplification by PBAD as applied for 
in vivo inducible promoters resulted in increased luciferase expression and lower 
background. This approach is suitable for Salmonella-mediated delivery of genes, which 
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are toxic to the carrier and/or the host. Even the most tightly regulated promoters display 
low levels of background expression and such leaky expression is proportional to the copy 
number of the plasmid. Therefore, it is desirable to keep the gene dosage very low during 
manufacture of the carrier strain and its migration within the host. It has been shown that 
expression of gene E from a single chromosomally located copy under control of PBAD did 
not interfere with growth, invasiveness and tumor colonization (this work and Loessner et 
al. 2007). Such exceptional tight control could be employed e.g. for the targeted delivery of 
pro-drug converting enzymes, like cytosine desaminase, or cytokines, like TNFα, by 
tumor-colonizing Salmonella. This way, strong expression of the therapeutic gene due to 
amplification of the gene dosage and initiation of transcription could be spatially and 
temporally regulated. The inducer could be administered after bacteria have accumulated 
in the tumor. In addition, a higher induction factor has been observed in tumors compared 
to liver and spleen, which can be attributed to the extracellular location of Salmonella 
within tumors (Loessner et al. 2007). Furthermore, repeated induction of plasmid 
amplification and protein expression is possible after bacterial colonization of the 
mammalian host. Thus, appropriate bacterial vectors may provide antitumor activity for a 
prolonged period of time.  
Plasmid amplification and protein expression could repeatedly be induced by L-arabinose 
in recombinant Salmonella in vivo. The reporter activity increased from the 1st to the 2nd 
induction time point. This might be due to activation of bacteria, which were incompletely 
or not at all induced before. On this score, a phenomenon called “all-or-nothing” induction 
of the PBAD promoter has to be reported. Subsaturating inducer concentrations as they occur 
very likely inside tissues in vivo can result in gene activation in one but not the other 
bacterium (Siegele and Hu 1997). This can be attributed to fluctuating expression of the 
L-arabinose transporter AraE in an uninduced state of the endogenous arabinose operon of 
Salmonella. Such bacteria that contain sufficient transporters to accumulate L-arabinose 
induce the synthesis of additional AraE. These transporters catalyze up-take of additional 
L-arabinose leading to more induction. This autocatalytic induction cycle continues until a 
fraction of bacteria becomes fully induced whereas the other subpopulation expressing 
transporter levels below the threshold is not induced.  
Moreover, S. typhimurium SL7207 contains functional araBAD genes encoding 
L-arabinose degrading enzymes. Degradation leads to depletion of the sugar and 
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progressive loss of induction at low L-arabinose concentrations. To circumvent the “all-or-
nothing” induction of the PBAD expression system, strains should be engineered that are 
deficient in L-arabinose transport and degradation genes as described (Morgan-Kiss et al. 
2002). In such strains, the sugar entered the cells in a concentration dependent manner due 
to expression of a mutant LacY transporter that performs facilitated diffusion of 
L-arabinose. 
In experiments with tumor-bearing mice, recombinant S. typhimurium strain SL7207 
showed a preferential colonization of tumors compared to liver and spleen after 
intravenous administration. A 10-100 fold enrichment of bacteria in tumor was observed, 
which is probably not sufficient for targeted tumor therapy. In contrast, higher 
accumulation ratios (1000:1 – 10000:1) have been observed with other S. typhimurium 
strains in mice (Clairmont et al. 2000, Rosenberg et al. 2002). Therefore, regulated reporter 
gene expression and plasmid amplification under control of PBAD should also be evaluated 
in Salmonella strains with better tumor-targeting properties in the future. In this context, 
one might also employ other remotely controllable promoters for the construction of 
multifunctional tumor-targeting bacteria, which can be manipulated in several ways in vivo. 
As an alternative to tumor therapy, remote control of plasmid amplification by L-arabinose 
might also be used for Salmonella-mediated delivery of heterologous antigens or DNA. 
This would allow bacteria to infect APC unhampered by expression of antigens and/or by 
high-copy number of plasmids, both tightly regulated by PBAD. In this setting, the time of 
induction could be synchronized with the course of the Salmonella infection, i.e. after 
strong accumulation in lymphoid tissues. Importantly, orally administered L-arabinose has 
been shown to induce protein expression in Salmonella colonizing Peyer’s Patches 
(H. Lößner, unpublished observation). Thus, it might be possible to develop an orally 
administered Salmonella vaccine, which is activated by orally administered L-arabinose. 
4.3 Concluding remarks 
Taken together, this work describes for the first time a system for in vivo inducible plasmid 
amplification in Salmonella. The system is designed to maintain low plasmid levels until 
activation of in vivo inducible promoters in APC of the host or administration of the 
external inducer L-arabinose. Both approaches for regulation of the system offer tight 
control, strong induction and a variety of applications. However, a number of possibilities 
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for improvement arise from the present work. For instance, the rational design of the 
carrier strain for vaccination or tumor therapy will be of high interest. Similarly, the system 
can be extended to other remotely controllable and Salmonella-specific promoters, e.g. 
newly identified tumor-specific promoters. Thus, it should lead to the optimization of 
Salmonella-mediated delivery of prophylactic and therapeutic molecules. This study 
represents an important step in this direction.  
5 Summary 
 
112 
5 Summary 
Live attenuated Salmonella are highly potential vectors for the delivery of proteins and 
DNA with applications in vaccination and tumor therapy. Conventional expression systems 
are based on maintenance of the expression plasmid at multi-copy numbers representing a 
high metabolic burden for the bacteria that results in a decreased performance of the vector. 
In this work, a system for inducible amplification of expression plasmids was established 
in Salmonella enterica serovar Typhimurium vaccine strain SL7207. Amplifiable plasmids 
were constructed that contain two replication origins. The first replicon ensures the 
minimal-copy number state under non-inducing conditions. A second medium-copy 
replicon derived from plasmid RK2 is responsible for conditional amplification of the 
expression plasmids. Activation of the second replication origin depends on the replication 
protein TrfA. Accordingly, expression of trfA was placed under control of a Salmonella-
specific in vivo inducible promoter or a promoter that can be deliberately activated by a 
low molecular weight inducer. 
As in vivo inducible promoters, PphoN, Pstm1630 and PsifA were tested in this work. Such 
promoters are claimed to regulate genes that are expressed in the vacuole of the host cell. 
PsifA was found to be most promising. It was silent under non-inducing conditions and 
exhibited strong amplification of the plasmid copy number up to 50-100 copies. 
Consequently, enhanced expression of plasmid-encoded antigen was observed in vitro in 
induction medium and upon infection of macrophages. Similar results were obtained after 
infection of mice. Expression could be further increased by controlling transcription of the 
antigen via PsifA at the same time.  
However, non-invasive in vivo imaging demonstrated that PsifA is activated already early in 
the intestine. This obviously impairs the invasion efficiency of orally administered plasmid 
amplifying strains. Nevertheless, after intravenous immunization, plasmid amplification 
resulted in substantial ovalbumin-specific CD4+ T cell responses. Induction of CD8+ T 
cells could not clearly be demonstrated under these conditions when listeriolysin O was 
used as antigen. This was attributed to the antigen localization in the bacterial cell and 
suggests further experiments with secreted antigens. In addition, Salmonella-mediated 
DNA vaccination should be tested using this newly established in vivo plasmid 
amplification system. 
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In the second part of this work, plasmid amplification could be induced at will by 
employing the promoter PBAD and addition of L-arabinose to bacterial cultures and when 
the bacteria resided within macrophages. More importantly, remote control of 
amplification was also possible in mice. Salmonella were used to colonize tumors of 
tumor-bearing mice as well as liver and spleen. The tight control of PBAD led to low 
background activity and exquisite in vitro and in vivo stability of amplifiable plasmids in 
the absence of inducer. Administration of L-arabinose resulted in high reporter activity 
especially when plasmid amplification and reporter expression were simultaneously driven 
by PBAD. In addition, repeated induction of reporter gene expression could be demonstrated 
in vivo.  
In tumor-bearing mice, strain SL7207 harboring amplifiable plasmids exhibited tumor 
accumulation ratios of 10-100:1 in comparison to normal tissues. An application of this 
system in bacterial strains with improved tumor-targeting properties should render it a 
powerful tool for tumor therapy. Furthermore, the deliberate induction of plasmid 
amplification could be employed for vaccination. In summary, inducible plasmid 
amplification should contribute to the optimization of Salmonella-mediated delivery of 
prophylactic and therapeutic molecules and should add to the tools that are available for 
clinical use of such bacteria. 
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6 Abbreviations 
ADCC antibody-dependent cell-mediated cytotoxicity 
AIDA adhesion involved in diffuse adherence 
AmpR ampicillin resistance gene 
APC antigen-presenting cells 
asd aspartate ß-semialdehyde dehydrogenase 
BAC bacterial artificial chromosome 
BCG bacille Calmette-Guerin 
BHI brain heart infusion 
bp basepairs 
CD cytosine desaminase 
CFSE carboxy fluorescein succinimidyl ester 
cfu colony forming units 
CmR chloramphenicol resistance gene 
CMV cytomegalovirus 
const. constitutive  
CpG cytosine phosphate guanosine 
CTL cytotoxic T lymphocyte 
DAP diaminopimelic acid 
DC dendritic cells 
DNA deoxyribonucleic acid 
EDTA ethylenediaminetetraacetate 
e.g. for example 
FAE follicle-associated epithelium 
FC fluorocytosine 
FCS fetal calf serum 
FDA Food and Drug Administration 
FU fluorouracil 
HBV hepatitis B virus 
HIV human immunodeficiency virus 
HPV human papillomavirus 
i.e. that is 
IFN interferon 
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Ig immunoglobulin 
IL interleukin 
IM induction medium 
IMDM Iscove’s modified Dulbecco’s Eagle’s medium 
i.p. intraperitoneal 
ISCOM immunostimulating complex 
i.v. intravenous 
IVI in vivo inducible 
KnR kanamycin resistance gene 
LB Luria Bertani 
LLO listeriolysin O 
LPS lipopolysaccharides 
M cell microfold cell 
MACS magnetic cell sorting 
MALT mucosa associated lymphoid tissue 
MDPR methylpurine-2’deoyriboside 
MFI median fluorescence intensity 
MHC major histocompatibility complex 
MLN mesenteric lymph node 
MOI multiplicity of infection 
Mp macrophage 
MVA modified vaccinia virus Ankara 
OD optical density 
ori origin of replication 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG polyethylenglycol 
p.i. post infection 
PI propidium iodide 
PMN polymorphonuclear cell 
PP Peyer’s Patches 
RLU relative light units 
Rpm rotations per minute 
RT room temperature 
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SARS severe acute respiratory syndrome 
s.c. subcutaneous 
SCV Salmonella-containing vacuole 
s.d. standard deviation 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SED subepithelial dome 
SPI Salmonella pathogenicity island 
Spp. Subspecies 
TAE tris-acetic acid EDTA 
TE trypsin-ETDA 
Th cell T-helper cell 
TLR toll-like receptor 
Tn transposon 
TNF tumor necrosis factor 
TO thiazole orange 
TTSS type III secretion system 
u unit 
UV ultraviolet 
v/v volume per volume 
w/v weight per volume 
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